US20070099900A1 - Methods of modulating neurotrophin-mediated activity - Google Patents
Methods of modulating neurotrophin-mediated activity Download PDFInfo
- Publication number
- US20070099900A1 US20070099900A1 US11/521,591 US52159106A US2007099900A1 US 20070099900 A1 US20070099900 A1 US 20070099900A1 US 52159106 A US52159106 A US 52159106A US 2007099900 A1 US2007099900 A1 US 2007099900A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- benzo
- formula
- tetrahydro
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 227
- 238000000034 method Methods 0.000 title claims abstract description 100
- 102000007072 Nerve Growth Factors Human genes 0.000 title claims description 86
- 230000000694 effects Effects 0.000 title claims description 57
- 230000001404 mediated effect Effects 0.000 title claims description 34
- 230000003993 interaction Effects 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims description 256
- -1 C1-6-alkene Chemical group 0.000 claims description 148
- 208000002193 Pain Diseases 0.000 claims description 141
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 120
- 230000036407 pain Effects 0.000 claims description 119
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 96
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims description 69
- 239000001257 hydrogen Substances 0.000 claims description 69
- 229910052739 hydrogen Inorganic materials 0.000 claims description 69
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims description 68
- 208000035475 disorder Diseases 0.000 claims description 67
- 125000003118 aryl group Chemical group 0.000 claims description 66
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 65
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 62
- 201000010099 disease Diseases 0.000 claims description 53
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 50
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 49
- 150000002431 hydrogen Chemical class 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 150000002367 halogens Chemical class 0.000 claims description 47
- 239000002253 acid Substances 0.000 claims description 46
- 125000001072 heteroaryl group Chemical group 0.000 claims description 45
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 43
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 41
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 33
- 239000004202 carbamide Substances 0.000 claims description 32
- 208000027866 inflammatory disease Diseases 0.000 claims description 32
- 150000003457 sulfones Chemical class 0.000 claims description 31
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 31
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 29
- 125000003725 azepanyl group Chemical group 0.000 claims description 29
- 125000002541 furyl group Chemical group 0.000 claims description 29
- 125000000335 thiazolyl group Chemical group 0.000 claims description 29
- 125000001544 thienyl group Chemical group 0.000 claims description 29
- 208000012902 Nervous system disease Diseases 0.000 claims description 24
- 125000004193 piperazinyl group Chemical group 0.000 claims description 22
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 21
- 210000005095 gastrointestinal system Anatomy 0.000 claims description 18
- 210000002229 urogenital system Anatomy 0.000 claims description 18
- 229910006069 SO3H Inorganic materials 0.000 claims description 17
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 229910018830 PO3H Inorganic materials 0.000 claims description 13
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000002883 imidazolyl group Chemical group 0.000 claims description 12
- ZOFSYPCICBTFHL-UHFFFAOYSA-N 17-(5-carboxy-2-chlorophenyl)-11,16,18-trioxo-3,10,17-triazahexacyclo[13.6.2.02,10.04,9.012,22.019,23]tricosa-1(22),2,4(9),5,7,12,14,19(23),20-nonaene-7-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)C(N2C(C3=CC=C4C(=O)N5C6=CC(=CC=C6N=C5C5=CC=C(C3=C54)C2=O)C(O)=O)=O)=C1 ZOFSYPCICBTFHL-UHFFFAOYSA-N 0.000 claims description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- YCOBIGFYUUTJAB-UHFFFAOYSA-N 3-[13-(4-carboxy-1-chlorocyclohexa-2,4-dien-1-yl)-5,7,12,14-tetraoxo-6,13-diazatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),2,4(16),8,10-pentaen-6-yl]-4-chlorobenzoic acid Chemical compound C1=CC(C(=O)O)=CCC1(Cl)N(C1=O)C(=O)C(C=C2)=C3C1=CC=C1C(=O)N(C=4C(=CC=C(C=4)C(O)=O)Cl)C(=O)C2=C31 YCOBIGFYUUTJAB-UHFFFAOYSA-N 0.000 claims description 7
- SDVSQAYRLDBEHL-UHFFFAOYSA-N C1=CC(=C23)C(=O)N4C5=CC(OC)=CC=C5N=C4C2=CC=C(C2=O)C3=C1C(=O)N2C1=CC(C(O)=O)=CC=C1Cl Chemical compound C1=CC(=C23)C(=O)N4C5=CC(OC)=CC=C5N=C4C2=CC=C(C2=O)C3=C1C(=O)N2C1=CC(C(O)=O)=CC=C1Cl SDVSQAYRLDBEHL-UHFFFAOYSA-N 0.000 claims description 7
- 125000005605 benzo group Chemical group 0.000 claims description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 7
- 125000003386 piperidinyl group Chemical group 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 229910004727 OSO3H Inorganic materials 0.000 claims description 6
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 6
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 6
- NWXFCMDXCPTSQR-UHFFFAOYSA-N C12=NC3=CC=C(C(O)=O)C=C3N2C(=O)C2=CC=C3C(=O)N(CCCC(=O)O)C(=O)C4=CC=C1C2=C43 Chemical compound C12=NC3=CC=C(C(O)=O)C=C3N2C(=O)C2=CC=C3C(=O)N(CCCC(=O)O)C(=O)C4=CC=C1C2=C43 NWXFCMDXCPTSQR-UHFFFAOYSA-N 0.000 claims description 5
- GYXZTVHUPCPKCN-UHFFFAOYSA-N C1=CC(=C23)C(=O)N(CCCC(=O)O)C(=O)C2=CC=C(C2=O)C3=C1C(=O)N2C1=CC(C(O)=O)=CC=C1Cl Chemical compound C1=CC(=C23)C(=O)N(CCCC(=O)O)C(=O)C2=CC=C(C2=O)C3=C1C(=O)N2C1=CC(C(O)=O)=CC=C1Cl GYXZTVHUPCPKCN-UHFFFAOYSA-N 0.000 claims description 5
- NYDPSALIKDYDPC-UHFFFAOYSA-N OC(=O)C1=CC=C(Cl)C(N2C(C3=CC=C4C(=O)N5C6=CC(=CC=C6N=C5C5=CC=C(C3=C54)C2=O)[N+]([O-])=O)=O)=C1 Chemical compound OC(=O)C1=CC=C(Cl)C(N2C(C3=CC=C4C(=O)N5C6=CC(=CC=C6N=C5C5=CC=C(C3=C54)C2=O)[N+]([O-])=O)=O)=C1 NYDPSALIKDYDPC-UHFFFAOYSA-N 0.000 claims description 5
- UJYUYCCDJOAPPK-UHFFFAOYSA-N OC(=O)C1=CC=C(Cl)C(N2C(C=3C=CC4=C5C(C(OC4=O)=O)=CC=C(C=35)C2=O)=O)=C1 Chemical compound OC(=O)C1=CC=C(Cl)C(N2C(C=3C=CC4=C5C(C(OC4=O)=O)=CC=C(C=35)C2=O)=O)=C1 UJYUYCCDJOAPPK-UHFFFAOYSA-N 0.000 claims description 5
- VQZBJPPMCFOOLQ-UHFFFAOYSA-N OC(=O)C1=CC=CC(N2C(C3=CC=C4C(=O)N5C6=CC(=CC=C6N=C5C5=CC=C(C3=C54)C2=O)C(O)=O)=O)=C1 Chemical compound OC(=O)C1=CC=CC(N2C(C3=CC=C4C(=O)N5C6=CC(=CC=C6N=C5C5=CC=C(C3=C54)C2=O)C(O)=O)=O)=C1 VQZBJPPMCFOOLQ-UHFFFAOYSA-N 0.000 claims description 5
- KROCRFLQAOZBDX-UHFFFAOYSA-N OC(=O)C1=CC=CC(N2C(C=3C=CC4=C5C(C(OC4=O)=O)=CC=C(C=35)C2=O)=O)=C1 Chemical compound OC(=O)C1=CC=CC(N2C(C=3C=CC4=C5C(C(OC4=O)=O)=CC=C(C=35)C2=O)=O)=C1 KROCRFLQAOZBDX-UHFFFAOYSA-N 0.000 claims description 5
- MUAIYJXUHJRIHI-UHFFFAOYSA-N molport-021-780-184 Chemical compound C1=CC(C(N(CCCC(=O)O)C2=O)=O)=C3C2=CC=C2C(=O)N(CCCC(O)=O)C(=O)C1=C32 MUAIYJXUHJRIHI-UHFFFAOYSA-N 0.000 claims description 5
- PFDOIWININZDKA-UHFFFAOYSA-N OC(=O)C1=CC=C(Cl)C(N2C(C3=CC=C4C(=O)N5C6=CC(Cl)=CC=C6N=C5C5=CC=C(C3=C54)C2=O)=O)=C1 Chemical compound OC(=O)C1=CC=C(Cl)C(N2C(C3=CC=C4C(=O)N5C6=CC(Cl)=CC=C6N=C5C5=CC=C(C3=C54)C2=O)=O)=C1 PFDOIWININZDKA-UHFFFAOYSA-N 0.000 claims description 4
- AWILRCLZZOUVET-UHFFFAOYSA-N 17-(5-carboxy-2-chlorophenyl)-14-methyl-11,16,18-trioxo-3,10,17-triazahexacyclo[13.6.2.02,10.04,9.012,22.019,23]tricosa-1(22),2,4(9),5,7,12,14,19(23),20-nonaene-7-carboxylic acid Chemical compound CC1=CC(C(N2C3=CC(=CC=C3N=C22)C(O)=O)=O)=C3C2=CC=C(C2=O)C3=C1C(=O)N2C1=CC(C(O)=O)=CC=C1Cl AWILRCLZZOUVET-UHFFFAOYSA-N 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 abstract description 139
- 102000015336 Nerve Growth Factor Human genes 0.000 abstract description 121
- 239000000203 mixture Substances 0.000 abstract description 57
- 239000002243 precursor Substances 0.000 abstract description 20
- 230000000508 neurotrophic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 77
- 208000014674 injury Diseases 0.000 description 54
- 101150111783 NTRK1 gene Proteins 0.000 description 50
- 208000027418 Wounds and injury Diseases 0.000 description 47
- 230000006378 damage Effects 0.000 description 44
- 206010061218 Inflammation Diseases 0.000 description 40
- 230000004054 inflammatory process Effects 0.000 description 40
- 238000009739 binding Methods 0.000 description 39
- 230000027455 binding Effects 0.000 description 38
- 210000002683 foot Anatomy 0.000 description 33
- 238000011282 treatment Methods 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- 239000003981 vehicle Substances 0.000 description 30
- 206010028980 Neoplasm Diseases 0.000 description 28
- 208000004454 Hyperalgesia Diseases 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 208000004296 neuralgia Diseases 0.000 description 26
- 210000002569 neuron Anatomy 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 25
- 229940079593 drug Drugs 0.000 description 25
- 208000021722 neuropathic pain Diseases 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- 108020003175 receptors Proteins 0.000 description 23
- 208000001294 Nociceptive Pain Diseases 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 230000001684 chronic effect Effects 0.000 description 20
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 125000000304 alkynyl group Chemical group 0.000 description 18
- 125000003342 alkenyl group Chemical group 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 210000000056 organ Anatomy 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 208000009935 visceral pain Diseases 0.000 description 15
- 0 [1*]N1C(=O)C2=C3C4=C(C(=O)N([1*])C(=O)/C4=C([3*])/C([2*])=C\3C1=O)C([4*])=C2[5*] Chemical compound [1*]N1C(=O)C2=C3C4=C(C(=O)N([1*])C(=O)/C4=C([3*])/C([2*])=C\3C1=O)C([4*])=C2[5*] 0.000 description 14
- 238000010171 animal model Methods 0.000 description 14
- 125000001309 chloro group Chemical group Cl* 0.000 description 14
- 230000003211 malignant effect Effects 0.000 description 14
- 210000005036 nerve Anatomy 0.000 description 14
- 201000001119 neuropathy Diseases 0.000 description 14
- 210000002345 respiratory system Anatomy 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 231100000673 dose–response relationship Toxicity 0.000 description 13
- 230000007823 neuropathy Effects 0.000 description 13
- 208000033808 peripheral neuropathy Diseases 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 208000025966 Neurological disease Diseases 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 12
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 11
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 11
- 208000000094 Chronic Pain Diseases 0.000 description 11
- 229960000583 acetic acid Drugs 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000000548 hind-foot Anatomy 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 208000018522 Gastrointestinal disease Diseases 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 208000005298 acute pain Diseases 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 10
- 239000003900 neurotrophic factor Substances 0.000 description 10
- 206010033675 panniculitis Diseases 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 210000004304 subcutaneous tissue Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 210000002808 connective tissue Anatomy 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 210000000653 nervous system Anatomy 0.000 description 9
- 239000002858 neurotransmitter agent Substances 0.000 description 9
- 230000003040 nociceptive effect Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
- 108090000742 Neurotrophin 3 Proteins 0.000 description 8
- 102000004230 Neurotrophin 3 Human genes 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- 239000000730 antalgic agent Substances 0.000 description 8
- 125000001246 bromo group Chemical group Br* 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 230000004968 inflammatory condition Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000014511 neuron projection development Effects 0.000 description 8
- 229940032018 neurotrophin 3 Drugs 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 210000003932 urinary bladder Anatomy 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 7
- 125000003282 alkyl amino group Chemical group 0.000 description 7
- 125000004947 alkyl aryl amino group Chemical group 0.000 description 7
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 7
- 125000001769 aryl amino group Chemical group 0.000 description 7
- 125000004658 aryl carbonyl amino group Chemical group 0.000 description 7
- 125000004986 diarylamino group Chemical group 0.000 description 7
- 208000037765 diseases and disorders Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 208000023504 respiratory system disease Diseases 0.000 description 7
- 210000003497 sciatic nerve Anatomy 0.000 description 7
- 230000005062 synaptic transmission Effects 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000008733 trauma Effects 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 208000035154 Hyperesthesia Diseases 0.000 description 6
- 206010065390 Inflammatory pain Diseases 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 102100033857 Neurotrophin-4 Human genes 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 6
- 206010053552 allodynia Diseases 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 125000004663 dialkyl amino group Chemical group 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- 208000011231 Crohn disease Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 208000007882 Gastritis Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000000112 Myalgia Diseases 0.000 description 5
- 208000028389 Nerve injury Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 208000004550 Postoperative Pain Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 5
- 125000004442 acylamino group Chemical group 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 5
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 229940121363 anti-inflammatory agent Drugs 0.000 description 5
- 239000002260 anti-inflammatory agent Substances 0.000 description 5
- 239000001961 anticonvulsive agent Substances 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 125000005129 aryl carbonyl group Chemical group 0.000 description 5
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 5
- 125000005110 aryl thio group Chemical group 0.000 description 5
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 description 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- 201000003146 cystitis Diseases 0.000 description 5
- 208000010643 digestive system disease Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 208000018685 gastrointestinal system disease Diseases 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000003447 ipsilateral effect Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000008764 nerve damage Effects 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 208000020431 spinal cord injury Diseases 0.000 description 5
- 210000001032 spinal nerve Anatomy 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 208000001640 Fibromyalgia Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108090000099 Neurotrophin-4 Proteins 0.000 description 4
- 108090000095 Neurotrophin-6 Proteins 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 201000007737 Retinal degeneration Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000007784 diverticulitis Diseases 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 208000035824 paresthesia Diseases 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 208000001297 phlebitis Diseases 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000013222 sprague-dawley male rat Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 208000019206 urinary tract infection Diseases 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 206010058019 Cancer Pain Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010013886 Dysaesthesia Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000034693 Laceration Diseases 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 201000002481 Myositis Diseases 0.000 description 3
- 101150117329 NTRK3 gene Proteins 0.000 description 3
- 206010029148 Nephrolithiasis Diseases 0.000 description 3
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 3
- 206010029279 Neurogenic bladder Diseases 0.000 description 3
- 101150056950 Ntrk2 gene Proteins 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 208000004983 Phantom Limb Diseases 0.000 description 3
- 206010056238 Phantom pain Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000027520 Somatoform disease Diseases 0.000 description 3
- 208000010040 Sprains and Strains Diseases 0.000 description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 230000001062 anti-nausea Effects 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 3
- 239000002327 cardiovascular agent Substances 0.000 description 3
- 229940125692 cardiovascular agent Drugs 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 206010013864 duodenitis Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000003193 general anesthetic agent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- YTVNOVQHSGMMOV-UHFFFAOYSA-N naphthalenetetracarboxylic dianhydride Chemical compound C1=CC(C(=O)OC2=O)=C3C2=CC=C2C(=O)OC(=O)C1=C32 YTVNOVQHSGMMOV-UHFFFAOYSA-N 0.000 description 3
- 230000003533 narcotic effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 150000002923 oximes Chemical group 0.000 description 3
- 208000027753 pain disease Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 201000007094 prostatitis Diseases 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 230000001235 sensitizing effect Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- HEMGYNNCNNODNX-UHFFFAOYSA-N 3,4-diaminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1N HEMGYNNCNNODNX-UHFFFAOYSA-N 0.000 description 2
- DMGFVJVLVZOSOE-UHFFFAOYSA-N 3-amino-4-chlorobenzoic acid Chemical compound NC1=CC(C(O)=O)=CC=C1Cl DMGFVJVLVZOSOE-UHFFFAOYSA-N 0.000 description 2
- AQMZIBAPQNCYIR-UHFFFAOYSA-N 4-(5,7,12,14-tetraoxo-6-oxatetracyclo[6.6.2.04,16.011,15]hexadeca-1(15),2,4(16),8,10-pentaen-13-yl)butanoic acid Chemical compound O=C1OC(=O)C2=CC=C3C(=O)C(CCCC(=O)O)C(=O)C4=CC=C1C2=C43 AQMZIBAPQNCYIR-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Chemical class C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000001387 Causalgia Diseases 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical group C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 239000004472 Lysine Chemical class 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 208000006670 Multiple fractures Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 244000308495 Potentilla anserina Species 0.000 description 2
- 235000016594 Potentilla anserina Nutrition 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000005089 alkenylaminocarbonyl group Chemical group 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003502 anti-nociceptive effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000005128 aryl amino alkyl group Chemical group 0.000 description 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 201000001352 cholecystitis Diseases 0.000 description 2
- 201000001883 cholelithiasis Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 208000018912 cluster headache syndrome Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000001752 female genitalia Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000000260 male genitalia Anatomy 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 208000020629 overactive bladder Diseases 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 208000000029 referred pain Diseases 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- XYMVZPOXZCDCNP-UHFFFAOYSA-N sulfamoyl cyanide Chemical compound NS(=O)(=O)C#N XYMVZPOXZCDCNP-UHFFFAOYSA-N 0.000 description 2
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical group 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000015533 trkA Receptor Human genes 0.000 description 2
- 108010064884 trkA Receptor Proteins 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- 125000006730 (C2-C5) alkynyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- VMPYFWTYGZZUMY-UHFFFAOYSA-N 2-morpholin-4-ylphenol Chemical group OC1=CC=CC=C1N1CCOCC1 VMPYFWTYGZZUMY-UHFFFAOYSA-N 0.000 description 1
- PYAZCFCEURLPSU-UHFFFAOYSA-N 3-methoxy-4-propoxybenzoic acid Chemical group CCCOC1=CC=C(C(O)=O)C=C1OC PYAZCFCEURLPSU-UHFFFAOYSA-N 0.000 description 1
- PEPBFCOIJRULGJ-UHFFFAOYSA-N 3h-1,2,3-benzodioxazole Chemical compound C1=CC=C2NOOC2=C1 PEPBFCOIJRULGJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- DFRRALWXTFSAEC-UHFFFAOYSA-N 5H-tetrazole Chemical group C1N=NN=N1 DFRRALWXTFSAEC-UHFFFAOYSA-N 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000019775 Back disease Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004637 Bile duct stone Diseases 0.000 description 1
- 206010005053 Bladder neck obstruction Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- XZSFFEYOFGFERR-UHFFFAOYSA-N CC(C)N(C(c(cc1)c2cc1C(O)=O)=O)C2=O Chemical compound CC(C)N(C(c(cc1)c2cc1C(O)=O)=O)C2=O XZSFFEYOFGFERR-UHFFFAOYSA-N 0.000 description 1
- LKBWUKSCKNKQBM-UHFFFAOYSA-N CC1=CC2=C(C=C1)C(=O)N(C(C)(C)C)C2=O Chemical compound CC1=CC2=C(C=C1)C(=O)N(C(C)(C)C)C2=O LKBWUKSCKNKQBM-UHFFFAOYSA-N 0.000 description 1
- NWNSCCNUYQTLDQ-UHFFFAOYSA-N COC(=O)C1=CC2=C(C=C1)N=C1C3=C4C(=CC=C5C(=O)N(C6=CC(C(=O)O)=CC=C6Cl)C(=O)C(=C\54)/C=C\3)C(=O)N12 Chemical compound COC(=O)C1=CC2=C(C=C1)N=C1C3=C4C(=CC=C5C(=O)N(C6=CC(C(=O)O)=CC=C6Cl)C(=O)C(=C\54)/C=C\3)C(=O)N12 NWNSCCNUYQTLDQ-UHFFFAOYSA-N 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010062746 Carditis Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000004845 Cholecystolithiasis Diseases 0.000 description 1
- 201000009331 Choledocholithiasis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 206010011777 Cystinosis Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 206010012435 Dermatitis and eczema Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010021333 Ileus paralytic Diseases 0.000 description 1
- 208000003941 Impacted Tooth Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 201000005081 Intestinal Pseudo-Obstruction Diseases 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000012741 Laemmli sample buffer Substances 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000002472 Morton Neuroma Diseases 0.000 description 1
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- JKFYCHYYFRAWEW-UHFFFAOYSA-N NC1=CC(C(=O)O)=CC=C1Cl.NC1=CC=C(C(=O)O)C=C1N.O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4C(=O)N5C(=NC6=C5C=C(C(=O)O)C=C6)C5=C4C3=C(/C=C\5)C2=O)=C1.O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4C(=O)OC(=O)C5=C4C3=C(/C=C\5)C2=O)=C1.O=C1OC(=O)/C2=C/C=C3/C(=O)OC(=O)C4=C3C2=C1C=C4 Chemical compound NC1=CC(C(=O)O)=CC=C1Cl.NC1=CC=C(C(=O)O)C=C1N.O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4C(=O)N5C(=NC6=C5C=C(C(=O)O)C=C6)C5=C4C3=C(/C=C\5)C2=O)=C1.O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4C(=O)OC(=O)C5=C4C3=C(/C=C\5)C2=O)=C1.O=C1OC(=O)/C2=C/C=C3/C(=O)OC(=O)C4=C3C2=C1C=C4 JKFYCHYYFRAWEW-UHFFFAOYSA-N 0.000 description 1
- HGVXZPWVOQNPSK-UHFFFAOYSA-N NC1=CC(C(=O)O)=CC=C1Cl.O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4C(=O)N(C5=C(Cl)C=CC(C(=O)O)=C5)C(=O)C5=C4C3=C(/C=C\5)C2=O)=C1.O=C1OC(=O)/C2=C/C=C3/C(=O)OC(=O)C4=C3C2=C1C=C4 Chemical compound NC1=CC(C(=O)O)=CC=C1Cl.O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4C(=O)N(C5=C(Cl)C=CC(C(=O)O)=C5)C(=O)C5=C4C3=C(/C=C\5)C2=O)=C1.O=C1OC(=O)/C2=C/C=C3/C(=O)OC(=O)C4=C3C2=C1C=C4 HGVXZPWVOQNPSK-UHFFFAOYSA-N 0.000 description 1
- RLRQLKXWGVACQQ-UHFFFAOYSA-N NC1=CC=C(C(=O)O)C=C1N.O=C(O)C1=CC=C2N=C3C4=C5C(=CC=C6C(=O)N7C(=NC8=C7C=C(C(=O)O)C=C8)C(=C65)/C=C\4)C(=O)N3C2=C1.O=C(O)C1=CC=C2N=C3C4=C5C(=CC=C6C5=C(/C=C\4)C(=O)N4C5=CC(C(=O)O)=CC=C5/N=C/64)C(=O)N3C2=C1.O=C1OC(=O)/C2=C/C=C3/C(=O)OC(=O)C4=C3C2=C1C=C4 Chemical compound NC1=CC=C(C(=O)O)C=C1N.O=C(O)C1=CC=C2N=C3C4=C5C(=CC=C6C(=O)N7C(=NC8=C7C=C(C(=O)O)C=C8)C(=C65)/C=C\4)C(=O)N3C2=C1.O=C(O)C1=CC=C2N=C3C4=C5C(=CC=C6C5=C(/C=C\4)C(=O)N4C5=CC(C(=O)O)=CC=C5/N=C/64)C(=O)N3C2=C1.O=C1OC(=O)/C2=C/C=C3/C(=O)OC(=O)C4=C3C2=C1C=C4 RLRQLKXWGVACQQ-UHFFFAOYSA-N 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- GRSMWKLPSNHDHA-UHFFFAOYSA-N Naphthalic anhydride Chemical class C1=CC(C(=O)OC2=O)=C3C2=CC=CC3=C1 GRSMWKLPSNHDHA-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 208000009546 Neurogenic bowel Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- HFMJXUUZLTXFGL-UHFFFAOYSA-N O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=C4C5=C(C=C3)C(=O)N(C3=C(Cl)C=CC(C(=O)O)=C3)C(=O)/C5=C/C=C\4C2=O)=C1 Chemical compound O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=C4C5=C(C=C3)C(=O)N(C3=C(Cl)C=CC(C(=O)O)=C3)C(=O)/C5=C/C=C\4C2=O)=C1 HFMJXUUZLTXFGL-UHFFFAOYSA-N 0.000 description 1
- ATBMOAZEJIQGEO-UHFFFAOYSA-N O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4C(=O)N5C(=NC6=C5C=CC=C6)C5=C4/C3=C(\C=C/5)C2=O)=C1 Chemical compound O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4C(=O)N5C(=NC6=C5C=CC=C6)C5=C4/C3=C(\C=C/5)C2=O)=C1 ATBMOAZEJIQGEO-UHFFFAOYSA-N 0.000 description 1
- DDZXLSOTHUKXTR-UHFFFAOYSA-N O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4N=C5C6=C(C=CC(C(=O)O)=C6)C(=O)N5C5=C4/C3=C(\C=C/5)C2=O)=C1 Chemical compound O=C(O)C1=CC=C(Cl)C(N2C(=O)C3=CC=C4N=C5C6=C(C=CC(C(=O)O)=C6)C(=O)N5C5=C4/C3=C(\C=C/5)C2=O)=C1 DDZXLSOTHUKXTR-UHFFFAOYSA-N 0.000 description 1
- QMXCDSOENGRMRX-UHFFFAOYSA-N O=C(O)C1=CC=CC(N2C(=O)C3=C4C5=C(C=C3)C(=O)N(C3=CC=CC(C(=O)O)=C3)C(=O)/C5=C/C=C\4C2=O)=C1 Chemical compound O=C(O)C1=CC=CC(N2C(=O)C3=C4C5=C(C=C3)C(=O)N(C3=CC=CC(C(=O)O)=C3)C(=O)/C5=C/C=C\4C2=O)=C1 QMXCDSOENGRMRX-UHFFFAOYSA-N 0.000 description 1
- DIJNLJLMJXLULT-UHFFFAOYSA-N O=C(O)CCCN1C(=O)C2=C3C4=C(C=C2)C(=O)OC(=O)/C4=C/C=C\3C1=O Chemical compound O=C(O)CCCN1C(=O)C2=C3C4=C(C=C2)C(=O)OC(=O)/C4=C/C=C\3C1=O DIJNLJLMJXLULT-UHFFFAOYSA-N 0.000 description 1
- JGXJVGYHWWMVKT-UHFFFAOYSA-N O=C(O)CCCN1C(=O)C2=CC=C3N=C4C5=C(C=CC(C(=O)O)=C5)C(=O)N4C4=C3/C2=C(\C=C/4)C1=O Chemical compound O=C(O)CCCN1C(=O)C2=CC=C3N=C4C5=C(C=CC(C(=O)O)=C5)C(=O)N4C4=C3/C2=C(\C=C/4)C1=O JGXJVGYHWWMVKT-UHFFFAOYSA-N 0.000 description 1
- XLFBWYFEORPAGE-UHFFFAOYSA-L O=C(O[Na])C1=CC=C2/N=C3C4=C/C=C5C6=C(C=CC(=C6/4)C(=O)N/3C2=C1)C(=O)N1C2=C(C=CC(C(=O)O[Na])=C2)\N=C\51 Chemical compound O=C(O[Na])C1=CC=C2/N=C3C4=C/C=C5C6=C(C=CC(=C6/4)C(=O)N/3C2=C1)C(=O)N1C2=C(C=CC(C(=O)O[Na])=C2)\N=C\51 XLFBWYFEORPAGE-UHFFFAOYSA-L 0.000 description 1
- DGBWPZSGHAXYGK-UHFFFAOYSA-N O=C1/C2=C/C=C3C4=C(C=CC(=C42)/C2=N/C4=CC=CC=C4N12)C(=O)N1C2=CC=CC=C2\N=C\31.[K+] Chemical compound O=C1/C2=C/C=C3C4=C(C=CC(=C42)/C2=N/C4=CC=CC=C4N12)C(=O)N1C2=CC=CC=C2\N=C\31.[K+] DGBWPZSGHAXYGK-UHFFFAOYSA-N 0.000 description 1
- YJMXFEJMIONBSQ-UHFFFAOYSA-N O=C1C2=C3C4=C(C=C2)C(=O)N(C2=CC(S(=O)(=O)O)=CC=C2)C(=O)/C4=C/C=C\3C(=O)N1C1=CC=CC(S(=O)(=O)O)=C1 Chemical compound O=C1C2=C3C4=C(C=C2)C(=O)N(C2=CC(S(=O)(=O)O)=CC=C2)C(=O)/C4=C/C=C\3C(=O)N1C1=CC=CC(S(=O)(=O)O)=C1 YJMXFEJMIONBSQ-UHFFFAOYSA-N 0.000 description 1
- KXWAXPQHXDKTDW-UHFFFAOYSA-N O=C1C2=C3C4=C(C=C2)C(=O)N(C2=CC=C(S(=O)(=O)O)C=C2)C(=O)/C4=C/C=C\3C(=O)N1C1=CC=C(S(=O)(=O)O)C=C1 Chemical compound O=C1C2=C3C4=C(C=C2)C(=O)N(C2=CC=C(S(=O)(=O)O)C=C2)C(=O)/C4=C/C=C\3C(=O)N1C1=CC=C(S(=O)(=O)O)C=C1 KXWAXPQHXDKTDW-UHFFFAOYSA-N 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010035623 Pleuritic pain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 201000006490 Spondylolysis Diseases 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044074 Torticollis Diseases 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 125000005091 alkenylcarbonylamino group Chemical group 0.000 description 1
- 125000005095 alkynylaminocarbonyl group Chemical group 0.000 description 1
- 125000005088 alkynylcarbonylamino group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000020466 alteration of consciousness Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical class C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002594 corticospinal effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- IBAHLNWTOIHLKE-UHFFFAOYSA-N cyano cyanate Chemical compound N#COC#N IBAHLNWTOIHLKE-UHFFFAOYSA-N 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- MGJYOHMBGJPESL-UHFFFAOYSA-L disodium;1-[8-(2,5-dioxo-3-sulfonatopyrrolidin-1-yl)oxy-8-oxooctanoyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].[Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S([O-])(=O)=O)CC1=O MGJYOHMBGJPESL-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960000618 fluprednisolone Drugs 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 208000018645 hepatic veno-occlusive disease Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Chemical group C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000021646 inflammation of heart layer Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000018197 inherited torticollis Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000004840 megacolon Diseases 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 229960001810 meprednisone Drugs 0.000 description 1
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000897 modulatory effect Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000001703 neuroimmune Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940121367 non-opioid analgesics Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000009210 ongoing activation Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000010 osteolytic effect Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 201000007620 paralytic ileus Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 210000004345 peroneal nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940124811 psychiatric drug Drugs 0.000 description 1
- 201000004537 pyelitis Diseases 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 230000003016 quadriplegic effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 206010061928 radiculitis Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 108010063338 receptorphin Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000008790 seltzer Nutrition 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 210000001590 sural nerve Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000008768 sympathetic hyperinnervation Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 208000024363 trachea neoplasm Diseases 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 210000003412 trans-golgi network Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
- C07D209/92—Naphthostyrils
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
Definitions
- the present invention relates to compositions which modulate the interaction of nerve growth factor, and precursors thereof, with the receptor TrkA, as well as the common neurotrophin receptor p75 NTR , and methods of use thereof.
- the neurotrophins are a family of structurally and functionally related proteins, including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), Neurotrophin-4/5 (NT-4/5) and Neurotrophin-6 (NT-6). These proteins promote the survival and differentiation of diverse neuronal populations in both the peripheral and central nervous systems and are involved in the pathogenesis of diverse neurological disorders (Hefti, J. Neurosci. 6:2155-2162 (1986); Hefti and Weiner, Annals of Neurology 20:275-281 (1986); Levi-Montalcini, EMBO J.
- NGF Nerve Growth Factor
- BDNF Brain-Derived Neurotrophic Factor
- NT-3 Neurotrophin-3
- Neurotrophin-4/5 NT-4/5
- NT-6 Neurotrophin-6
- NGF neurotrophin-derived neurotrophin
- NGF has been shown to play a role in bladder overactivity (Lamb, K. et al., J. Pain. 2004; 5(3): 150-156), bladder outlet obstruction (Kim, J. C.
- pancreatic cancer Shi, X. et al., Pancreatology. 2001; 1(5):517-524
- intestinal inflammation Li, A. et al., Exp. Neurol. 2005; 191(2):337-43.
- NGF is synthesized as a larger precursor form (referred to herein as “proNGF,” also known as “preproNGF” or “pro-peptide NGF”) which is then processed by proteolytic cleavages to produce the mature neurotrophic factor.
- This prepro region is located at the amino terminus of the precursor molecule and is needed for proper folding and secretion of the NGF protein.
- the mature form of NGF has arginine residues at its carboxy termini which requires that a leucine residue be inserted between the naturally occurring arginine and the hydrophilic spacer.
- the primary structure of proNGF has been deduced from the nucleotide sequence of the mouse NGF cDNA (Scott et al. Nature 302:538 (1983); Ullrich et al. Nature 303:821 (1983)).
- the common neurotrophin receptor p75 NTR is a transmembrane glycoprotein structurally related to the tumor necrosis factor and CD-40 receptors (Meakin and Shooter, Trends Neurosci. 15:323-331 (1992), Rydén and Ibá ⁇ ez, J. Biol. Chem. 271:5623-5627 (1996)).
- All neurotrophins bind to p75 NTR with similar affinities (Rodrigues-Tébar et al., Neuron 4:487-492 (1990); Hallbook et al., Neuron 6:845-858 (1991); Rodrigues-Tébar et al., EMBO J.
- p75 NTR possesses unique, neurotrophin dependent, Trk-independent signaling properties which involve ceramide production through activation of the sphingomyelin cycle (Dobrowsky et al., Science 265:1596-1599 (1994)), apoptosis (cell death) (Cassacia-Bonnefil et al., Nature 383:716-719 (1996)), and activation of the transcription factor NFKB (Carter et al., Science 272:542-545 (1996)).
- TrkA, TrkB and TrkC exhibit selectivity for specific neurotrophins.
- TrkA, TrkB and TrkC exhibit selectivity for specific neurotrophins.
- TrkA primarily binds NGF (Kaplan et al., 1991; Klein et al., 1991) and has been reported to bind NT-3 (J. Biol. Chem. 271(10):5623-7, 1996); TrkB binds BDNF and NT-4/5 (Soppet et al., 1991; Squinto et al., 1991; Berkemeier et al., 1991; Escandon et al., 1993; Lamballe et al., 1991; Klein et al., 1992; Vale and Shooter, Methods Enzymol.
- TrkC exclusively binds NT-3 (Lamballe et al., 1991; Vale and Shooter, 1985). This is particularly evident when the Trk receptors are coexpressed with the common neurotrophin receptor p75 NTR . (For review see Meakin and Shooter, 1992; Barbacid, 1993; Chao, 1994; Bradshaw et al., 1994; Ibá ⁇ ez, 1995).
- NGF neurotrophin receptor p75 NTR
- Trk receptor TrkA TrkA
- the invention provides a compound of the invention of the Formula 16, Formula 17, Formula 18, Formula 19, Formula 20, Formula 21 and Formula 22, as well as the compounds of Table 1.
- the invention provides a method of modulating the interaction of a neurotrophin and a neurotrophin receptor, comprising contacting cells expressing a neurotrophin receptor with an effective amount of a compound of the invention.
- the neurotrophin is nerve growth factor and/or precursors thereof.
- the neurotrophin receptor is selected from the group consisting of p75 NTR and TrkA.
- the neurotrophin receptor is p75 NTR .
- the neurotrophin receptor is TrkA.
- the compound further modulates the interaction of NGF and/or proNGF with TrkA.
- the method is used to modulate a neurotrophin-mediated activity in a subject in need thereof.
- the neurotrophin-mediated activity is associated with pain.
- the neurotrophin-mediated activity is associated with an inflammatory disorder.
- the neurotrophin-mediated activity is associated with a neurological disorder.
- the pain treated by the compounds of the invention is selected from the group consisting of cutaneous pain, somatic pain, visceral pain and neuropathic pain. In another embodiment the pain is acute pain or chronic pain.
- the cutaneous pain is associated with injury, disease, disorder or neoplasms of the skin, subcutaneous tissues and related organs.
- the injury, disease or disorder of the skin, subcutaneous tissues and related organs is selected from the group consisting of traumas, cuts, lacerations, punctures, burns, surgical incisions, infections, psoriasis, eczema, and inflammation (e.g., acute inflammation).
- the somatic pain is associated with an injury, disease, disorder or neoplasms of the musculoskeletal and connective system.
- the injury, disease or disorder of the musculoskeletal and connective system is selected from the group consisting of sprains, broken bones, arthritis, arthralgia, myalgia, chronic lower back pain, cancer-associated pain, dental pain, fibromyalgia, idiopathic pain disorder, chronic non-specific pain, post-operative pain, and referred pain.
- the visceral pain is associated with an injury, disease, disorder or neoplasms of the circulatory system, the respiratory system, the gastrointestinal system, or the genitourinary system.
- the disease or disorder of the circulatory system treated by the compounds of the invention is selected from the group consisting of ischaemic heart disease, angina, acute myocardial infarction, cardiac arrhythmia, phlebitis, intermittent claudication, varicose veins and hemorrhoids.
- the disease or disorder of the respiratory system treated by the compounds of the invention is selected from the group consisting of asthma, Chronic Obstructive Pulmonary Disease (COPD), respiratory infection, chronic bronchitis and emphysema.
- COPD Chronic Obstructive Pulmonary Disease
- the disease or disorder of the gastrointestinal system treated by the compounds of the invention is selected from the group consisting of gastritis, duodenitis, irritable bowel syndrome, colitis, Crohn's disease, ulcers and diverticulitis.
- the disease or disorder of the genitourinary system treated by the compounds of the invention is selected from the group consisting of cystitis, urinary tract infections, glomuerulonephritis, polycystic kidney disease, and kidney stones.
- the neuropathic pain is associated with an injury, disease, disorder or neoplasms of the nervous system.
- the injury, disease or disorder of the nervous system is selected from the group consisting of neuralgia, neuropathy, headache, chronic cephalic pain, phantom limb pain and spinal cord injury.
- the inflammatory disorder treated by the compounds of the invention is selected from an inflammatory disorder of the skin and subcutaneous tissues, the musculoskeletal and connective tissue system, the respiratory system, the circulatory system, the genitourinary system, the gastrointestinal system or the nervous system.
- the inflammatory disorder of the skin and subcutaneous tissues is selected from the group consisting of psoriasis, dermatitis and eczema.
- the inflammatory disorder of the musculoskeletal and connective tissue system is selected from the group consisting of arthritis, gout, myositis, bursitis and synovitis.
- the inflammatory disorder of the respiratory system treated by the compounds of the invention is selected from the group consisting of asthma, bronchitis, sinusitis, pharyngitis, rhinitis and respiratory infections.
- the inflammatory disorder of the circulatory system is selected from the group consisting of vasculitis, artherosclerosis, phlebitis, carditis and coronary heart disease.
- the inflammatory disorder of the gastrointestinal system treated by the compounds of the invention is selected from the group consisting of inflammatory bowel disorder, ulcerative colitis, Crohn's disease, diverticulitis, viral infection, bacterial infection, chronic hepatitis, gingivitis, stomatitis, and gastritis.
- the inflammatory disorder of the genitourinary system treated by the compounds of the invention is selected from the group consisting of cystitis, nephritic syndrome, glomerulonephritis, urinary tract infection, prostatitis, salpingitis, endometriosis and cystinosis.
- the neurological disorder treated by the compounds of the invention is selected from the group consisting of schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, stroke, cerebral ischemia, neuropathy, retinal pigment degeneration, glaucoma, cardiac arrhythmia, shingles, Huntington's chorea, and Parkinson's disease.
- the invention provides a method of treating pain in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the invention.
- the pain is selected from the group consisting of cutaneous pain, somatic pain, visceral pain and neuropathic pain.
- the pain is acute pain, breakthrough pain or chronic pain.
- the invention provides a method of treating an inflammatory disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the invention.
- the inflammatory disorder is inflammatory disorder of the musculoskeletal and connective tissue system, the respiratory system, the circulatory system, the genitourinary system, the gastrointestinal system or the nervous system.
- the invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering an effective amount of a compound of the invention.
- the neurological disorder is selected from the group consisting of schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, stroke, cerebral ischemia, neuropathy, retinal pigment degeneration, glaucoma, cardiac arrhythmia, Huntington's chorea, and Parkinson's disease.
- the invention provides a method of treating a disease or disorder associated with the genitourinary and/or gastrointestinal systems of a subject in need thereof, comprising administering to the subject an effective amount of a compound of the invention.
- the disease or disorder of the gastrointestinal system is selected from the group consisting of gastritis, duodenitis, irritable bowel syndrome, colitis, Crohn's disease, ulcers and diverticulitis.
- the disease or disorder of the genitourinary system is selected from the group consisting of cystitis, urinary tract infections, glomuerulonephritis, polycystic kidney disease, kidney stones and cancers of the genitourinary system.
- the invention provides a method comprising administering to the subject an additional therapeutic agent.
- the additional therapeutic agent is selected from the group consisting of an analgesic, an anti-inflammatory agent, an anesthetic, a corticosteroid, an anti-convulsant, an antidepressant, an anti-nausea/anti-emetic agent, an anti-psychiatric agent, a cardiovascular agent and a cancer therapeutic.
- FIG. 1 shows a typical Western blot with immunodetection of phosphorylated Erk 1/2 proteins extracted from NGF-stimulated PC12 cells in the presence or absence of Compound 90, as described in Example 3. These results demonstrate that Compound 90 inhibits NGF (5 ng/mL)-induced Erk 1/2 phosphorylation in PC12 cells.
- FIG. 2A shows a dose-response curve for Compound 90 from an individual NGF binding displacement experiment in PC 12 cells as described in Example 1.
- the dose-response curve demonstrates that Compound 90 effectively blocks NGF binding to cells expressing TrkA and p75.
- FIG. 2B shows a dose-response curve for Compound 90 from an individual NGF binding displacement experiment in A875 cells as described in Example 1.
- the dose-response curve demonstrates that Compound 90 effectively blocks NGF binding to cells expressing p75.
- FIG. 3A shows a binding displacement curve for Compound 90 from an individual NGF binding displacement experiment in HEK_trk cells as described in Example 1.
- the dose-response curve demonstrates that Compound 90 effectively blocks NGF binding to cells expressing TrkA.
- FIG. 3B shows a neurite outgrowth inhibition curve for Compound 90 resulting from an experiment as described in Example 4. The curve demonstrates that Compound 90 effectively inhibits neurite outgrowth induced by NGF.
- FIG. 4A shows a dose-response curve for Compound 91 from an individual NGF binding displacement experiment in PC12 cells as described in Example 1.
- the dose-response curve demonstrates that Compound 91 effectively blocks NGF binding to cells expressing TrkA and p75.
- FIG. 4B shows a typical Western blot with immunodetection of phosphorylated Erk 1/2 proteins extracted from NGF-stimulated PC12 cells in the presence or absence of Compound 91, as described in Example 3. These results demonstrate that Compound 91 inhibits NGF-induced Erk 1/2 phosphorylation in PC12 cells.
- FIG. 5 shows a dose-response curve for Compound 18 from an individual NGF binding displacement experiment in PC12 cells as described in Example 1.
- the dose-response curve demonstrates that Compound 18 effectively blocks NGF binding to cells expressing TrkA and p75.
- FIG. 6 shows a phospho-Erk 1/2 blot for Compound 90 as acquired using the procedure in Example 3, which demonstrates that Compound 90 inhibits NGF (1 ng/mL)-induced Erk 1/2 phosphorylation in PC12 cells.
- FIG. 7 illustrates the significant antinociceptive effects of Compound 91 in the Writhing Test in mice, as described in Example 6.
- the present invention relates to the discovery of compounds which modulate the interaction of a neurotrophin—either in its mature (e.g., NGF) or precursor (e.g., proNGF) form—with a neurotrophin receptor, for example, the common neurotrophin receptor p75 NTR and/or a Trk receptor.
- a neurotrophin either in its mature (e.g., NGF) or precursor (e.g., proNGF) form—with a neurotrophin receptor, for example, the common neurotrophin receptor p75 NTR and/or a Trk receptor.
- a neurotrophin receptor for example, the common neurotrophin receptor p75 NTR and/or a Trk receptor.
- Such compounds are of use, for example, for modulating the interaction of NGF and/or a precursor thereof (e.g., proNGF) to p75 NTR , and the compounds within the invention can also have the ability to modulate the interaction of NGF and/or proNGF with TrkA.
- a compound that modulates the binding of NGF or proNGF to p75 NTR can further modulate the binding of the neurotrophin to TrkA.
- Such compounds can also be used to treat a subject having a condition with at least one symptom that is directly or indirectly mediated, at least in part, by the interaction of NGF and/or a precursor thereof with p75 NTR and/or TrkA.
- Nerve growth factor (also referred to hereinafter as “NGF”) is a prototypic neurotrophin, and is best known for its essential role during development of peripheral sensory and sympathetic neurons.
- NGF is produced as a high-molecular weight precursor (pro-NGF) that contains a pro-domain linked to the N-terminus which is cleaved by the endoprotease furin in the trans-Golgi network of neurons (Mowla et al., J. Biol. Chem. 276:12660-12666, 2001; Mowla et al., J. Neurosci. 19:2069-2080, 1999).
- Pro-NGF has been shown to be induced and secreted after injury to the CNS in an active form that is capable of triggering cell apoptosis (e.g., of neuronal cells and oligodendrocytes), and disruption of the interaction of pro-NGF and p75 NTR has been demonstrated to rescue injured adult rat corticospinal neurons (e.g., Harrington et al., PNAS USA 101(16):6226-6230, 2004).
- apoptosis e.g., of neuronal cells and oligodendrocytes
- phenotype e.g., cell body and dendrite size, gene expression and neurotransmitter phenotype
- NGF has been implicated in the pathogenesis of Alzheimer's disease, epilepsy and pain (Ben Ari and Represa, TINS 13:312-318 (1990); McKee et al., Ann. Neurol. 30:156 (1991); Leven and Mendel, TINS 16:353-359 (1993); Woolf and Doubell, Current Opinions in Neurobiol. 4:525-534 (1994); Rashid et al., Proc. Natl. Acad. Sci. U.S.A. 92:9495-9499 (1995); McMahon et al., Nature Med. 1:774-780 (1995)).
- the interaction of NGF with its receptors is determined by distinct sequences within its primary amino acid structure. While several regions of NGF participate in the NGF/TrkA interaction, mutation studies suggest that relatively few key residues, namely those located in the NGF amino and carboxyl termini, are primarily required for high affinity binding to TrkA.
- NGF may play a role in inflammation and disorders of the respiratory, genitourinary and gastrointestinal systems.
- neurotrophins and neurotrophic factors regulate neuropeptide expression, interact with immunoregulatory cells and epithelial cells, and regulate motility during inflammation (Reinshagen, M. et al., Curr. Opin. Investig. Drugs. 2002; 3(4): 565-568).
- NGF has been shown to be a potentially relevant treatment target for bladder overactivity (Lamb, K. et al., J. Pain. 2004; 5(3): 150-156). Studies by Kim et al.
- NGF neuroprotective factor
- enteric nervous system has been demonstrated, as has its role in the mechanism by which intestinal inflammation can give rise to a permanent imbalance between excitatory and inhibitory pathways, thus tending to compromise intestinal function (Maruccio, L. et al. Histol. Histopathol. 2004; 19(2):349-356; Lin, A.
- NGF has also been shown to play an important role in the development of the rat ovary (Romero, C. et al., 2002; 143(4):1485-1494). Data has further suggested that NGF may play a role in inflammation, bronchial hyperresponsiveness and airway remodeling in asthma, and may help us to understand the neuro-immune cross-talk involved in chronic inflammatory airway diseases (Frossard, N. et al., Eur. J. Pharmacol. 2004; 500(1-3): 453-465).
- NGF in vivo is largely in the mature form of NGF, and that mature NGF accounts for the molecule's biological activity.
- proNGF is abundant in central nervous system tissues whereas mature NGF is undetectable, suggesting that proNGF may have a function distinct from its role as a precursor.
- this data suggests that proNGF may be responsible for some of the biological activity normally attributed to mature NGF in vivo (Fahnestock, M. et al., J. Neurochem. 2004; 89(3):581-592; Fahnestock, M. et al., Prog. Brain Res. 2004; 146: 107-110).
- proNGF levels increase during the preclinical stage of Alzheimer's disease (Peng, S. et al., J. Neuropathol. Exp. Neurol. June 2004; 63(6):641-9). Additionally, studies by Beattie et al. (Neuron Oct. 24, 2002; 36(3): 275-386) have shown that proNGF plays an important role in eliminating damaged cells by activating the apoptotic machinery via p75 NTR after spinal cord injury.
- compositions which modulate the interaction of nerve growth factor, and precursors thereof, with the receptor TrkA, as well as the common neurotrophin receptor p75 NTR are provided.
- electronegative atom refers to an atom which carries a partial or full negative charge in a particular compound under physiological conditions.
- the electronegative atom can be, for example, an oxygen atom, a nitrogen atom, a sulfur atom or a halogen atom, such as a fluorine, chlorine, bromine or iodine atom.
- the electronegative atom is an oxygen atom.
- electronegative functional group refers to a functional group which includes at least one electronegative atom. Electronegative groups include acid functional groups and other polar functional groups.
- suitable electronegative functional groups include, but are not limited to, carbonyl, thiocarbonyl, ester, imino, amido, amine, carboxylic acid, sulfonic acid, sulfinic acid, sulfamic acid, phosphonic acid, boronic acid, sulfate ester, hydroxyl, mercapto, cyano, cyanate, thiocyanate, isocyanate, isothiocyanate, carbonate, nitrate and nitro groups. It is to be understood that, unless otherwise indicated, reference herein to an acidic functional group also encompasses salts of that functional group in combination with a suitable cation.
- the term “acid” refers to any substituent that can readily donate a hydrogen ion to another compound.
- Particularly preferred acid functional groups include carboxylic acid, sulfonic acid, sulfinic acid, sulfamic acid, phosphonic acid and boronic acid functional groups.
- alkyl includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
- straight-chain alkyl groups e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl,
- alkyl also includes alkenyl groups and alkynyl groups.
- C x -C y -alkyl indicates a particular alkyl group (straight- or branched-chain) of a particular range of carbons.
- C 1 -C 4 -alkyl includes, but is not limited to, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl and isobutyl.
- alkyl further includes alkyl groups which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
- a straight chain or branched chain alkyl has 10 or fewer carbon atoms in its backbone (e.g., C 1 -C 10 for straight chain, C 3 -C 10 for branched chain), and more preferably 6 or fewer carbons.
- preferred cycloalkyls have from 4-7 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
- alkyl e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, etc.
- alkyl include both “unsubstituted alkyl” and “substituted alkyl”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, which allow the molecule to perform its intended function.
- substituted is intended to describe moieties having substituents replacing a hydrogen on one or more atoms, e.g. C, O or N, of a molecule.
- substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, al
- substituents of the invention include moieties selected from straight or branched alkyl (preferably C 1 -C 5 ), cycloalkyl (preferably C 3 -C 8 ), alkoxy (preferably C 1 -C 6 ), thioalkyl (preferably C 1 -C 6 ), alkenyl (preferably C 2 -C 6 ), alkynyl (preferably C 2 -C 6 ), heterocyclic, carbocyclic, aryl (e.g., phenyl), aryloxy (e.g., phenoxy), aralkyl (e.g., benzyl), aryloxyalkyl (e.g., phenyloxyalkyl), arylacetamidoyl, alkylaryl, heteroaralkyl, alkylcarbonyl and arylcarbonyl or other such acyl group, heteroarylcarbonyl, or heteroaryl group, (CR′R′′)
- substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, oxime, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro,
- a carbonyl moiety may be further derivatized with an oxime moiety, e.g., an aldehyde moiety may be derivatized as its oxime (—C ⁇ N—OH) analog.
- an oxime moiety e.g., an aldehyde moiety may be derivatized as its oxime (—C ⁇ N—OH) analog.
- Cycloalkyls can be further substituted, e.g., with the substituents described above.
- An “aralkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (i.e., benzyl)).
- alkenyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one double bond.
- alkenyl includes straight-chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups.
- alkenyl includes straight-chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, de
- alkenyl further includes alkenyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
- a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
- cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
- C 2 -C 6 includes alkenyl groups containing 2 to 6 carbon atoms.
- alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
- substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
- alkynyl includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
- alkynyl includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups.
- alkynyl further includes alkynyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone.
- a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C 2 -C 6 for straight chain, C 3 -C 6 for branched chain).
- the term C 2 -C 6 includes alkynyl groups containing 2 to 6 carbon atoms.
- alkynyl includes both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
- substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,
- amine or “amino” should be understood as being broadly applied to both a molecule, or a moiety or functional group, as generally understood in the art, and may be primary, secondary, or tertiary.
- amine or “amino” includes compounds where a nitrogen atom is covalently bonded to at least one carbon, hydrogen or heteroatom.
- alkyl amino comprises groups and compounds wherein the nitrogen is bound to at least one additional alkyl group.
- dialkyl amino includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups.
- arylamino and diarylamino include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively.
- alkylarylamino refers to an amino group which is bound to at least one alkyl group and at least one aryl group.
- alkaminoalkyl refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
- amide includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group.
- the term includes “alkaminocarbonyl” or “alkylaminocarbonyl” groups which include alkyl, alkenyl, aryl or alkynyl groups bound to an amino group bound to a carbonyl group. It includes arylaminocarbonyl and arylcarbonylamino groups which include aryl or heteroaryl moieties bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group.
- alkylaminocarbonyl “alkenylaminocarbonyl,” “alkynylaminocarbonyl,” “arylaminocarbonyl,” “alkylcarbonylamino,” “alkenylcarbonylamino,” “alkynylcarbonylamino,” and “arylcarbonylamino” are included in term “amide.” Amides also include urea groups (aminocarbonylamino) and carbamates (oxycarbonylamino).
- the term “amine” or “amino” refers to substituents fo the formulas N(R 8 )R 9 , CH 2 N(R 8 )R 9 and CH(CH 3 )N(R 8 )R 9 , wherein R 8 and R 9 are each, independently, selected from the group consisting of —H and —(C 1-4 alkyl) 0-1 G, wherein G is selected from the group consisting of —COOH, —H, —PO 3 H, —SO 3 H, —Br, —Cl, —F, —O—C 1-4 alkyl, —S—C 1-4 alkyl, aryl, —C(O)OC 1 -C 6 -alkyl, —C(O)C 1-4 alkyl-COOH, —C(O)C 1 -C 4 -alkyl and —C(O)-aryl;
- N(R 8 )R 9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidinyl-2-one, dimethylpyrrolyl, imidazolyl, morpholino or
- aryl includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
- aryl includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, anthryl, phenanthryl, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine.
- multicyclic aryl groups e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, anthryl, phenanthryl, napthridine, indole, benzofuran, purine,
- aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles”, “heterocycles,” “heteroaryls” or “heteroaromatics.”
- the aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, alkyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino,
- the structures of some of the compounds of this invention include asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof. Compounds described herein may be obtained through art recognized synthesis strategies.
- any combination thereof implies that any number of the listed functional groups and molecules may be combined to create a larger molecular architecture.
- the terms “phenyl,” “carbonyl” (or “ ⁇ O”), “—O—,” “—OH,” and C 1-6 i.e., —CH 3 and —CH 2 CH 2 CH 2 —) can be combined to form a 3-methoxy-4-propoxybenzoic acid substituent; or the terms “acid” (i.e., —COOH) and C 1-6 (i.e., —CH 2 CH 3 ) can be combined to form an ethyl ester substituent.
- hydrogens can be removed or added, as required to satisfy the valence of each atom.
- salts refers to salts of the invention prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids and organic acids.
- suitable non-toxic acids include inorganic and organic acids such as acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic and the like.
- Particularly preferred salts are sodium, lysine and argentine salts of the compounds of the invention.
- neurotrophic factor or “neurotrophin” (also referred to herein as “NT”) refers to members of a family of proteins, usually in the form of dimers, which are structurally homologous to NGF.
- the term includes the precursors (pro-neurotrophins, e.g., pro-NGF) and the mature proteins which include three surface 3-hairpin loops, a p-strand, an internal reverse turn region, and N- and C-termini.
- Neurotrophins promote at least one of the biological activities related to vertebrate neuron survival, differentiation, and function, as determined using assays described, for example, in US 2002/0169182A1 and Riopelle et al., Can J. of Phys.
- Neurotrophic factors include, for example, brain-derived neurotrophic factor (BDNF), NGF, neurotrophin 3 (NT-3), neurotrophin 4/5 (NT-4/5), and neurotrophin 6 (NT-6) (R. M. Lindsay et al.: TINS, vol. 17, p. 182 (1994) and R. M. Lindsay: Phil. Trans. R. Soc. Lond. B. vol. 351, p. 365-373 (1996)).
- BDNF brain-derived neurotrophic factor
- NGF neurotrophin 3
- NT-4/5 neurotrophin 4/5
- NT-6 neurotrophin 6
- ciliary neurotrophic factor CNTF
- GDNF glia-derived neurotrophic factor
- GGF2 glia growth factor
- AF-1 central nerve growth factor
- HGF hepatocyte growth factor
- biotechnologically engineered products of the above neurotrophic factors which are derived by a partial substitution, an addition, a deletion or a removal by conventional genetic engineering techniques, are also included within the scope of the neurotrophic factors of the present invention as far as such product shows biological activities of the naturally-occurred neurotrophic factors.
- neurotrophin receptor As used herein, the term “neurotrophin receptor” (also referred to herein as “NTR”) is meant to refer to a receptor which binds a neurotrophin.
- the neurotrophin receptor is a member of the tyrosine kinase family of receptors, generally referred to as the “Trk” receptors or “Trks”, which are expressed on cellular surfaces.
- the Trk family includes, but is not limited to, TrkA, TrkB, and TrkC.
- the neurotrophin receptor is TrkA.
- the neurotrophin receptor is p75 NTR , also called p75 or low-affinity nerve growth factor receptor or common neurtotrophin receptor.
- These receptors may be from any animal species that expresses neurotrophin receptors (e.g. human, murine, rabbit, porcine, equine, etc.), and include full length receptors, their truncated and variant forms, such as those arising by alternate splicing and/or insertion, and naturally-occurring allelic variants, as well as functional derivatives of such receptors.
- neurotrophin receptors e.g. human, murine, rabbit, porcine, equine, etc.
- full length receptors such as those arising by alternate splicing and/or insertion, and naturally-occurring allelic variants, as well as functional derivatives of such receptors.
- Neurotrophin-mediated activity is a biological activity that is normally modulated (e.g., inhibited or promoted), either directly or indirectly, in the presence of a neurotrophin.
- Neurotrophin-mediated activities include, for example, neurotrophin binding to the p75 NTR receptor or neurotrophin binding to one of the Trk receptors (e.g., TrkA), the ability to promote neurotrophin receptor dimerization and/or phosphorylation, neuron survival, neuron differentiation including neuron process formation and neurite outgrowth, neurotransmission and biochemical changes such as enzyme induction.
- a biological activity that is mediated by a particular neurotrophin, e.g. NGF or pro-NGF, is referred to herein by reference to that neurotrophin, e.g.
- NGF-mediated activity also includes “proNGF-mediated activity.”
- a receptor binding assay such as the assay described in US 2002/0169182 A1
- Inhibition of neurite survival and outgrowth can be determined using the in vitro assay described by Riopelle et al. in the Can. J. of Phys. and Pharm., 1982, 60: 707.
- Other examples of in vitro and in vivo assays for use in determining the ability of a compound to inhibit a neurotrophin-mediated activity are described in the “Exemplification of the Invention” section of the application.
- Neurotransmission is a process by which small signaling molecules, termed neurotransmitters, are rapidly passed in a regulated fashion from a neuron to another cell.
- a neurotransmitter is secreted from the presynaptic neuronal terminal.
- the neurotransmitter then diffuses across the synaptic cleft to act on specific receptors on the postsynaptic cell, which is most often a neuron but can also be another cell type (such as muscle fibers at the neuromuscular junction).
- the action of neurotransmitters can either be excitatory, depolarizing the postsynaptic cell, or inhibitory, resulting in hyperpolarization.
- Neurotransmission can be rapidly increased or decreased by neuromodulators, which typically act either pre-synaptically or post-synaptically.
- the neurotrophin family (notably NGF and BDNF) have been shown to have prominent neuromodulatory effects on diverse neuronal types (Lohof et al, Nature. 363(6427):350-3 (1993); Li et al. J Neurosci. 18(24):10231-40. (1998)).
- BDNF has also been shown to behave like a neurotransmitter, acting directly on target cells to alter their excitability by rapidly and directly gating ion certain ion channels (Rose et al., Bioessays. 26(11):1185-94. (2004)).
- neurotransmission can be studied.
- the release of neurotransmitters from cultured neurons can be directly quantified using HPLC, radiolabled neurotransmitters or other methodologies.
- Neurotransmission can be estimated by dyes such as FM 1-43, a fluorescent marker of synaptic vesicle cycling.
- neurotransmission between neurons can be directly monitored using standard electrophysiological techniques, as can any direct neurotransmitter-like effects of neurotrophins on ion channel currents.
- neurotrophins such as BDNF and NGF
- contacting refers to bringing a compound of the invention and a target, e.g., NGF, p75 NTR and/or TrkA together in such a manner that the compound can affect the activity of the target, either directly; i.e., by interacting with the target itself, or indirectly; i.e., by interacting with another target on which the catalytic activity of the target is dependent.
- a compound of the invention may effect the activity of TrkA by contacting (e.g., binding to) TrkA directly, or by contacting (e.g., binding to) p75 NTR , which may effect the activity of TrkA.
- Such “contacting”” can be accomplished “in vitro,” i.e., in a test tube, a petri dish or the like, or “in vivo,” i.e., administered to a subject such as a mouse, rat or human.
- contacting may involve only a compound and a target of interest or it may involve whole cells. Cells may also be maintained or grown in cell culture dishes and contacted with a compound in that environment.
- Contacting can refer to a compound of the invention directly binding to a target, or being in the vicinity of a target.
- neurotrophin-mediated activities include, but are not limited to, pain (e.g., inflammatory pain, acute pain, chronic malignant pain, chronic nonmalignant pain and neuropathic pain), inflammatory disorders, diseases and disorders of the genitourinary and gastrointestinal systems, and neurological disorders (e.g., neurodegenerative or neuropsychiatric disorders).
- Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage (International Association for the Study of Pain—IASP). Pain is classified most often based on duration (i.e., acute vs. chronic pain) and/or the underlying pathophysiology (i.e., nociceptive vs. neuropathic pain).
- Acute pain can be described as an unpleasant experience with emotional and cognitive, as well as sensory, features that occur in response to tissue trauma and disease and serves as a defensive mechanism.
- Acute pain is usually accompanied by a pathology (e.g., trauma, surgery, labor, medical procedures, acute disease states) and the pain resolves with healing of the underlying injury.
- Acute pain is mainly nociceptive, but may also be neuropathic.
- Chronic pain is pain that extends beyond the period of healing, with levels of identified pathology that often are low and insufficient to explain the presence, intensity and/or extent of the pain (American Pain Society—APS). Unlike acute pain, chronic pain serves no adaptive purpose. Chronic pain may be nociceptive, neuropathic, or both and caused by injury (e.g., trauma or surgery), malignant conditions, or a variety of chronic conditions (e.g., arthritis, fibromyalgia and neuropathy). In some cases, chronic pain exists de novo with no apparent cause.
- Nociceptive pain is pain that results from damage to tissues and organs. Nociceptive pain is caused by the ongoing activation of pain receptors in either the surperficial or deep tissues of the body. Nociceptive pain is further characterized as “somatic pain”, including “cutaneous pain” and “deep somatic pain”, and “visceral pain”.
- Somatic pain includes “cutaneous pain” and “deep somatic pain.” Cutaneous pain is caused by injury, diseases, disorders or neoplasms of the skin, subcutaneous tissues and related organs. Examples of conditions associated with cutaneous pain include, but are not limited to, cuts, burns, infections, lacerations, as well as traumatic injury and post-operative or surgical pain (e.g., at the site of incision).
- Deep somatic pain results from injuries, diseases, disorders or neoplasms of the musculoskeletal tissues, including ligaments, tendons, bones, blood vessels and connective tissues.
- Examples of deep somatic pain or conditions associated with deep somatic pain include, but are not limited to, sprains, broken bones, arthralgia, vasculitis, myalgia and myofascial pain.
- Arthralgia refers to pain caused by a joint that has been injured (such as a contusion, break or dislocation) and/or inflamed (e.g., arthritis).
- Vaculitis refers to inflammation of blood vessels with pain.
- Myalgia refers to pain originating from the muscles.
- Myofascial pain refers to pain stemming from injury or inflammation of the fascia and/or muscles.
- Visceral pain is associated with injury, inflammation, disease or neoplasms of the body organs and internal cavities, including but not limited to, the circulatory system, respiratory system, gastrointestinal system, genitourinary system, immune system, as well as the ear, nose and throat. Visceral pain can also be associated with infectious and parasitic diseases that affect the body organs and tissues. Visceral pain is extremely difficult to localize, and several injuries to visceral tissue exhibit “referred” pain, where the sensation is localized to an area completely unrelated to the site of injury.
- myocardial ischaemia (the loss of blood flow to a part of the heart muscle tissue) is possibly the best known example of referred pain; the sensation can occur in the upper chest as a restricted feeling, or as an ache in the left shoulder, arm or even hand.
- Phantom limb pain is the sensation of pain from a limb that one no longer has or no longer gets physical signals from—an experience almost universally reported by amputees and quadriplegics.
- Neuroneuropathic pain or “neurogenic pain” is pain initiated or caused by a primary lesion, dysfunction or perturbation in the nervous system. “Neuropathic pain” can occur as a result of trauma, inflammation, disease or neoplasms of the peripheral nervous system (“peripheral neuropathic pain”) and/or the central nervous system (“central pain”). For example, neuropathic pain can be caused by a nerve or nerves that are irritated, trapped, pinched, severed or inflamed (neuritis).
- neuropathic pain syndromes such as diabetic neuropathy, trigeminal neuralgia, postherpetic neuralgia (“shingles”), post-stroke pain, and complex regional pain syndromes (also called reflex sympathetic dystrophy or “RSD” and causalgia).
- shingles postherpetic neuralgia
- RSD reflex sympathetic dystrophy
- inflammatory disease or disorder includes diseases or disorders which are caused, at least in part, or exacerbated by, inflammation, which is generally characterized by increased blood flow, edema, activation of immune cells (e.g., proliferation, cytokine production, or enhanced phagocytosis), heat, redness, swelling, pain and loss of function in the affected tissue and organ.
- the cause of inflammation may be due to physical damage, chemical substances, micro-organisms, tissue necrosis, cancer or other agents.
- Inflammatory disorders include acute inflammatory disorders, chronic inflammatory disorders, and recurrent inflammatory disorders. Acute inflammatory disorders are generally of relatively short duration, and last for from about a few minutes to about one to two days, although they may last several weeks.
- the main characteristics of acute inflammatory disorders include increased blood flow, exudation of fluid and plasma proteins (edema) and emigration of leukocytes, such as neutrophils.
- Chronic inflammatory disorders generally, are of longer duration, e.g., weeks to months to years or longer, and are associated histologically with the presence of lymphocytes and macrophages and with proliferation of blood vessels and connective tissue.
- Recurrent inflammatory disorders include disorders which recur after a period of time or which have periodic episodes. Some disorders may fall within one or more categories.
- Neurological disorder and neurodegenerative disorders refer to injuries, diseases and dysfunctions of the nervous system, including the peripheral nervous system and central nervous system.
- Neurological disorders and neurodegenerative disorders include, but are not limited to, diseases and disorders that are associated with neurotrophin-mediated biological activity.
- Examples of neurological disorders include, but are not limited to, Alzheimer's disease, epilepsy, cancer, neuromuscular diseases, multiple sclerosis, amyotrophic lateral sclerosis, stroke, cerebral ischemia, neuropathy (e.g., chemotherapy-induced neuropathy, diabetic neuropathy), retinal pigment degeneration, Huntington's chorea, and Parkinson's disease, and ataxia-telangiectasia.
- neuroopathy is defined as a failure of the nerves that carry information to and from the brain and spinal cord resulting in one or more of pain, loss of sensation, and inability to control muscles. In some cases, the failure of nerves that control blood vessels, intestines, and other organs results in abnormal blood pressure, digestion problems, and loss of other basic body processes. Peripheral neuropathy may involve damage to a single nerve or nerve group (mononeuropathy) or may affect multiple nerves (polyneuropathy).
- treatment includes the diminishment or alleviation of at least one symptom associated with the pain, inflammatory disorder, neurological disorder, genitourinary disorder or gastrointestinal disorder (e.g., associated with or caused by neurotrophin mediated activity) being treated.
- the treatment comprises the modulation of the interaction of a neurotrophin (e.g., monomer or dimer) and its receptor by an NT/NTR modulating compound, for example an NGF/NTR modulating compound, which would in turn diminish or alleviate at least one symptom directly or indirectly associated with or caused by the neurotrophin-mediated activity being treated.
- treatment can be diminishment of one or several symptoms of a disorder or complete eradication of a disorder.
- the phrase “therapeutically effective amount” of the compound is the amount necessary or sufficient to treat or prevent pain, an inflammatory disorder, a neurological disorder, a gastrointestinal disorder or a genitourinary disorder, (e.g., to prevent the various morphological and somatic symptoms of a neurotrophin-mediated activity).
- an effective amount of the compound is the amount sufficient to alleviate at least one symptom of the disorder, e.g., pain, inflammation, a neurological disorder, a gastrointestinal disorder or a genitourinary disorder, in a subject.
- subject is intended to include animals, which are capable of suffering from or afflicted with a neurotrophin-associated state or neurotrophin-associated disorder, or any disorder involving, directly or indirectly, neurotrophin signaling.
- a subject is also intended to include animals, which are capable of suffering from pain, an inflammatory disorder, a neurological disorder, a respiratory disorder, a gastrointestinal disorder or a genitourinary disorder.
- subjects include mammals, e.g., humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals.
- the subject is a human, e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from pain, inflammation, a neurological disorder, a gastrointestinal disorder or a genitourinary disorder (e.g. associated with neurotrophin-associated activity).
- a human e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from pain, inflammation, a neurological disorder, a gastrointestinal disorder or a genitourinary disorder (e.g. associated with neurotrophin-associated activity).
- NGF/NTR modulator refers to compounds that modulate, i.e., inhibit, promote or otherwise alter the interaction of a neurotrophin with a neurotrophin receptor.
- NGF/NTR modulator refers to compounds that modulate, e.g., inhibit, promote, or otherwise alter, the interaction of NGF (or proNGF) with p75 NTR , TrkA, or p75 NTR and TrkA.
- Examples of NGF/NTR modulators include compounds of Formulas 16, 17, 18, 19, 20, 21 and 22, including salts thereof, e.g., a pharmaceutically acceptable salt.
- NGF/NTR modulators include compounds of Table 1, or derivatives and fragments thereof, including salts thereof, e.g., a pharmaceutically acceptable salt.
- Compounds of Formulas 16, 17, 18, 19, 20, 21 and 22, as well as the compounds of Table 1, i.e., the NT/NTR modulators or NGF/NTR modulators of the invention, are also referred to herein as “compounds of the invention.”
- the NGF/NTR modulators of the invention, including the compounds of Table 1 can be used to treat a disease or disorder associated with pain, inflammation, neurological disorders, respiratory disorders, gastrointestinal disorders or genitourinary disorders in a subject in need thereof.
- the compounds of the invention, including the compounds of Table 1 can be used to treat an inflammatory disorder in a subject in need thereof.
- the present invention provides compounds which modulate the interaction of a neurotrophin with a neurotrophin receptor.
- the compounds modulate the interaction of nerve growth factor (NGF) and/or a precursor thereof with a neurotrophin receptor (NTR).
- NGF nerve growth factor
- NTR neurotrophin receptor
- the compound modulates the interaction of NGF and/or a precursor thereof with the p75 NTR receptor.
- the compound also modulates the interaction of NGF (or proNGF) with the TrkA receptor.
- the compound modulates the interaction of NGF (or proNGF) with both the p75 NTR and TrkA receptor.
- the compounds of the invention treat pain, inflammatory disorders, neurological disorders, respiratory disorders, gastrointestinal disorders or genitourinary disorders in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the invention.
- an electronegative atom of the compound of the invention bears a full or partial negative charge under physiological conditions and can, therefore, interact electrostatically with the positively charged side chain of an NGF lysine residue.
- an interaction such as, for example, a hydrogen bond, an ion/ion interaction, an ion/dipole interaction or a dipole/dipole interaction.
- the hydrophobic region or moiety of the NGF/NTR modulator can interact with a hydrophobic region of NGF via a hydrophobic interaction.
- the compound of the invention is of the general Formula 16, wherein R 1 , R 2 , R 3 , R 4 and R 5 are each, independently, selected from the group consisting of a hydrogen atom, —N(H)—, alkyl, alkoxy, amino, halogen, hydroxyl, acid, cyano, sulfonamide, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amide, ester, ether, thioether, alkene, furan, thiophene, thiazole, nitro, alkene, tetrazole, sulfone, urea, thiourea, morpholine, piperidine, piperazine, azepane, and any combination thereof; or a pharmaceutical
- R 1 , R 1a , R 2 , R 3 , R 4 and R 5 are each, independently, selected from the group consisting of hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, hydroxyl, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -alkene, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
- alkyl, C 1-6 -alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, hydroxyl, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -alkene, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazin
- R 2 , R 3 , R 4 and R 5 are each, independently, selected from the group consisting of hydrogen, C 1 -C 6 -alkyl, halogen, NO 2 , COOH, and N(R 8 )R 9 , wherein R 8 and R 9 are each, independently, selected from the group consisting of —H and —C 1-4 alkyl) 0-1 G, wherein G is selected from the group consisting of —COOH, —PO 3 H, —SO 3 H, —Br, —Cl, —F, —OC 1-4 alkyl, —SC 1-4 alkyl, aryl, C 1 -C 6 -alkyl, —C(O)OC 1 -C 6 -alkyl, —C(O)C 1 -C 4 -alkyl and —C(O)-aryl.
- R 2 , R 3 , R 4 and R 5 are hydrogen, and R 1 and R 1a are (CH 2 ) x R 13 , wherein R 13 is selected from the group consisting of hydrogen, C 1-6 -alkyl, amino, C 1-6 -alkoxy, —OH, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and x is 0, 1, 2, 3 or 4.
- R 13 is selected from the group consisting of —COOH, imidazolyl, —SO 3 H, —OSO 3 H, —OH, morpholino, piperazinyl, —PO 3 H, —PO 3 C 1-4 alkyl and —NO 2 .
- R 13 is selected from the group consisting of —COOH and —COO ⁇ Na + .
- x is 3 and R 13 is COOH.
- R 13 is C(O)N(R 8 )R 9 or N(R 8 )R 9 , wherein R 8 and R 9 are each, independently, selected from the group consisting of —H and —C 1-4 alkyl) 0-1 G, wherein G is selected from the group consisting of —COOH, —H, —PO 3 H, —SO 3 H, —Br, —Cl, —F, —OC 1-4 alkyl, —SC 1-4 alkyl, aryl, —C(O)OC 1 -C 6 -alkyl, —C(O)C 1-4 alkyl-COOH, —C(O)C 1 -C 4 -alkyl and —C(O)-aryl; or N(R 8 )
- R 13 is NH 2 or N(CH 3 ) 2 .
- R 2 , R 3 , R 4 and R 5 are hydrogen, and R 1 and R 1a are: wherein
- R 6 , R 7 and R 12 are each, independently, selected from the group consisting of hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
- R 6 and R 7 are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C 1 -C 4 -alkyl, —NH 2 , —N(H)C(O)C 1-4 alkyl, methoxy, morpholino, piperazinyl and C 1 -C 4 -alkyl-ester; and R 12 is hydrogen.
- R 6 and R 7 are each, independently, selected from the group consisting of hydrogen, SO 3 H, chloro, fluoro, —OH, —COOH, and —COO ⁇ Na + ; and R 12 is hydrogen.
- R 6 and R 12 are hydrogen, and R 7 is —COOH; or R 6 is chloro, R 12 is hydrogen, and R 7 is —COOH; or R 6 and R 12 are hydrogen, and R 7 is SO 3 H.
- R 2 , R 3 , R 4 and R 5 are hydrogen, R 1 is (CH 2 ) x R 13 , wherein
- R 13 is selected from the group consisting of hydrogen, C 1-6 -alkyl, amino, C 1-6 -alkoxy, —OH, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; x is 0, 1, 2, 3 or 4; and
- R 1a is: wherein
- R 6 , R 7 and R 12 are each, independently, selected from the group consisting of hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
- R 13 is C(O)N(R 8 )R 9 or N(R 8 )R 9 , wherein R 8 and R 9 are each, independently, selected from the group consisting of —H and —C 1-4 alkyl) 0-1 G, wherein G is selected from the group consisting of —COOH, —H, —PO 3 H, —SO 3 H, —Br, —Cl, —F, —OC 1-4 alkyl, —SC 1-4 alkyl, aryl, —C(O)OC 1 -C 6 -alkyl, —C(O)C 1-4 alkyl-COOH, —C(O)C 1 -C 4 -alkyl and —C(O)-aryl; or N(R 8 )R 9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morph
- R 2 , R 3 , R 4 and R 5 are hydrogen
- R 1 is (CH 2 ) x R 13 , wherein R 13 is selected from the group consisting of —COOH, imidazolyl, —SO 3 H, —OSO 3 H, —OH, morpholino, piperazinyl, —PO 3 H, —PO 3 C 1-4 alkyl and —NO 2 ;
- x 0, 1, 2, 3 or 4;
- R 6 and R 7 are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C 1 -C 4 -alkyl, —NH 2 , —N(H)C(O)C 1-4 alkyl, methoxy, morpholino, piperazinyl and C 1 -C 4 -alkyl-ester; and
- R 12 is hydrogen
- x is 3 and R 13 is COOH, R 6 and R 12 are hydrogen, and R 7 is —COOH; or R 6 is chloro, R 12 is hydrogen, and R 7 is —COOH; or R 6 and R 12 are hydrogen, and R 7 is SO 3 H.
- the compound of the invention is of the general Formula 17, wherein R 6 , R 7 , R 12 , R 6a , R 7a and R 12a are each, independently, selected from the group consisting of a hydrogen atom, —N(H)—, alkyl, alkoxy, amino, halogen, hydroxyl, acid, cyano, sulfonamide, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amide, ester, ether, thioether, alkene, furan, thiophene, thiazole, nitro, alkene, tetrazole, sulfone, urea, thiourea, morpholine, piperidine, piperazine, azepane, and any combination thereof or a pharmaceutically acceptable salt thereof.
- R 6 , R 6a , R 7 and R 7a are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C 1 -C 4 -alkyl, —NH 2 , —C(O)N(H)C 1-4 alkyl, methoxy, morpholino, piperazinyl and C 1 -C 4 -alkyl-ester; and R 12 and R 12a are hydrogen.
- R 6 and R 7 are each, independently, selected from the group consisting of hydrogen, chloro, fluoro, —OH, —COOH, and —COO ⁇ Na + ;
- R 12 is hydrogen;
- R 6a is selected from the group consisting of hydrogen, chloro, fluoro, —OH, —COOH, and —COO ⁇ Na + ; and
- R 7a and R 12a are hydrogen.
- R 6 is COOH
- R 7 is Cl
- R 6a is —H, NO 2 , OCH 3 , COOCH 3 or Cl
- R 7a , R 12 and R 12a are hydrogen.
- R 6 and R 6a are COOH
- R 7 , R 7a , R 12 and R 12a are hydrogen.
- the compound of the invention is of the general Formula 18,
- R 6a , R 7a and R 12a are each, independently, selected from the group consisting of hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, hydroxyl, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -alkene, furanyl, thiophenyl, thiazolyl, nitro, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl; and
- R 1 is (CH 2 ) x R 13 , wherein R 13 is selected from the group consisting of hydrogen, C 1-6 -alkyl, amino, C 1-6 -alkoxy, -OH, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and
- x 0, 1, 2, 3 or 4.
- R 13 is selected from the group consisting of —COOH, imidazolyl, —SO 3 H, —OSO 3 H, —OH, morpholino, piperazinyl, —PO 3 H, —PO 3 C 1-4 alkyl and —NO 2 .
- x is 3 and R 13 is COOH.
- R 13 is C(O)N(R 8 )R 9 or N(R 8 )R 9 , wherein R 8 and R 9 are each, independently, selected from the group consisting of —H and —(C 1-4 alkyl) 0-1 G, wherein G is selected from the group consisting of —COOH, —H, —PO 3 H, —SO 3 H, —Br, —Cl, —F, —OC 1-4 alkyl, —SC 1-4 alkyl, aryl, —C(O)OC 1-C 6 -alkyl, —C(O)C 1-4 alkyl-COOH, —C(O)C 1 -C 4 -alkyl and —C(O)-aryl; or N(R 8 )R 9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morph
- the compound of the invention is of the general Formula 19or20,
- R 6a , R 7a , R 8a and R 9a are each, independently, selected from the group consisting of hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, hydroxyl, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -alkene, furanyl, thiophenyl, thiazolyl, nitro, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
- R 6a and R 8a are hydrogen, and R 7a and R 9a are COONa; or R 6a , R 7a , R 8a and R 9a are hydrogen.
- the compound of the invention is of the general Formula 21,
- R 1 , R 8a , and R 9a are each, independently, selected from the group consisting of a hydrogen atom, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, hydroxyl, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -alkene, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
- alkyl, C 1-6 -alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, hydroxyl, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -alkene, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazin
- R 1 is (CH 2 ) x R 13 , wherein
- R 13 is selected from the group consisting of hydrogen, C 1-6 -alkyl, amino, C 1-6 -alkoxy, —OH, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and
- x 0, 1, 2, 3 or 4.
- R 13 is C(O)N(R 8 )R 9 or N(R 8 )R 9 , wherein R 8 and R 9 are each, independently, selected from the group consisting of —H and —C 1-4 alkyl) 0-1 G, wherein G is selected from the group consisting of —COOH, —H, —PO 3 H, —SO 3 H, —Br, —Cl, —F, —OC 1-4 alkyl, —SC 1-4 alkyl, aryl, —C(O)OC 1 -C 6 -alkyl, —C(O)C 1-4 alkyl-COOH, —C(O)C 1 -C 4 -alkyl and —C(O)-aryl;
- N(R 8 )R 9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morpholino.
- R 13 is NH 2 or N(CH 3 ) 2 .
- x is 3, R 13 is COOH, R 8a is H and R 9a is COOH.
- R 1 is wherein R 6 , R 7 and R 12 are each, independently, selected from the group consisting of hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazin
- R 6 and R 7 are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C 1 -C 4 -alkyl, —NH 2 , —N(H)C(O)C 1-4 alkyl, methoxy, morpholino, piperazinyl and C 1 -C 4 -alkyl-ester; and R 12 is hydrogen.
- R 6 is COOH
- R 7 is Cl
- R 12 is H
- R 8a is H
- R 9a is COOH.
- the compound of the invention is of the general Formula 22,
- R 1 , R 2 , R 3 , R 4 and R 5 are each, independently, selected from the group consisting of a hydrogen atom, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, hydroxyl, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -alkene, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
- alkyl, C 1-6 -alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, hydroxyl, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, O—C 1-6 -alkyl, S—C 1-6 -alkyl, C 1-6 -alkene, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazin
- R 2 , R 3 , R 4 and R 5 are hydrogen, and each R 1 is: (CH 2 ) x R 13 , wherein
- R 13 is selected from the group consisting of hydrogen, C 1-6 -alkyl, amino, C 1-6 -alkoxy, —OH, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and
- x 0, 1, 2, 3 or 4.
- R 13 is C(O)N(R 8 )R 9 or N(R 8 )R 9 , wherein R 8 and R 9 are each, independently, selected from the group consisting of —H and —(C 1-4 alkyl) 0-1 G, wherein G is selected from the group consisting of —COOH, —H, —PO 3 H, —SO 3 H, —Br, —Cl, —F, —OC 1-4 alkyl, —SC 1-4 alkyl, aryl, —C(O)OC 1 -C 6 -alkyl, —C(O)C 1-4 alkyl-COOH, —C(O)C 1 -C 4 -alkyl and —C(O)-aryl;
- N(R 8 )R 9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morpholino.
- R 13 is NH 2 or N(CH 3 ) 2 .
- R 13 is selected from the group consisting of —COOH, imidazolyl, —SO 3 H, —OSO 3 H, —OH, morpholino, piperazinyl, —PO 3 H, —PO 3 C 1-4 alkyl and —NO 2 .
- R 13 is selected from the group consisting of —COOH and —COO ⁇ Na + .
- x is 3 and R 13 is COOH.
- R 2 , R 3 , R 4 and R 5 are hydrogen, and each R 1 is: wherein
- R 6 , R 7 and R 12 are each, independently, selected from the group consisting of hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, amino, halogen, acid, cyano, C 1-6 -alkyl-sulfonamide, aryl, heteroaryl, C 3-6 -cycloalkyl, C 3-6 -heterocycloalkyl, C 1-6 -alkyl-amide, C 1-6 -alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C 1-6 -alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
- R 6 and R 7 are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C 1 -C 4 -alkyl, —NH 2 , —N(H)C(O)C 1-4 alkyl, methoxy, morpholino, piperazinyl and C 1 -C 4 -alkyl-ester; and R 12 is hydrogen.
- R 6 and R 7 are each, independently, selected from the group consisting of hydrogen, chloro, fluoro, —OH, —COOH, and —COO ⁇ Na + ; and R 12 is hydrogen.
- R 6 and R 12 are hydrogen, and R 7 is —COOH; or R 6 is Cl, R 12 is hydrogen, and R 7 is COOH.
- the NGF/NTR modulator of Formulas 16, 17, 18, 19, 20, 21 and 22 are any one of the compounds of Table 1 or derivatives and fragments thereof, including salts thereof, e.g., pharmaceutically acceptable salts.
- the invention pertains to the NGF/NTR modulators of Formulas 16, 17, 18, 19, 20, 21 and 22, including salts thereof, e.g., pharmaceutically acceptable salts.
- Particular embodiments of the invention pertain to the modulating compounds of Table 1 or derivatives thereof, including salts thereof, e.g., pharmaceutically acceptable salts.
- the invention pertains to pharmaceutical compositions comprising NT/NTR modulating compounds described herein and a pharmaceutical acceptable carrier.
- the invention includes any novel compound or pharmaceutical compositions containing compounds of the invention described herein.
- compounds and pharmaceutical compositions containing compounds set forth herein are part of this invention, including salts thereof, e.g., pharmaceutically acceptable salts.
- 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (Compound 90) is used to treat inflammation in a subject.
- the modulating compounds of the invention are capable of chemically interacting with NGF, p75 NTR , and/or TrkA.
- the language “chemical interaction” is intended to include, but is not limited to, reversible interactions such as hydrophobic/hydrophilic, ionic (e.g., coulombic attraction/repulsion, ion-dipole, charge-transfer), covalent bonding, Van der Waals, and hydrogen bonding.
- the chemical interaction is a reversible Michael addition.
- the Michael addition involves, at least in part, the formation of a covalent bond.
- Acid addition salts of the compounds of the invention are most suitably formed from pharmaceutically acceptable acids, and include for example those formed with inorganic acids, e.g., hydrochloric, sulphuric or phosphoric acids and organic acids e.g. succinic, maleic, acetic or fumaric acid.
- Other non-pharmaceutically acceptable salts e.g., oxalates, may be used for example in the isolation of the invention, and the compounds of Table 1 for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- solvates and hydrates of the invention are also included within the scope of the invention.
- aqueous solution of the given salt is treated with a solution of base, e.g., sodium carbonate or potassium hydroxide, to liberate the free base which is then extracted into an appropriate solvent, such as ether.
- base e.g., sodium carbonate or potassium hydroxide
- the free base is then separated from the aqueous portion, dried, and treated with the requisite acid to give the desired salt.
- Particularly preferred salts are sodium, lysine and argentine salts of the compounds of the invention.
- In vivo hydrolyzable esters or amides of certain compounds of the invention can be formed by treating those compounds having a free hydroxy or amino functionality with the acid chloride of the desired ester in the presence of a base in an inert solvent such as methylene chloride or chloroform.
- Suitable bases include triethylamine or pyridine.
- compounds of the invention, and the compounds of Table 1 having a free carboxy group may be esterified using standard conditions which may include activation followed by treatment with the desired alcohol in the presence of a suitable base.
- the present invention also relates to a method of modulating the interaction of NGF (or proNGF) with a neurotrophin receptor, e.g, p75 NTR and/or TrkA.
- the method comprises contacting NGF and/or a precursor thereof (proNGF) in the presence of p75 NTR and/or TrkA with a NGF/NTR modulating amount of a NGF/NTR modulator compound (i.e., a compound of the invention), thereby modulating the interaction of NGF (and/or proNGF) with p75 NTR and/or TrkA.
- a NGF/NTR modulator compound i.e., a compound of the invention
- the methods of the invention can be practiced in vitro, for example, in a cell culture screening assay to screen compounds which potentially modulate, directly or indirectly, receptor function.
- the modulating compound can function by interacting with and eliminating any function or activity (e.g., receptor binding) of NGF and/or a precursor thereof in the sample or culture.
- the modulating compounds can also be used to control NGF activity in neuronal cell culture.
- cross-linking assays for determining the ability of a compound within the scope of the invention to modulate the interaction of NGF with p75 NTR and/or TrkA are well known in the art and described in the examples herein.
- neurotrophin polypeptides for use in the assays described herein can be readily produced by standard biological techniques or by chemical synthesis. For example, a host cell transfected with an expression vector containing a nucleotide sequence encoding the desired neurotrophin can be cultured under appropriate conditions to allow expression of the peptide to occur. The secreted peptide can then be isolated according to standard techniques. Coding polynucleotides, precursors and promoters for a number of neurotrophins are known, including coding sequences for neurotrophins of some mammalian species.
- GenBank M61176 sets for the coding sequence for BDNF (see also, XM.006027); BDNF precursor is set forth at BF439589; and a BDNF specific promoter is set forth at Eo5933.
- a similar range of coding sequences for other neurotrophins, including proNGF and mature NGF (e.g., NCBI ACCESSION NO P01138 and CAA37703), NT-4/5 and NT-3, are also available through GenBank and other publicly accessible nucleotide and amino acid sequence databases.
- the neurotrophin e.g., NGF
- the neurotrophin can be obtained by culturing a primary cell culture or an established cell line that can produce the neurotrophin, and isolating from the culture broth thereof (e.g., culture supernatant, cultured cells).
- the method can also be practiced in vivo, for example, to modulate one or more processes mediated by the interaction of NGF (and/or proNGF) with p75 NTR , and/or the interaction of NGF with TrkA.
- Animal models for determining the ability of a compound of the invention to treat a disorder associated with or caused by a neurotrophin-mediated biological activity are well known and readily available to the skilled artisan.
- animal models of neuropathic pain based on injury inflicted to a nerve are described in Zeltser et al., 2000, Pain 89:19-24; Bennett et al., 1988, Pain 33:87-107; Seltzer et al., 1990, Pain 43:205-218; Kim et al., 1992, Pain 50:355-363; Decosterd et al., 2000, Pain 87:149-158 and DeLeo et al., 1994, Pain 56:9-16.
- diabetic neuropathy STZ induced diabetic neuropathy—Courteix et al., 1994, Pain 57:153-160
- drug induced neuropathies vincristine induced neuropathy—Aley et al., 1996, Neuroscience 73: 259-265; oncology-related immunotherapy, anti-GD2 antibodies—Slart et al., 1997, Pain 60:119-125
- Acute pain in humans can be reproduced using in murine animals chemical stimulation: Martinez et al., Pain 81: 179-186; 1999 (the writhing test—intraperitoneal acetic acid in mice), Coderre et al., Pain. 1993, 54:43-50 (intraplantar injection of formalin).
- Intracapsular injection of irritant agents is used to develop arthritis models in animals (Fernihough et al., 2004, Pain 112:83-93; Coderre and Wall, 1987, Pain 28:379-393; Otsuki et al., 1986, Brain Res. 365:235-240).
- a stress-induced hyperalgesia model is described in Quintero et al., 2000, Pharmacology, Biochemistry and Behavior 67:449-458. Further animal models for pain are considered in an article of Walker et al.
- Genitourinary models include methods for reducing the bladder capacity of test animals by infusing either protamine sulfate and potassium chloride (See, Chuang, Y. C. et al., Urology 61(3): 664-670, 2003) into the bladder. These methods also include the use of a well accepted model of for urinary tract disorders involving the bladder using intravesically administered acetic acid as described in Sasaki et al. (2002) J. Urol. 168: 1259-64. Efficacy for treating spinal cord injured patients can be tested using methods as described in Yoshiyama et al. (1999) Urology 54: 929-33.
- Gastrointestinal models can be found in: Gawad, K. A., et al., Ambulatory long-term pH monitoring in pigs, Surg Endosc, (2003); Johnson, S. E. et al., Esophageal Acid Clearance Test in Healthy Dogs, Can. J. Vet. Res. 53(2): 244-7 (1989); and Cicente, Y. et al., Esophageal Acid Clearance: More Volume-dependent Than Motility Dependent in Healthy Piglets, J. Pediatr. Gastroenterol. Nutr. 35(2): 173-9 (2002). Models for a variety of assays can be used to assess visceromotor and pain responses to rectal distension.
- Gastrointestinal motility can be assessed based on either the in vivo recording of mechanical or electrical events associated intestinal muscle contractions in whole animals or the activity of isolated gastrointestinal intestinal muscle preparations recorded in vitro in organ baths (see, for example, Yaun et al., Br. J. Pharmacol., 112(4):1095-1100 (1994), Jin et al., J. Pharm. Exp. Ther., 288(1): 93-97 (1999) and Venkova et al., J. Pharm. Exp. Ther., 300(3): 1046-1052 (2002)). Tatersall et al.
- Animal models for investigating neurological disorders include, but are not limited to, those described in Morris et al., (Learn. Motiv. 1981; 12: 239-60) and Abeliovitch et al., Cell 1993; 75: 1263-71).
- neurological models for studying spinal cord injury are described in Yoshiyama, M. et al., Urology 54(5): 929-933 (1999).
- animal models for pain and inflammation include, but are not limited to the models listed in Table 2.
- Table 2 TABLE 2 Modality
- Non-limiting examples of potential Model Name tested Brief Description clinical indications (Reference) ACUTE PHASIC PAIN Tail-flick Thermal Tip of tail of rats is immersed if hot water and time Acute nociceptive pain to withdrawal from water is measured.
- a radiant heat source is applied to the tail and time Ben-Bassat et al. Arch Intern to withdrawal is determined.
- Analgesic effect is Pharmacodyn Ther 1959; 122: 434-47.) evidenced by a prolongation of the latency period hot-plate Thermal Rats walk over a heated surface with increasing Acute nociceptive pain temperature and observed for specific nociceptive (Woolfe et al. J Pharmacol Exp Ther behavior such paw licking, jumping. Time to 1944; 80: 300-7.) appearance of such behavior is measured.
- Analgesic effects are evidenced by a prolonged latency. Hargreaves Thermal A focused beam of light is projected onto a small Acute nociceptive pain Test surface of the hind leg of a rat with increasing (Yeomans et al. Pain 1994; 59: 85-94.) temperature. Time to withdrawal is measured.
- Analgesic effect translates into a prolonged latency Pin Test or Mechanical
- Pressure intensity is (Green et al. Br J Pharmacol 1951; 6: 572- Selitto measured. Alternatively increased pressure is 85.; Randall et al. Arch Int Pharmacodyn applied to the paw using a caliper until pain Ther 1957; 111: 409-19) threshold is reached and animals withdraw the paw.
- HYPERALGESIA MODELS/CHRONIC INFLAMMATORY PAIN MODELS Hargreaves or Thermal A sensitizing agent e.g, complete Freund's Chronic pain associated with tissue Randal & and/or adjuvant (CFA).
- carrageenin, turpentine etc. is inflammation, e.g. post-surgical pain, Selitto mechanical injected into the paw of rats creating a local (Hargreaves et al. Pain 1988; 32: 77- inflammation and sensitivities to mechanical 88.) (Randall & Selitto) and/or therma (Hargreaves)l Randall L O, Selitto J J. Arch Int stimulation are measured with comparison to the Pharmacodyn1957; 3: 409-19.
- contralateral non-sensitized paw Yeomans Thermal Rat hind paw in injected with capsaicin, a Chronic pain associated with tissue model sensitizing agent for small C-fibers or DMSO, a inflammation, e.g.
- a radiant heat is (Yeomans et al. Pain 1994; 59: 85-94.; applied with different gradient to differentially Otsuki et al. Brain Res 1986; 365: 235- stimulate C-fibers or A-delta fibers and discriminate 240.) between the effects mediated by both pathways CHRONIC MALIGNANT PAIN (CANCER PAIN) Bone Cancer Thermal
- osteolytic mouse sarcoma Bone cancer pain Model and/or NCTC2472 cells are used to induce bone cancer by (Schwei et al., J. Neurosci.
- an agent identified as described herein e.g., an NGF/NTR modulator
- an NGF/NTR modulator can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
- this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein
- compositions comprise a therapeutically (or prophylactically) effective amount of a NGF/NTR modulator, and preferably one or more compounds of the invention described above, and a pharmaceutically acceptable carrier or excipient.
- Suitable pharmaceutically acceptable carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
- the carrier and composition can be sterile.
- the formulation should suit the mode of administration.
- phrases “pharmaceutically acceptable carrier” is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals.
- the carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject.
- materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer'
- wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- antioxidants examples include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, ⁇ -tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- oil-soluble antioxidants such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin
- Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions (e.g., NaCl), alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, cyclodextrin, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrolidone, etc.
- salt solutions e.g., NaCl
- alcohols e.g., gum arabic
- vegetable oils e.g., benzyl alcohols
- polyethylene glycols e.g., gelatin
- carbohydrates such as lactose, amylose or starch, cyclodextrin, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrolidone, etc.
- the pharmaceutical preparations can be sterilized and if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- the composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder.
- the composition can be formulated as a suppository, with traditional binders and carriers such as trilycerides.
- Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrollidone, sodium saccharine, cellulose, magnesium carbonate, etc.
- compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
- the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection.
- the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachet indicating the quantity of active agent.
- composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose/water.
- an ampule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- compositions of the invention can also include an agent which controls release of the compound of the invention, thereby providing a timed or sustained relase composition.
- the present invention also relates to prodrugs of the compounds disclosed herein, as well as pharmaceutical compositions comprising such prodrugs.
- compounds of the invention which include acid functional groups or hydroxyl groups can also be prepared and administered as a corresponding ester with a suitable alcohol or acid. The ester can then be cleaved by endogenous enzymes within the subject to produce the active agent.
- Formulations of the present invention include those suitable for oral, nasal, topical, transmucosal, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient.
- a compound of the present invention may also be administered as a bolus, electuary or paste.
- the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostea
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions that can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and e
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
- dosage forms can be made by dissolving or dispersing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
- Ophthalmic formulations are also contemplated as being within the scope of this invention.
- compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
- the absorption of the drug in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- the invention provides a method of treating a condition mediated by an NGF/NTR interaction in a subject, including, but not limited to, pain, inflammatory disorders, respiratory disorders, neurological disorders, gastrointestinal disorders and genitourinary disorders.
- the method comprises the step of administering to the subject a therapeutically effective amount of a NGF/NTR modulator.
- the condition to be treated can be any condition which is mediated, at least in part, by the interaction of a neurotrophin (e.g. NGF) with a neurotrophin receptor (e.g., p75 NTR and TrkA).
- the quantity of a given compound to be administered will be determined on an individual basis and will be determined, at least in part, by consideration of the individual's size, the severity of symptoms to be treated and the result sought.
- the NGF/NTR modulators described herein can be administered alone or in a pharmaceutical composition comprising the modulator, an acceptable carrier or diluent and, optionally, one or more additional drugs.
- the NGF/NTR modulator can be administered subcutaneously, intravenously, parenterally, intraperitoneally, intradermally, intramuscularly, topically, enterally (e.g., orally), rectally, nasally, buccally, sublingually, systemically, vaginally, by inhalation spray, by drug pump or via an implanted reservoir in dosage formulations containing conventional non-toxic, physiologically acceptable carriers or vehicles.
- the preferred method of administration is by oral delivery.
- the form in which it is administered e.g., syrup, elixir, capsule, tablet, solution, foams, emulsion, gel, sol) will depend in part on the route by which it is administered.
- mucosal e.g., oral mucosa, rectal mucosa, intestinal mucosa, bronchial mucosa
- nose drops aerosols, inhalants, nebulizers, eye drops or suppositories
- nebulizers e.g., nebulizers
- eye drops e.g., suppositories
- agents such as analgesics, e.g., opiates, anti-inflammatory agents, e.g., NSAIDs, anesthetics and other agents which can control one or more symptoms or causes of an NTR-mediated condition.
- analgesics e.g., opiates
- anti-inflammatory agents e.g., NSAIDs
- anesthetics e.g., anesthetics and other agents which can control one or more symptoms or causes of an NTR-mediated condition.
- the agents of the invention may be desirable to administer the agents of the invention locally to a localized area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, transdermal patches, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes or fibers.
- the agent can be injected into the joints or the urinary bladder.
- the compounds of the invention can, optionally, be administered in combination with one or more additional drugs which, for example, are known for treating and/or alleviating symptoms of the condition mediated by NGF p75 NTR or TrkA.
- additional drug can be administered simultaneously with the compound of the invention, or sequentially.
- the compounds of the invention can be administered in combination with at least one of an analgesic, an anti-inflammatory agent, an anesthetic, a corticosteroid (e.g., dexamethasone, beclomethasone diproprionate (BDP) treatment), an anti-convulsant, an antidepressant, an anti-nausea agent, an anti-psychotic agent, a cardiovascular agent (e.g., a beta-blocker) or a cancer therapeutic.
- the compounds of the invention are administered in combination with a pain drug.
- pain drugs is intended to refer to analgesics, anti-inflammatory agents, anesthetics, corticosteroids, antiepileptics, barbiturates, antidepressants, and marijuana.
- the methods of the invention can further include the step of administering a second treatment, such as a second treatment for the disease or disorder or to ameliorate side effects of other treatments.
- a second treatment can include, e.g., anti-inflammatory medication and any treatment directed toward treating pain.
- further treatment can include administration of drugs to further treat the disease or to treat a side effect of the disease or other treatments (e.g., anti-nausea drugs, anti-inflammatory drugs, anti-depressants, anti-psychiatric drugs, anti-convulsants, steroids, cardiovascular drugs, and cancer chemotherapeutics).
- an “analgesic” is an agent that relieves pain without significant impairment of consciousness or sense perception and may result in the reduction of inflammation as do corticosteroids, e.g., an anti-inflammatory agent.
- Analgesics can be subdivided into NSAIDs (non-steroidal-anti-inflammatory agents), narcotic analgesics, and non-narcotic analgesics.
- NSAIDs can be further subdivided into non-selective COX (cyclooxygenase) inhibitors, and selective COX2 inhibitors.
- Opioid analgesics can be natural, synthetic or semi-synthetic opioid (narcotic) analgesics, and include for example, morphine, codeine, meperidine, propxyphen, oxycodone, hydromorphone, heroine, tramadol, and fentanyl.
- Non-opioid analgesics (non-narcotic) analgesics include, for example, acetaminophen, clonidine, NMDA antagonists, and cannabinoids.
- Non-selective COX inhibitors include, but are not limited to acetylsalicylic acid (ASA), ibuprofen, naproxen, ketoprofen, piroxicam, etodolac, and bromfenac.
- Selective COX2 inhibitors include, but are not limited to celecoxib, valdecoxib, parecoxib, and etoricoxib.
- an “anesthetic” is an agent that interferes with sense perception near the site of administration, a local anesthetic, or result in alteration or loss of consciousness, e.g., systemic anesthetic agents.
- Local anesthetics include but are not limited to lidocaine and buvicaine.
- Non-limiting examples of antiepileptic agents are carbamazepine, phenytoin and gabapentin.
- Non-limiting examples of antidepressants are amitriptyline and desmethylimiprimine.
- Non-limiting examples of anti-inflammatory drugs include corticosteroids (e.g., hydrocortisone, cortisone, prednisone, prednisolone, methyl prednisone, triamcinolone, fluprednisolone, betamethasone and dexamethasone), salicylates, antihistamines and H 2 receptor antagonists.
- corticosteroids e.g., hydrocortisone, cortisone, prednisone, prednisolone, methyl prednisone, triamcinolone, fluprednisolone, betamethasone and dexamethasone
- salicylates e.g., salicylates, antihistamines and H 2 receptor antagonists.
- parenteral administration and “administered parenterally” as used herein mean modes of administration other than enteral and topical administration, usually by injection, and include, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- systemic administration means the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the subject's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- the compounds of the present invention which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject.
- the selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well known in the medical arts.
- a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required.
- dosages of a compound of the invention may be determined by deriving dose-response curves using an animal model for the condition to be treated.
- the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
- intravenous and subcutaneous doses of the compounds of this invention for a subject when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 100 mg per kg per day, and still more preferably from about 1.0 to about 50 mg per kg per day.
- An effective amount is that amount treats a neurotrophin-associated state or neurotrophin disorder.
- the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- a compound of the present invention While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
- the above compounds can be used for administration to a subject for the modulation of a neurotrophin-mediated activity, involved in, but not limited to, pain, inflammatory disorders, neurological disorders, and any abnormal function of cells, organs, or physiological systems that are modulated, at least in part, directly or indirectly by a neurotrophin-mediated activity. Additionally, it is understood that the compounds may also alleviate or treat one or more additional symptoms of a disease or disorder discussed herein.
- the compounds of the invention may be used to treat pain, including acute, chronic, malignant and non-malignant somatic pain (including cutaneous pain and deep somatic pain), visceral pain, and neuropathic pain. It is further understood that the compounds may also alleviate or treat one or more additional signs or symptoms of pain and sensory deficits (e.g., hyperalgesia, allodynia, dysesthesia, hyperesthesia, hyperpathia, paresthesia).
- pain including acute, chronic, malignant and non-malignant somatic pain (including cutaneous pain and deep somatic pain), visceral pain, and neuropathic pain.
- the compounds may also alleviate or treat one or more additional signs or symptoms of pain and sensory deficits (e.g., hyperalgesia, allodynia, dysesthesia, hyperesthesia, hyperpathia, paresthesia).
- the compounds of the invention may be used to treat somatic or cutaneous pain associated with injuries, inflammation, diseases and disorders of the skin, subcutaneous tissues and related organs including, but not limited to, cuts, burns, lacerations, punctures, incisions, surgical pain, post-operative pain, orodental surgery, psoriasis, eczema, dermatitis, and allergies.
- the compounds of the invention may also be used to treat somatic pain associated with malignant and non-malignant neoplasm of the skin, subcutaneous tissues and related organs (e.g., melanoma, basal cell carcinoma).
- the compounds of the invention may be used to treat deep somatic pain associated with injuries, inflammation, diseases and disorders of the musculoskeletal and connective tissues including, but not limited to, arthralgias, myalgias, fibromyalgias, myofascial pain syndrome, dental pain, lower back pain, pain during labor and delivery, surgical pain, post-operative pain, headaches, idiopathic pain disorder, sprains, bone fractures, bone injury, osteoporosis, severe burns, gout, arthiritis, osteoarthithis, myositis, and dorsopathies (e.g., spondylolysis, subluxation, sciatica, and torticollis).
- the compounds of the invention may also be used to treat deep somatic pain associated with malignant and non-malignant neoplasm of the musculoskeletal and connective tissues (e.g., sarcomas, rhabdomyosarcomas, and bone cancer).
- malignant and non-malignant neoplasm of the musculoskeletal and connective tissues e.g., sarcomas, rhabdomyosarcomas, and bone cancer.
- compounds of the invention may be used to treat visceral pain associated with injuries, inflammation, diseases or disorders of the circulatory system, the respiratory system, the genitourinary system, the gastrointestinal system and the eye, ear, nose and throat.
- the compounds of the invention may be used to treat visceral pain associated with injuries, inflammation and disorders of the circulatory system including, but are not limited to, ischaemic diseases, ischaemic heart diseases (e.g., angina pectoris, acute myocardial infarction, coronary thrombosis, coronary insufficiency), diseases of the blood and lymphatic vessels (e.g., peripheral vascular disease, intermittent claudication, varicose veins, haemorrhoids, embolism or thrombosis of the veins, phlebitis, thrombophlebitis lymphadenitis, lymphangitis), and visceral pain associated with malignant and non-malignant neoplasm of the circulatory system (e.g., lymphomas, myelomas, Hodgkin's disease).
- ischaemic diseases e.g., angina pectoris, acute myocardial infarction, coronary thrombosis, coronary insufficiency
- the compounds of the invention may be used to treat visceral pain associated with injuries, inflammation, diseases and disorders of the respiratory system including, but are not limited to, upper respiratory infections (e.g., nasopharyngitis, sinusitis, and rhinitis), influenza, pneumoniae (e.g., bacterial, viral, parasitic and fungal), lower respiratory infections (e.g., bronchitis, bronchiolitis, tracheobronchitis), interstitial lung disease, emphysema, bronchiectasis, status asthmaticus, asthma, pulmonary fibrosis, chronic obstructive pulmonary diseases (COPD), diseases of the pleura, and visceral pain associated with malignant and non-malignant neoplasm of the respiratory system (e.g., small cell carcinoma, lung cancer, neoplasm of the trachea, of the larynx).
- upper respiratory infections e.g., nasopharyngitis, sinusitis,
- the compounds of the invention may be used to treat visceral pain associated with injuries, inflammation and disorders of the gastrointestinal system including, but are not limited to, injuries, inflammation and disorders of the tooth and oral mucosa (e.g., impacted teeth, dental caries, periodontal disease, oral aphthae, pulpitis, gingivitis, periodontitis, and stomatitis), of the oesophagus, stomach and duodenum (e.g., ulcers, dyspepsia, oesophagitis, gastritis, duodenitis, diverticulitis and appendicitis), of the intestines (e.g., Crohn's disease, paralytic ileus, intestinal obstruction, irritable bowel syndrome, neurogenic bowel, megacolon, inflammatory bowel disease, ulcerative colitis, and gastroenteritis), of the peritoneum (e.g.
- the tooth and oral mucosa e.g., impacted teeth, dental caries
- liver peritonitis of the liver (e.g., hepatitis, liver necrosis, infarction of liver, hepatic veno-occlusive diseases), of the gallbladder, biliary tract and pancreas (e.g., cholelithiasis, cholecystolithiasis, choledocholithiasis, cholecystitis, and pancreatitis), functional abdominal pain syndrome (FAPS), gastrointestinal motility disorders, as well as visceral pain associated with malignant and non-malignant neoplasm of the gastrointestinal system (e.g., neoplasm of the oesophagus, stomach, small intestine, colon, liver and pancreas).
- FAPS functional abdominal pain syndrome
- gastrointestinal motility disorders as well as visceral pain associated with malignant and non-malignant neoplasm of the gastrointestinal system (e.g., neoplasm of the oesophagus
- the compounds of the invention may be used to treat visceral pain associated with injuries, inflammation, diseases, and disorders of the genitourinary system including, but are not limited to, injuries, inflammation and disorders of the kidneys (e.g., nephrolithiasis, glomerulonephritis, nephritis, interstitial nephritis, pyelitis, pyelonephritis), of the urinay tract (e.g. include urolithiasis, urethritis, urinary tract infections), of the bladder (e.g.
- the kidneys e.g., nephrolithiasis, glomerulonephritis, nephritis, interstitial nephritis, pyelitis, pyelonephritis
- the urinay tract e.g. include urolithiasis, urethritis, urinary tract infections
- the bladder
- cystitis neuropathic bladder, neurogenic bladder dysfunction, overactive bladder, bladder-neck obstruction
- male genital organs e.g., prostatitis, orchitis and epididymitis
- female genital organs e.g., inflammatory pelvic disease, endometriosis, dysmenorrhea, ovarian cysts
- pain associated with malignant and non-malignant neoplasm of the genitourinary system e.g., neoplasm of the bladder, the prostate, the breast, the ovaries.
- compounds of the invention may be used to treat neuropathic pain associated with injuries, inflammation, diseases and disorders of the nervous system, including the central nervous system and the peripheral nervous systems.
- injuries, inflammation, diseases or disorders associated with neuropathic pain include, but are not limited to, neuropathy (e.g., diabetic neuropathy, drug-induced neuropathy, radiotherapy-induced neuropathy), neuritis, radiculopathy, radiculitis, neurodegenerative diseases (e.g., muscular dystrophy), spinal cord injury, peripheral nerve injury, nerve injury associated with cancer, Morton's neuroma, headache (e.g., nonorganic chronic headache, tension-type headache, cluster headache and migraine), multiple somatization syndrome, postherpetic neuralgia (shingles), trigeminal neuralgia complex regional pain syndrome (also known as causalgia or Reflex Sympathetic Dystrophy), radiculalgia, phantom limb pain, chronic cephalic pain, nerve trunk pain, somatoform pain disorder
- neuropathy e.g., diabet
- the compounds of the invention may be used to treat inflammation associated with injuries, diseases or disorders of the skin, subcutaneous tissues and related organs, the musculoskeletal and connective tissue system, the respiratory system, the circulatory system, the genitourinary system and the gastrointestinal system.
- examples of inflammatory conditions, diseases or disorders of the skin, subcutaneous tissues and related organs that may be treated with the compounds of the invention include, but are not limited to allergies, atopic dermatitis, psoriasis, eczema and dermatitis.
- inflammatory conditions, diseases or disorders of the musculoskeletal and connective tissue system that may be treated with the compounds of the invention include, but are not limited to arthritis, osteoarthritis, and myositis.
- inflammatory conditions, diseases or disorders of the respiratory system include, but are not limited to allergies, asthma, rhinitis, neurogenic inflammation, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, nasopharyngitis, sinusitis, and bronchitis.
- COPD chronic obstructive pulmonary disease
- inflammatory conditions, disease or disorders of the circulatory system that may be treated with the compounds of the invention include, but are not limited to, endocarditis, pericarditis, myocarditis, phlebitis, lymphadenitis and artherosclerosis.
- inflammatory conditions, diseases or disorders of thegenitourinary system that may be treated with the compounds of the invention include, but are not limited to, inflammation of the kidney (e.g., nephritis, interstitial nephritis), of the bladder (e.g., cystitis), of the urethra (e.g., urethritis), of the male genital organs (e.g., prostatitis), and of the female genital organs (e.g., inflammatory pelvic disease).
- inflammation of the kidney e.g., nephritis, interstitial nephritis
- the bladder e.g., cystitis
- the urethra e.g., urethritis
- the male genital organs e.g., prostatitis
- female genital organs e.g., inflammatory pelvic disease
- inflammatory conditions, diseases or disorders of the gastrointestinal system that may be treated with the compounds of the invention include, but are not limited to, gastritis, gastroenteritis, colitis (e.g., ulcerative colitis), inflammatory bowel syndrome, Crohn's disease, cholecystitis, pancreatitis and appendicitis.
- colitis e.g., ulcerative colitis
- inflammatory bowel syndrome Crohn's disease
- cholecystitis cholecystitis
- pancreatitis pancreatitis and appendicitis.
- inflammatory conditions, diseases or disorders that may be treated with the compounds of the invention, but are not limited to inflammation associated with microbial infections (e.g., bacterial, viral and fungal infections), physical agents (e.g., burns, radiation, and trauma), chemical agents (e.g., toxins and caustic substances), tissue necrosis and various types of immunologic reactions and autoimmune diseases (e.g., Lupus erythematosus).
- microbial infections e.g., bacterial, viral and fungal infections
- physical agents e.g., burns, radiation, and trauma
- chemical agents e.g., toxins and caustic substances
- tissue necrosis e.g., erythematosus
- the compounds of the invention may be used to treat injuries, diseases or disorders of the nervous system including, but not limited to neurodegenerative diseases (e.g., Alzheimer's disease, Duchenne's disease), epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, stroke, cerebral ischemia, neuropathies (e.g., chemotherapy-induced neuropathy, diabetic neuropathy), retinal pigment degeneration, trauma of the central nervous system (e.g., spinal cord injury), and cancer of the nervous system (e.g., neuroblastoma, retinoblastoma, brain cancer, and glioma), and other certain cancers (e.g., melanoma, pancreatic cancer).
- neurodegenerative diseases e.g., Alzheimer's disease, Duchenne's disease
- epilepsy multiple sclerosis
- amyotrophic lateral sclerosis e.g., stroke, cerebral ischemia
- neuropathies e.g., chemotherapy-induced neuropathy, diabetic neuropathy
- the compounds of the invention may also be used to treat other disorders of the skin, subcutaneous tissues and related organs (e.g., hair loss), of the respiratory system (e.g., asthma), of the circulatory system, (e.g., cardiac arrhythmias and fibrillation and sympathetic hyper-innervation), and of the genitourinary system (e.g., neurogenic bladder dysfunction and overactive bladder).
- the respiratory system e.g., asthma
- the circulatory system e.g., cardiac arrhythmias and fibrillation and sympathetic hyper-innervation
- genitourinary system e.g., neurogenic bladder dysfunction and overactive bladder.
- the present invention provides a method for treating a subject that would benefit from administration of a composition of the present invention. Any therapeutic indication that would benefit from a NGF/NTR modulator (i.e., a compound of the invention) can be treated by the methods of the invention.
- the method includes the step of administering to the subject a composition of the invention, such that the disease or disorder is treated.
- the invention further provides a method for preventing in a subject, a disease or disorder which can be treated with administration of the compositions of the invention.
- Subjects “at risk” may or may not have detectable disease, and may or may not have displayed detectable disease prior to the treatment methods described herein.
- At risk denotes that an individual who is determined to be more likely to develop a symptom based on conventional risk assessment methods or has one or more risk factors that correlate with development of a disease or disorder that may be treated according the methods of the invention.
- risk factors include family history, medication history, and history of exposure to an environmental substance which is known or suspected to increase the risk of disease.
- Subjects at risk for a disease or condition which can be treated with the agents mentioned herein can also be identified by, for example, any or a combination of diagnostic or prognostic assays known to those skilled in the art.
- Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the disease or disorder, such that the disease or disorder is prevented or, alternatively, delayed in its progression.
- the invention is further illustrated by the following example, which could be used to examine the neurotrophin/neurotrophin precursor binding inhibition of the compounds of the invention.
- the example should not be construed as further limiting.
- the animal models used throughout the Examples are accepted animal models and the demonstration of efficacy in these animal models is predictive of efficacy in humans.
- the compound was prepared from 1,4,5,8-naphthalene tetracarboxylic dianhydride (1.34 g, 5 mmol) and 3-amino-4-chlorobenzoic acid (1.71 g, 10 mmol) in 100 mL glacial acetic acid using the general procedure shown in Example 1.
- the intermediate compound was prepared from 1,4,5,8-naphthalene tetracarboxylic dianhydride (1.34 g, 5 mmol) and 3-amino-4-chlorobenzoic acid (0.86 g, 5 mmol) in 100 mL glacial acetic acid using the general procedure from Example 1.
- Compound 90 was prepared from the intermediate (Example 1; 0.42 g, 1 mmol) and 3,4-diamino benzoic acid (0.15 g, 1 mmol) in 20 mL glacial acetic acid using the general procedure from Example 1.
- the compound was prepared from 1,4,5,8-naphthalene tetracarboxylic dianhydride (1.34 g, 5 mmol) and 3,4-diaminobenzoic acid (10 mmol) in 100 mL glacial acetic acid using the general procedure shown in Example 1.
- PC12 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS).
- FBS fetal bovine serum
- A875 human melanoma cells were maintained in DMEM with 10% FBS.
- HEK 293 cells were stably transfected with human TrkA plasmid (see below) and maintained in DMEM with 10% FBS and G418 (600 ⁇ g/mL) for selection.
- TrkA expression vector was achieved by transfecting the cells with the TrkA expression vector using Lipofectamine (Invitrogen) reagent.
- HEK cells were plated in 100 mm Petri dishes at a concentration of 10 6 cells per dish. The next day, a solution of DNA diluted in 1 mL OptiMEM (Invitrogen) per dish was prepared and incubated for 15 min at room temperature. Concurrently, 42 ⁇ l of Lipofectamine reagent was prepared in OPtiMEM (1 mL per dish) and incubated for 15 min at room temperature. The DNA and lipofectamine reagent solutions were then mixed together and incubated for a further 15 minutes.
- Lipofectamine Invitrogen
- the cells were rinsed twice with OptiMEM.
- the DNA-lipofectamine solution in OptiMEM was then added to the dish, which was then placed in the incubator (37° C.; 5% CO 2 ) for 3 h. This solution was then aspirated and the cells were rinsed with DMEM. From this point, cells were grown in DMEM+FBS (10%), their normal growth medium.
- the culture medium contained G418 (600 ⁇ g/mL) a selection agent for maintenance of TrkA expression in the cells. The presence of TrkA was confirmed with 125 I-NGF binding (see below) and Western blots (see below) labeled with TrkA specific antisera.
- NGF binding was evaluated using methods familiar to those who are skilled in the art. Briefly, cells expressing one or both NGF receptors (PC12: TrkA+p75; A875: p75 alone; HEK_TrkA: TrkA alone) were harvested by replacing the medium with calcium-magnesium free balanced salt (Grey's) solution and incubating at 37° C. for 15 min.
- PC12 TrkA+p75
- A875 p75 alone
- HEK_TrkA TrkA alone
- HEPES-Krebs-Ringer (HKR) buffer 10 mM HEPES; 125 mM NaCl; 4.8 mM KCl; 1.3 mM CaCl 2 ; 1.2 mM MgSO 4 ; 1.2 mM KH 2 PO 4 ; 1 mg/ml BSA; 1 mg/ml glucose; pH 7.4
- 125 I-NGF ⁇ 0.1 nM
- Non-specific binding was determined for reference by incubating 125 I-NGF with an excess of non-radioactive NGF in the abence of compound.
- 125 I-NGF bound to the cells was quantified in a gamma radiation counter following separation from unbound NGF by filtration or centrifugation through glycerol (10% in HKR). Inhibition of binding was calculated as a percent of the specific binding (calculated as the differential between 125 I-NGF binding in the absence and presence of an excess of non-radioactive NGF without compound). Dose-response inhibition curves were typically generated with seven concentrations of a given compound, with three replicates for each concentration. For most compounds, multiple dose-response curves were generated.
- IC 50 data shown in Table 1 were acquired using the procedure described herein using PC12 cells. Examples of IC 50 calculation curves from individual experiments using this procedure are shown in FIGS. 2A, 2B , 3 A, 4 A, and 5 , in which compounds 90, 91 and 18 are shown to effectively block NGF binding to TrkA and/or p75.
- NGF binding to TrkA and p75 was qualitatively evaluated following chemical cross-linking, and separation of proteins according to molecular weight with SDS-PAGE.
- PC12 for p75 and TrkA binding
- HEK_TrkA for TrkA only
- A875 for p75 only
- BS 3 Bis[sulfosuccinimidyl]suberate) crosslinker was added for a final concentration 0.4 mM and incubated, rocking, for an additional 30 min at room temperature. Cells were washed twice in HKR. Following centrifugation, the pellets were solubilized directly in SDS sample buffer and heated for 10 min at 95° C. All samples were electrophoresed on a 6% SDS-PAGE gel, which was then dried and autoradiographed.
- BS 3 Bis[sulfosuccinimidyl]suberate
- Erk 1/2 is a kinase activated down stream of TrkA and is a well studied member of the NGF-induced signal transduction cascade.
- PC12 cells expressing TrkA and p75 were acutely exposed to 5 ng/mL NGF (15 min; 37° C.; 5% CO 2 ) that was pre-incubated (30 min; room temperature) with or without the compounds.
- Cells were lysed in Laemmli sample buffer (for SDS-PAGE) or a lysis buffer containing Triton X-100 (for ELISA). Following SDS-PAGE, proteins were electroblotted onto nitrocellulose and immunoprobed for phosphorylated Erk 1 and 2.
- Blocking and primary antibody incubations of immunoblots were performed in Tris-buffered saline-Tween (10 mM Tris, pH 8.0, 150 mM NaCl, and 0.2% Tween 20) supplemented with 5% (w/v) bovine serum albumin (BSA); secondary antibody incubations were performed in 5% (w/v) dried skim milk powder. Immunoreactive bands were detected by chemiluminescence.
- FIGS. 1 and 4 A Representative examples of a phosphoryated Erk 1/2 blot for Compound 90 and 91 are shown in FIGS. 1 and 4 A, which demonstrate that Compounds 90 and 91 inhibit NGF-induced Erk 1/2 phosphorylation in PC12 cells.
- FIG. 6 shows an additional phosphorylated Erk 1/2 blot for Compound 90 as acquired using this procedure, which demonstrates that Compound 90 inhibits NGF-induced Erk 1/2 phosphorylation in PC12 cells.
- phosphorylated Erk 1/2 by ELISA, a kit from R&D (Minneapolis, Minn.) Systems is used. Briefly, cells are lysed in buffer (1 mM EDTA, 0.5% Triton X-100, 5 mM NaF, 1 M urea, 10 ⁇ g/mL, Leupeptin, 10 ⁇ g/mL Pepstatin, 100 ⁇ M PMSF, 3 ⁇ g/mL Aprotinin, 2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate in PBS, pH 7.2-7.4). Lysates are incubated overnight at 4° C. in ELISA plates coated with an anti-Erk 1/2 capture antibody. Immobilized Erk 1/2 is then exposed to a biotinylated detection antibody specific for phosphorylated Erk. The quantity of phosphoryated Erk 1/2 is quantified colorometrically with a standard HRP-streptavidin reaction.
- This assay was run as a further functional marker of NGF antagonism and takes advantage of the differentiation of PC12 cells (neurite outgrowth) induced by NGF.
- Cultures of PC12 cells were grown on Terasaki plates pre-coated with poly-D-lysine. Cells were exposed to NGF (1-50 (preferably 5) ng/ml) to induce neurite outgrowth as described elsewhere [ L A Greene & A S Tischler, Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor, Proc Natl Acad Sci USA. July 1976; 73(7): 2424-2428]. In addition to NGF, cells were exposed to varying concentration of the compounds or vehicle.
- neurite outgrowth was quantified. A neurite was scored if its caliber from origin to terminal was approximately the same and the length was equal to or greater than 1.5 the cell body diameter. The number of neurite bearing cells per total number of viable cells was calculated for each condition; the number of cells with neurites in the presence of NGF (without compound exposure) was considered to represent maximal (100%) outgrowth, to which the inhibitory effect of compounds of the invention on NGF-induced outgrowth was compared.
- FIG. 3B Results from this experiment are shown in FIG. 3B , which demonstrates that compound 90 effectively inhibits neurite outgrowth induced by 5 ng/mL NGF in a dose-dependent fashion.
- the x-axis represents the log concentration in M.
- mice Male Sprague-Dawley rats are given a subcutaneous injection of 50 ⁇ l of 2.5% formalin into the plantar surface of one hindpaw using a 27 gauge syringe needle, and nociceptive responses are measured for the next 60 min. The compound or vehicle was administered (i.p. or s.c.) 15-45 minutes prior to the formalin injection. A nociceptive score was determined for each 5 min.
- a weighted nociceptive score ranging from 0 to 3 is calculated by multiplying the time spent in each category by the category weight, summing these products, and dividing by the total time for each 5 min block of time (Coderre et al., Pain 1993; 54: 43). On the basis of the resulting response patterns, 2 phases of nociceptive behaviour are identified and scored: first phase (P1; 0-5 min) and second phase (P2; 11-40 min).
- the acetic acid abdominal contraction test (Martinez et al., Pain 1999; 81: 179) was used to determine the efficacy of different compounds in a model of acute visceral chemical nociception. Mice were given an intraperitoneal (i.p.) injection of 200 ⁇ l of 0.6% acetic acid in saline and observed for the number of abdominal contractions (writhing) they exhibited in the 30 minutes following the injection. Compound or vehicle was administered (i.p. or s.c.) 15-45 minutes prior to the acetic acid injection. Each episode of writhing is characterized by a lengthwise stretching of the torso with a concomitant arching of the back.
- Results from this experiment are shown in FIG. 7 .
- Animals were treated with vehicle (VEH) or Compound 91 (5 mg/kg i.p.; [CMP 1] and 50 mg/kg i.p. [CMP 2])) 10-20 minutes before the intraperitoneal injection of acetic acid, as described in this example.
- CFA complete Freunds adjuvant
- the instrument incorporates a dual channel scale that separately measures the weight of the animal distributed to each hindpaw. While normal rats distribute their body weight equally between the two hindpaws (50-50), the discrepancy of weight distribution between an injured and non-injured paw is a natural reflection of the discomfort level in the injured paw (nocifensive behavior). The rats are placed in a plastic chamber designed so that each hindpaw rests on a separate transducer pad.
- the averager is set to record the load on the transducer over 5 s time period and two numbers displayed represent the distribution of the rat's body weight on each paw in grams (g). For each rat, three readings from each paw are taken and then averaged. Side-to-side weight bearing difference is calculated as the average of the absolute value of the difference between two hindpaws from three trials (right paw reading—left paw reading).
- the Partial Nerve Ligation (PNL) model (Seltzer et al., Pain 1990; 43:205) is used to induce chronic neuropathic pain.
- Male Sprague-Dawley rats are anesthetized with isoflurane, and injury to the sciatic nerve is achieved by tying a tight ligature around 1 ⁇ 3 to 1 ⁇ 2 of the sciatic nerve just proximal to the nerve's trifurcation in the mid-thigh. Animals develop thermal and mechanical hyperalgesia and allodynia, as well as a long-lasting spontaneous pain or dysesthesia after the nerve injury.
- the Spared Nerve Injury (SNI) model (Decosterd et al., Pain 2000; 87: 149) is used to induce chronic neuropathic pain.
- Male Sprague-Dawley rats are anesthetized with isoflurane, and two of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) are transected, leaving the remaining sural nerve intact.
- Animals develop thermal and mechanical hyperalgesia and allodynia, as well as a long-lasting spontaneous pain or dysesthesia the last month after the nerve injury.
- the Spinal Nerve Ligation (SNL) model (Kim and Chung, Pain 1992; 50: 355) is used to induce chronic neuropathic pain.
- Male Sprague-Dawley rats (Harlan, Indianapolis, Ind., USA) are anesthetized with isoflurane, the left L5 transverse process is removed, and the L5 and L6 spinal nerves aree tightly ligated with 6-0 silk suture. The wound is then closed with internal sutures and external staples.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Disclosed are compositions which modulate the interaction with nerve growth factor and precursors thereof with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration.
Description
- This application claims priority to U.S. Provisional Application No. 60/718,256, Attorney Docket No. PCI-030-1, filed Sep. 15, 2005, entitled “METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY.” The contents of any patents, patent applications, and references cited throughout this specification are hereby incorporated by reference in their entireties.
- The present invention relates to compositions which modulate the interaction of nerve growth factor, and precursors thereof, with the receptor TrkA, as well as the common neurotrophin receptor p75NTR, and methods of use thereof.
- The neurotrophins are a family of structurally and functionally related proteins, including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF), Neurotrophin-3 (NT-3), Neurotrophin-4/5 (NT-4/5) and Neurotrophin-6 (NT-6). These proteins promote the survival and differentiation of diverse neuronal populations in both the peripheral and central nervous systems and are involved in the pathogenesis of diverse neurological disorders (Hefti, J. Neurosci. 6:2155-2162 (1986); Hefti and Weiner, Annals of Neurology 20:275-281 (1986); Levi-Montalcini, EMBO J. 6:1145-1154 (1987); Barde, Neuron 2:1525-1534 (1989); Leibrock et al., Nature 341:149-152 (1989); Maisonpierre et al., Science 247:1446-1451 (1990); Rosenthal et al., Neuron 4:767-773 (1990); Hohn et al., Nature 344:339-341 (1990); Gotz et al., Nature 372:266-269 (1994); Maness et al., Neurosci. Biobehav. Rev. 18:143-159 (1994); Dechant et al., Nature Neurosci. 5:1131-1136 (2002)). This broad spectrum of biological activities exerted by the neurotrophins results from their ability to bind and activate two structurally unrelated receptor types, the p75 neurotrophin receptor (p75NTR) and the three members of the Trk receptor family of tyrosine kinases (Kaplan et al., Curr. Opin. Cell Biol. 9:213-221 (1997); Friedman et al., Exp. Cell Res. 253:131-142 (1999); Patapoutian et al., Curr. Opin. Neurobiol. 11:272-280 (2001)).
- While NGF was initially studied for its essential role in neuronal growth and survival, recent reports indicate that this neurotrophin may also play a role in inflammation and disorders of the respiratory, the genitourinary and the gastrointestinal systems. For example, in the gastrointestinal tract, neurotrophins and neurotrophic factors regulate neuropeptide expression, interact with immunoregulatory cells and epithelial cells, and regulate motility during inflammation (Reinshagen, M. et al., Curr. Opin. Investig. Drugs. 2002; 3(4): 565-568). NGF has been shown to play a role in bladder overactivity (Lamb, K. et al., J. Pain. 2004; 5(3): 150-156), bladder outlet obstruction (Kim, J. C. et al., BJU Int. 2004; 94(6): 915-918), pancreatic cancer (Shi, X. et al., Pancreatology. 2001; 1(5):517-524), and intestinal inflammation (Lin, A. et al., Exp. Neurol. 2005; 191(2):337-43).
- NGF is synthesized as a larger precursor form (referred to herein as “proNGF,” also known as “preproNGF” or “pro-peptide NGF”) which is then processed by proteolytic cleavages to produce the mature neurotrophic factor. This prepro region is located at the amino terminus of the precursor molecule and is needed for proper folding and secretion of the NGF protein. The mature form of NGF has arginine residues at its carboxy termini which requires that a leucine residue be inserted between the naturally occurring arginine and the hydrophilic spacer. The primary structure of proNGF has been deduced from the nucleotide sequence of the mouse NGF cDNA (Scott et al. Nature 302:538 (1983); Ullrich et al. Nature 303:821 (1983)).
- The common neurotrophin receptor p75NTR is a transmembrane glycoprotein structurally related to the tumor necrosis factor and CD-40 receptors (Meakin and Shooter, Trends Neurosci. 15:323-331 (1992), Rydén and Ibáñez, J. Biol. Chem. 271:5623-5627 (1996)). As all neurotrophins bind to p75NTR with similar affinities (Rodrigues-Tébar et al., Neuron 4:487-492 (1990); Hallbook et al., Neuron 6:845-858 (1991); Rodrigues-Tébar et al., EMBO J. 11:917-922 (1992); Ibáñez, Trends Biotech. 13:217-227 (1995)), neurotrophin specificity is conventionally thought to be conferred by the binding selectivity for Trk receptors which are differentially expressed in different neuronal populations (Ibáñez, Trends Biotech. 13:217-227 (1995)). However, accumulated experimental data on neurotrophin activity reveal important functional aspects of p75NTR (Heldin et al., J. Biol. Chem. 264:8905-8912 (1989); Jing et al., Neuron 9:1067-1079 (1992); Herrmann et al., Mol. Biol. 4:1205-1216 (1993); Barker and Shooter, Neuron 13:203-215 (1994); Dobrowsky et al., Science 265:1596-1599 (1994), Matsumoto et al., Cancer Res. 55:1798-1806 (1995); Marchetti et al., Cancer Res. 56:2856-2863 (1996); Washiyama et al., Amer. J. Path. 148:929-940 (1996)). The common neurotrophin receptor enhances functions and increases binding specificity of Trk receptors (Barker and Shooter, Neuron 13:203-215 (1994); Mahadeo et al., J. Biol. Chem. 269:6884-6891 (1994); Chao and Hempstead, Trends Neurosci. 18:321-326 (1995); Rydén and Ibáñz, J. Biol. Chem. 271:5623-5627 (1996)). In addition, p75NTR possesses unique, neurotrophin dependent, Trk-independent signaling properties which involve ceramide production through activation of the sphingomyelin cycle (Dobrowsky et al., Science 265:1596-1599 (1994)), apoptosis (cell death) (Cassacia-Bonnefil et al., Nature 383:716-719 (1996)), and activation of the transcription factor NFKB (Carter et al., Science 272:542-545 (1996)).
- Moreover, while initially studied primarily in neurons, p75NTR has also been found to play critical roles in vascular biology (von Schack et al., Nat. Neurosci. 4:977-978, 2001; Wan et al., Am. J. Pathol. 157:1247-1258, 2001), glial biology (Bentley et al., J. Neurosci. 20:7706-7715, 2000; Syroid et al., J. Neurosci. 20:5741-5747, 2000), the immune system (Tokuoka et al., Br. J. Pharmacol. 134:1580-1586, 2001), and tumor biology (Sakamoti et al., Oncol. Rep. 8:973-980, 2001; Descamps et al., J. Biol. Chem. 276:17864017870, 2001). For example, p75NTR has been demonstrated to participate in human melanoma progression (Herrmann et al., Mol. Biol. 4:1205-1216 (1993); Marchetti et al., Cancer Res. 56:2856-2863 (1996)). Furthermore, NGF and NT-3 increase the production of heparin by 70W melanoma cells, which is associated with their metastatic potential (Marchetti et al., Cancer Res. 56:2856-2863 (1996)).
- Unlike p75NTR, the Trk receptors (TrkA, TrkB and TrkC) exhibit selectivity for specific neurotrophins. (Kaplan et al., Science 252:554-558 (1991); Klein et al., Cell 65:189-197 (1991); Klein et al., Neuron 8:947-956 (1992); Soppet et al., Cell 65:895-903 (1991); Squinto et al., Cell 65:885-893 (1991); Berkemeier et al., Neuron 7:857-866 (1991); Escandon et al., Neurosci. Res. 34:601-613 (1993); Lamballe et al., Cell 66:967-970 (1991)). For example, TrkA primarily binds NGF (Kaplan et al., 1991; Klein et al., 1991) and has been reported to bind NT-3 (J. Biol. Chem. 271(10):5623-7, 1996); TrkB binds BDNF and NT-4/5 (Soppet et al., 1991; Squinto et al., 1991; Berkemeier et al., 1991; Escandon et al., 1993; Lamballe et al., 1991; Klein et al., 1992; Vale and Shooter, Methods Enzymol. 109:21-39 (1985); Barbacid, Oncogene 8:2033-2042 (1993)); and TrkC exclusively binds NT-3 (Lamballe et al., 1991; Vale and Shooter, 1985). This is particularly evident when the Trk receptors are coexpressed with the common neurotrophin receptor p75NTR. (For review see Meakin and Shooter, 1992; Barbacid, 1993; Chao, 1994; Bradshaw et al., 1994; Ibáñez, 1995).
- Biochemical experiments indicate that neurotrophin receptors form at least three different types of complexes: homodimers of Trk receptors, homomeric p75NTR receptors and mixed complexes of both Trk and p75NTR. These complexes may coexist in cells and may be linked through biochemical equilibria. Functionally, their signaling has been shown to be independent, synergistic or antagonistic. The response of a cell to neurotrophins is thus determined by the quantitative and qualitative composition of its receptor complement in combination with biochemical equilibria between pools of active and inactive receptors (Dechant, Cell Tissue Res. 305:229-238, (2001)), as well as other cellular and biochemical components downstream of the neurotrophin receptors, e.g., the availability of proteins, lipids and inorganic molecules involved in signal transduction.
- Due to the implication of NGF, and its precursor proNGF, binding to homomeric and heteromeric neurotrophin receptor complexes in various disease states, especially pain, inflammation, neurological disorders and disorders of the respiratory, genitourinary and gastrointestinal systems, a need exists for pharmaceutical agents and methods of use thereof for modulating the interactions of NGF with the common neurotrophin receptor p75NTR, and the Trk receptor TrkA.
- There remains a need for new treatments and therapies for neurotophin-mediated activity, and conditions, diseases and disorders related to neurotophin-mediated activity. There is also a need for compounds useful in the treatment or prevention or amelioration of one or more symptoms of pain, inflammatory disorders, neurological disorders, respiratory disorders, genitourinary disorders, and/or gastrointestinal disorders. Furthermore, there is a need for methods for modulating the activity of NGF, proNGF, p75NTR, and/or TrkA, using the compounds provided herein.
- In one aspect, the invention provides a compound of the invention of the Formula 16, Formula 17, Formula 18, Formula 19, Formula 20, Formula 21 and Formula 22, as well as the compounds of Table 1.
- In another aspect, the invention provides a method of modulating the interaction of a neurotrophin and a neurotrophin receptor, comprising contacting cells expressing a neurotrophin receptor with an effective amount of a compound of the invention.
- In one embodiment, the neurotrophin is nerve growth factor and/or precursors thereof. In another embodiment, the neurotrophin receptor is selected from the group consisting of p75NTR and TrkA. In yet another embodiment, the neurotrophin receptor is p75NTR. In still another embodiment, the neurotrophin receptor is TrkA. In another embodiment the compound further modulates the interaction of NGF and/or proNGF with TrkA.
- In another embodiment, the method is used to modulate a neurotrophin-mediated activity in a subject in need thereof. In another embodiment, the neurotrophin-mediated activity is associated with pain. In still another embodiment, the neurotrophin-mediated activity is associated with an inflammatory disorder. In another embodiment, the neurotrophin-mediated activity is associated with a neurological disorder.
- In another embodiment, the pain treated by the compounds of the invention is selected from the group consisting of cutaneous pain, somatic pain, visceral pain and neuropathic pain. In another embodiment the pain is acute pain or chronic pain.
- In still another embodiment, the cutaneous pain is associated with injury, disease, disorder or neoplasms of the skin, subcutaneous tissues and related organs. In another embodiment, the injury, disease or disorder of the skin, subcutaneous tissues and related organs is selected from the group consisting of traumas, cuts, lacerations, punctures, burns, surgical incisions, infections, psoriasis, eczema, and inflammation (e.g., acute inflammation).
- In another embodiment, the somatic pain is associated with an injury, disease, disorder or neoplasms of the musculoskeletal and connective system. In another embodiment, the injury, disease or disorder of the musculoskeletal and connective system is selected from the group consisting of sprains, broken bones, arthritis, arthralgia, myalgia, chronic lower back pain, cancer-associated pain, dental pain, fibromyalgia, idiopathic pain disorder, chronic non-specific pain, post-operative pain, and referred pain.
- In another embodiment, the visceral pain is associated with an injury, disease, disorder or neoplasms of the circulatory system, the respiratory system, the gastrointestinal system, or the genitourinary system. In one embodiment, the disease or disorder of the circulatory system treated by the compounds of the invention is selected from the group consisting of ischaemic heart disease, angina, acute myocardial infarction, cardiac arrhythmia, phlebitis, intermittent claudication, varicose veins and hemorrhoids. In one embodiment, the disease or disorder of the respiratory system treated by the compounds of the invention is selected from the group consisting of asthma, Chronic Obstructive Pulmonary Disease (COPD), respiratory infection, chronic bronchitis and emphysema. In one embodiment, the disease or disorder of the gastrointestinal system treated by the compounds of the invention is selected from the group consisting of gastritis, duodenitis, irritable bowel syndrome, colitis, Crohn's disease, ulcers and diverticulitis. In one embodiment, the disease or disorder of the genitourinary system treated by the compounds of the invention is selected from the group consisting of cystitis, urinary tract infections, glomuerulonephritis, polycystic kidney disease, and kidney stones.
- In another embodiment, the neuropathic pain is associated with an injury, disease, disorder or neoplasms of the nervous system. In still another embodiment, the injury, disease or disorder of the nervous system is selected from the group consisting of neuralgia, neuropathy, headache, chronic cephalic pain, phantom limb pain and spinal cord injury.
- In one embodiment, the inflammatory disorder treated by the compounds of the invention is selected from an inflammatory disorder of the skin and subcutaneous tissues, the musculoskeletal and connective tissue system, the respiratory system, the circulatory system, the genitourinary system, the gastrointestinal system or the nervous system. In one embodiment, the inflammatory disorder of the skin and subcutaneous tissues is selected from the group consisting of psoriasis, dermatitis and eczema. In one embodiment, the inflammatory disorder of the musculoskeletal and connective tissue system is selected from the group consisting of arthritis, gout, myositis, bursitis and synovitis. In one embodiment, the inflammatory disorder of the respiratory system treated by the compounds of the invention is selected from the group consisting of asthma, bronchitis, sinusitis, pharyngitis, rhinitis and respiratory infections. In another embodiment, the inflammatory disorder of the circulatory system is selected from the group consisting of vasculitis, artherosclerosis, phlebitis, carditis and coronary heart disease. In one embodiment, the inflammatory disorder of the gastrointestinal system treated by the compounds of the invention is selected from the group consisting of inflammatory bowel disorder, ulcerative colitis, Crohn's disease, diverticulitis, viral infection, bacterial infection, chronic hepatitis, gingivitis, stomatitis, and gastritis. In one embodiment, the inflammatory disorder of the genitourinary system treated by the compounds of the invention is selected from the group consisting of cystitis, nephritic syndrome, glomerulonephritis, urinary tract infection, prostatitis, salpingitis, endometriosis and cystinosis.
- In another embodiment, the neurological disorder treated by the compounds of the invention is selected from the group consisting of schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, stroke, cerebral ischemia, neuropathy, retinal pigment degeneration, glaucoma, cardiac arrhythmia, shingles, Huntington's chorea, and Parkinson's disease.
- In another aspect, the invention provides a method of treating pain in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the pain is selected from the group consisting of cutaneous pain, somatic pain, visceral pain and neuropathic pain. In another embodiment, the pain is acute pain, breakthrough pain or chronic pain.
- In another aspect, the invention provides a method of treating an inflammatory disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the inflammatory disorder is inflammatory disorder of the musculoskeletal and connective tissue system, the respiratory system, the circulatory system, the genitourinary system, the gastrointestinal system or the nervous system.
- In another aspect, the invention provides a method of treating a neurological disorder in a subject in need thereof, comprising administering an effective amount of a compound of the invention. In one embodiment, the neurological disorder is selected from the group consisting of schizophrenia, bipolar disorder, depression, Alzheimer's disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, stroke, cerebral ischemia, neuropathy, retinal pigment degeneration, glaucoma, cardiac arrhythmia, Huntington's chorea, and Parkinson's disease.
- In another aspect, the invention provides a method of treating a disease or disorder associated with the genitourinary and/or gastrointestinal systems of a subject in need thereof, comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the disease or disorder of the gastrointestinal system is selected from the group consisting of gastritis, duodenitis, irritable bowel syndrome, colitis, Crohn's disease, ulcers and diverticulitis. In another embodiment the disease or disorder of the genitourinary system is selected from the group consisting of cystitis, urinary tract infections, glomuerulonephritis, polycystic kidney disease, kidney stones and cancers of the genitourinary system.
- In another aspect, the invention provides a method comprising administering to the subject an additional therapeutic agent. In one embodiment, the additional therapeutic agent is selected from the group consisting of an analgesic, an anti-inflammatory agent, an anesthetic, a corticosteroid, an anti-convulsant, an antidepressant, an anti-nausea/anti-emetic agent, an anti-psychiatric agent, a cardiovascular agent and a cancer therapeutic.
-
FIG. 1 shows a typical Western blot with immunodetection of phosphorylatedErk 1/2 proteins extracted from NGF-stimulated PC12 cells in the presence or absence ofCompound 90, as described in Example 3. These results demonstrate thatCompound 90 inhibits NGF (5 ng/mL)-inducedErk 1/2 phosphorylation in PC12 cells. -
FIG. 2A shows a dose-response curve forCompound 90 from an individual NGF binding displacement experiment inPC 12 cells as described in Example 1. The dose-response curve demonstrates thatCompound 90 effectively blocks NGF binding to cells expressing TrkA and p75. -
FIG. 2B shows a dose-response curve forCompound 90 from an individual NGF binding displacement experiment in A875 cells as described in Example 1. The dose-response curve demonstrates thatCompound 90 effectively blocks NGF binding to cells expressing p75. -
FIG. 3A shows a binding displacement curve forCompound 90 from an individual NGF binding displacement experiment in HEK_trk cells as described in Example 1. The dose-response curve demonstrates thatCompound 90 effectively blocks NGF binding to cells expressing TrkA. -
FIG. 3B shows a neurite outgrowth inhibition curve forCompound 90 resulting from an experiment as described in Example 4. The curve demonstrates thatCompound 90 effectively inhibits neurite outgrowth induced by NGF. -
FIG. 4A shows a dose-response curve forCompound 91 from an individual NGF binding displacement experiment in PC12 cells as described in Example 1. The dose-response curve demonstrates thatCompound 91 effectively blocks NGF binding to cells expressing TrkA and p75. -
FIG. 4B shows a typical Western blot with immunodetection of phosphorylatedErk 1/2 proteins extracted from NGF-stimulated PC12 cells in the presence or absence ofCompound 91, as described in Example 3. These results demonstrate thatCompound 91 inhibits NGF-inducedErk 1/2 phosphorylation in PC12 cells. -
FIG. 5 shows a dose-response curve forCompound 18 from an individual NGF binding displacement experiment in PC12 cells as described in Example 1. The dose-response curve demonstrates thatCompound 18 effectively blocks NGF binding to cells expressing TrkA and p75. -
FIG. 6 shows a phospho-Erk 1/2 blot forCompound 90 as acquired using the procedure in Example 3, which demonstrates thatCompound 90 inhibits NGF (1 ng/mL)-inducedErk 1/2 phosphorylation in PC12 cells. -
FIG. 7 illustrates the significant antinociceptive effects ofCompound 91 in the Writhing Test in mice, as described in Example 6. - The present invention relates to the discovery of compounds which modulate the interaction of a neurotrophin—either in its mature (e.g., NGF) or precursor (e.g., proNGF) form—with a neurotrophin receptor, for example, the common neurotrophin receptor p75NTR and/or a Trk receptor. Such compounds are of use, for example, for modulating the interaction of NGF and/or a precursor thereof (e.g., proNGF) to p75NTR, and the compounds within the invention can also have the ability to modulate the interaction of NGF and/or proNGF with TrkA. For example, a compound that modulates the binding of NGF or proNGF to p75NTR can further modulate the binding of the neurotrophin to TrkA. Such compounds can also be used to treat a subject having a condition with at least one symptom that is directly or indirectly mediated, at least in part, by the interaction of NGF and/or a precursor thereof with p75NTR and/or TrkA.
- Nerve growth factor (also referred to hereinafter as “NGF”) is a prototypic neurotrophin, and is best known for its essential role during development of peripheral sensory and sympathetic neurons. NGF is produced as a high-molecular weight precursor (pro-NGF) that contains a pro-domain linked to the N-terminus which is cleaved by the endoprotease furin in the trans-Golgi network of neurons (Mowla et al., J. Biol. Chem. 276:12660-12666, 2001; Mowla et al., J. Neurosci. 19:2069-2080, 1999). Pro-NGF has been shown to be induced and secreted after injury to the CNS in an active form that is capable of triggering cell apoptosis (e.g., of neuronal cells and oligodendrocytes), and disruption of the interaction of pro-NGF and p75NTR has been demonstrated to rescue injured adult rat corticospinal neurons (e.g., Harrington et al., PNAS USA 101(16):6226-6230, 2004). Mature NGF regulates the phenotype (e.g., cell body and dendrite size, gene expression and neurotransmitter phenotype) of peripheral neurons and certain CNS neurons, notably, basal forebrain and striatal cholinergic neurons throughout the life of an animal (Miller et al., Neuron 32:767-770, 2001; Ruberti et al., J. Neurosci. 20(7):2589, 2000; Chen et al, J. Neurosci. 17(19):7288-96, 1997; Fagan et al., J. Neurosci. 17(20):7644-54, 1997). NGF has been implicated in the pathogenesis of Alzheimer's disease, epilepsy and pain (Ben Ari and Represa, TINS 13:312-318 (1990); McKee et al., Ann. Neurol. 30:156 (1991); Leven and Mendel, TINS 16:353-359 (1993); Woolf and Doubell, Current Opinions in Neurobiol. 4:525-534 (1994); Rashid et al., Proc. Natl. Acad. Sci. U.S.A. 92:9495-9499 (1995); McMahon et al., Nature Med. 1:774-780 (1995)). The interaction of NGF with its receptors is determined by distinct sequences within its primary amino acid structure. While several regions of NGF participate in the NGF/TrkA interaction, mutation studies suggest that relatively few key residues, namely those located in the NGF amino and carboxyl termini, are primarily required for high affinity binding to TrkA.
- Recent results have also shown that NGF may play a role in inflammation and disorders of the respiratory, genitourinary and gastrointestinal systems. For example, in the gastrointestinal tract, neurotrophins and neurotrophic factors regulate neuropeptide expression, interact with immunoregulatory cells and epithelial cells, and regulate motility during inflammation (Reinshagen, M. et al., Curr. Opin. Investig. Drugs. 2002; 3(4): 565-568). NGF has been shown to be a potentially relevant treatment target for bladder overactivity (Lamb, K. et al., J. Pain. 2004; 5(3): 150-156). Studies by Kim et al. show that increases in NGF may be related to the irritative symptoms resulting from correction of bladder outlet obstruction (BJU Int. 2004; 94(6): 915-918). Shi et al. have demonstrated that NGF and its receptor are overexpressed in pancereatic cancer and contribute to its malignant phenotype (Pancreatology. 2001; 1(5):517-524). The potential of NGF as a neuroprotective factor in the enteric nervous system has been demonstrated, as has its role in the mechanism by which intestinal inflammation can give rise to a permanent imbalance between excitatory and inhibitory pathways, thus tending to compromise intestinal function (Maruccio, L. et al. Histol. Histopathol. 2004; 19(2):349-356; Lin, A. et al., Exp. Neurol. 2005; 191(2):337-43). NGF has also been shown to play an important role in the development of the rat ovary (Romero, C. et al., 2002; 143(4):1485-1494). Data has further suggested that NGF may play a role in inflammation, bronchial hyperresponsiveness and airway remodeling in asthma, and may help us to understand the neuro-immune cross-talk involved in chronic inflammatory airway diseases (Frossard, N. et al., Eur. J. Pharmacol. 2004; 500(1-3): 453-465).
- It has been assumed, based on studies in the mouse submandibular gland that NGF in vivo is largely in the mature form of NGF, and that mature NGF accounts for the molecule's biological activity. However, it has been recently shown that proNGF is abundant in central nervous system tissues whereas mature NGF is undetectable, suggesting that proNGF may have a function distinct from its role as a precursor. Moreover, this data suggests that proNGF may be responsible for some of the biological activity normally attributed to mature NGF in vivo (Fahnestock, M. et al., J. Neurochem. 2004; 89(3):581-592; Fahnestock, M. et al., Prog. Brain Res. 2004; 146: 107-110). For example, it has been demonstrated that proNGF levels increase during the preclinical stage of Alzheimer's disease (Peng, S. et al., J. Neuropathol. Exp. Neurol. June 2004; 63(6):641-9). Additionally, studies by Beattie et al. (Neuron Oct. 24, 2002; 36(3): 275-386) have shown that proNGF plays an important role in eliminating damaged cells by activating the apoptotic machinery via p75NTR after spinal cord injury.
- Based on the above, there is a need for compositions which modulate the interaction of nerve growth factor, and precursors thereof, with the receptor TrkA, as well as the common neurotrophin receptor p75NTR, and methods of use thereof.
- The term “electronegative atom,” as used herein, refers to an atom which carries a partial or full negative charge in a particular compound under physiological conditions. The electronegative atom can be, for example, an oxygen atom, a nitrogen atom, a sulfur atom or a halogen atom, such as a fluorine, chlorine, bromine or iodine atom. Preferably, the electronegative atom is an oxygen atom. The term “electronegative functional group,” as used herein, refers to a functional group which includes at least one electronegative atom. Electronegative groups include acid functional groups and other polar functional groups. For example, suitable electronegative functional groups include, but are not limited to, carbonyl, thiocarbonyl, ester, imino, amido, amine, carboxylic acid, sulfonic acid, sulfinic acid, sulfamic acid, phosphonic acid, boronic acid, sulfate ester, hydroxyl, mercapto, cyano, cyanate, thiocyanate, isocyanate, isothiocyanate, carbonate, nitrate and nitro groups. It is to be understood that, unless otherwise indicated, reference herein to an acidic functional group also encompasses salts of that functional group in combination with a suitable cation.
- As used herein, the term “acid” refers to any substituent that can readily donate a hydrogen ion to another compound. Particularly preferred acid functional groups include carboxylic acid, sulfonic acid, sulfinic acid, sulfamic acid, phosphonic acid and boronic acid functional groups.
- The term “alkyl” includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl (alicyclic) groups (cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. The term “alkyl” also includes alkenyl groups and alkynyl groups. Furthermore, the expression “Cx-Cy-alkyl”, wherein x is 1-5 and y is 2-10 indicates a particular alkyl group (straight- or branched-chain) of a particular range of carbons. For example, the expression C1-C4-alkyl includes, but is not limited to, methyl, ethyl, propyl, butyl, isopropyl, tert-butyl and isobutyl.
- The term alkyl further includes alkyl groups which can further include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In an embodiment, a straight chain or branched chain alkyl has 10 or fewer carbon atoms in its backbone (e.g., C1-C10 for straight chain, C3-C10 for branched chain), and more preferably 6 or fewer carbons. Likewise, preferred cycloalkyls have from 4-7 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure.
- Moreover, alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, etc.) include both “unsubstituted alkyl” and “substituted alkyl”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone, which allow the molecule to perform its intended function. The term “substituted” is intended to describe moieties having substituents replacing a hydrogen on one or more atoms, e.g. C, O or N, of a molecule. Such substituents can include, for example, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, morpholino, phenol, benzyl, phenyl, piperizine, cyclopentane, cyclohexane, pyridine, 5H-tetrazole, triazole, piperidine, or an aromatic or heteroaromatic moiety.
- Further examples of substituents of the invention, which are not intended to be is limiting, include moieties selected from straight or branched alkyl (preferably C1-C5), cycloalkyl (preferably C3-C8), alkoxy (preferably C1-C6), thioalkyl (preferably C1-C6), alkenyl (preferably C2-C6), alkynyl (preferably C2-C6), heterocyclic, carbocyclic, aryl (e.g., phenyl), aryloxy (e.g., phenoxy), aralkyl (e.g., benzyl), aryloxyalkyl (e.g., phenyloxyalkyl), arylacetamidoyl, alkylaryl, heteroaralkyl, alkylcarbonyl and arylcarbonyl or other such acyl group, heteroarylcarbonyl, or heteroaryl group, (CR′R″)0-3NR′R″ (e.g., —NH2), (CR′R″)0-3CN (e.g., —CN), —NO2, halogen (e.g., —F, —Cl, —Br, or —I), (CR′R″)0-3C(halogen)3 (e.g., —CF3), (CR′R″)0-3CH(halogen)2, (CR′R″)0-3CH2(halogen), (CR′R″)0-3CONR′R″, (CR′R″)0-3(CNH)NR′R″, (CR′R″)0-3S(O)1-2NR′R″, (CR′R″)0-3CHO, (CR′R″)0-3O(CR′R″)0-3H, (CR′R″)0-3S(O)0-3R′ (e.g., —SO3H, —OSO3H), (CR′R″)0-3O(CR′R″)0-3H (e.g., —CH2OCH3 and —OCH3), (CR′R″)0-3S(CR′R″)0-3H (e.g., —SH and —SCH3), (CR′R″)0-3OH (e.g., —OH), (CR′R″)0-3COR′, (CR′R″)0-3(substituted or unsubstituted phenyl), (CR′R″)0-3(C3-C8 cycloalkyl), (CR′R″)0-3CO2R′ (e.g., —CO2H), or (CR′R″)0-3OR′ group, or the side chain of any naturally occurring amino acid; wherein R′ and R″ are each independently hydrogen, a C1-C5 alkyl, C2-C5 alkenyl, C2-C5 alkynyl, or aryl group. Such substituents can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, oxime, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety. In certain embodiments, a carbonyl moiety (C═O) may be further derivatized with an oxime moiety, e.g., an aldehyde moiety may be derivatized as its oxime (—C═N—OH) analog. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. Cycloalkyls can be further substituted, e.g., with the substituents described above. An “aralkyl” moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (i.e., benzyl)).
- The term “alkenyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one double bond.
- For example, the term “alkenyl” includes straight-chain alkenyl groups (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched-chain alkenyl groups, cycloalkenyl (alicyclic) groups (cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl groups, and cycloalkyl or cycloalkenyl substituted alkenyl groups. The term alkenyl further includes alkenyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkenyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-C6 for straight chain, C3-C6 for branched chain). Likewise, cycloalkenyl groups may have from 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbons in the ring structure. The term C2-C6 includes alkenyl groups containing 2 to 6 carbon atoms.
- Moreover, the term alkenyl includes both “unsubstituted alkenyls” and “substituted alkenyls”, the latter of which refers to alkenyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
- The term “alkynyl” includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but which contain at least one triple bond.
- For example, the term “alkynyl” includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), branched-chain alkynyl groups, and cycloalkyl or cycloalkenyl substituted alkynyl groups. The term alkynyl further includes alkynyl groups that include oxygen, nitrogen, sulfur or phosphorous atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight chain or branched chain alkynyl group has 6 or fewer carbon atoms in its backbone (e.g., C2-C6 for straight chain, C3-C6 for branched chain). The term C2-C6 includes alkynyl groups containing 2 to 6 carbon atoms.
- Moreover, the term alkynyl includes both “unsubstituted alkynyls” and “substituted alkynyls”, the latter of which refers to alkynyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, alkyl groups, alkynyl groups, halogens, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
- The term “amine” or “amino” should be understood as being broadly applied to both a molecule, or a moiety or functional group, as generally understood in the art, and may be primary, secondary, or tertiary. The term “amine” or “amino” includes compounds where a nitrogen atom is covalently bonded to at least one carbon, hydrogen or heteroatom. The terms include, for example, but are not limited to, “alkyl amino,” “arylamino,” “diarylamino,” “alkylarylamino,” “alkylaminoaryl,” “arylaminoalkyl,” “alkaminoalkyl,” “amide,” “amido,” and “aminocarbonyl.” The term “alkyl amino” comprises groups and compounds wherein the nitrogen is bound to at least one additional alkyl group. The term “dialkyl amino” includes groups wherein the nitrogen atom is bound to at least two additional alkyl groups. The term “arylamino” and “diarylamino” include groups wherein the nitrogen is bound to at least one or two aryl groups, respectively. The term “alkylarylamino,” “alkylaminoaryl” or “arylaminoalkyl” refers to an amino group which is bound to at least one alkyl group and at least one aryl group. The term “alkaminoalkyl” refers to an alkyl, alkenyl, or alkynyl group bound to a nitrogen atom which is also bound to an alkyl group.
- The term “amide,” “amido” or “aminocarbonyl” includes compounds or moieties which contain a nitrogen atom which is bound to the carbon of a carbonyl or a thiocarbonyl group. The term includes “alkaminocarbonyl” or “alkylaminocarbonyl” groups which include alkyl, alkenyl, aryl or alkynyl groups bound to an amino group bound to a carbonyl group. It includes arylaminocarbonyl and arylcarbonylamino groups which include aryl or heteroaryl moieties bound to an amino group which is bound to the carbon of a carbonyl or thiocarbonyl group. The terms “alkylaminocarbonyl,” “alkenylaminocarbonyl,” “alkynylaminocarbonyl,” “arylaminocarbonyl,” “alkylcarbonylamino,” “alkenylcarbonylamino,” “alkynylcarbonylamino,” and “arylcarbonylamino” are included in term “amide.” Amides also include urea groups (aminocarbonylamino) and carbamates (oxycarbonylamino).
- In a particular embodiment of the invention, the term “amine” or “amino” refers to substituents fo the formulas N(R8)R9, CH2N(R8)R9 and CH(CH3)N(R8)R9, wherein R8 and R9 are each, independently, selected from the group consisting of —H and —(C1-4alkyl)0-1G, wherein G is selected from the group consisting of —COOH, —H, —PO3H, —SO3H, —Br, —Cl, —F, —O—C1-4alkyl, —S—C1-4alkyl, aryl, —C(O)OC1-C6-alkyl, —C(O)C1-4alkyl-COOH, —C(O)C1-C4-alkyl and —C(O)-aryl;
-
- The term “aryl” includes groups, including 5- and 6-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, phenyl, pyrrole, furan, thiophene, thiazole, isothiaozole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like. Furthermore, the term “aryl” includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, anthryl, phenanthryl, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles”, “heterocycles,” “heteroaryls” or “heteroaromatics.” The aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, alkyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminoacarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as to form a polycycle (e.g., tetralin).
- It will be noted that the structures of some of the compounds of this invention include asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of this invention. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof. Compounds described herein may be obtained through art recognized synthesis strategies.
- Additionally, the phrase “any combination thereof” implies that any number of the listed functional groups and molecules may be combined to create a larger molecular architecture. For example, the terms “phenyl,” “carbonyl” (or “═O”), “—O—,” “—OH,” and C1-6 (i.e., —CH3 and —CH2CH2CH2—) can be combined to form a 3-methoxy-4-propoxybenzoic acid substituent; or the terms “acid” (i.e., —COOH) and C1-6 (i.e., —CH2CH3) can be combined to form an ethyl ester substituent. It is to be understood that when combining functional groups and molecules to create a larger molecular architecture, hydrogens can be removed or added, as required to satisfy the valence of each atom.
- As used herein, the term “pharmaceutically acceptable salts” refers to salts of the invention prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids and organic acids. Suitable non-toxic acids include inorganic and organic acids such as acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic and the like. Particularly preferred salts are sodium, lysine and argentine salts of the compounds of the invention.
- As used herein, the term “neurotrophic factor” or “neurotrophin” (also referred to herein as “NT”) refers to members of a family of proteins, usually in the form of dimers, which are structurally homologous to NGF. The term includes the precursors (pro-neurotrophins, e.g., pro-NGF) and the mature proteins which include three surface 3-hairpin loops, a p-strand, an internal reverse turn region, and N- and C-termini. Neurotrophins promote at least one of the biological activities related to vertebrate neuron survival, differentiation, and function, as determined using assays described, for example, in US 2002/0169182A1 and Riopelle et al., Can J. of Phys. and Pharm. 60:707 (1982); Harrington et al. PNAS USA 101(16):6226-6230, (2004)). Neurotrophic factors include, for example, brain-derived neurotrophic factor (BDNF), NGF, neurotrophin 3 (NT-3),
neurotrophin 4/5 (NT-4/5), and neurotrophin 6 (NT-6) (R. M. Lindsay et al.: TINS, vol. 17, p. 182 (1994) and R. M. Lindsay: Phil. Trans. R. Soc. Lond. B. vol. 351, p. 365-373 (1996)). In addition, ciliary neurotrophic factor (CNTF), glia-derived neurotrophic factor (GDNF), glia growth factor (GGF2), central nerve growth factor (AF-1), hepatocyte growth factor (HGF) (A. Ebens et al., Neuron, vol. 17, p. 1157-1172 (1996)) can also be considered as neurotrophic factors. Moreover, biotechnologically engineered products of the above neurotrophic factors, which are derived by a partial substitution, an addition, a deletion or a removal by conventional genetic engineering techniques, are also included within the scope of the neurotrophic factors of the present invention as far as such product shows biological activities of the naturally-occurred neurotrophic factors. - As used herein, the term “neurotrophin receptor” (also referred to herein as “NTR”) is meant to refer to a receptor which binds a neurotrophin. In certain embodiments, the neurotrophin receptor is a member of the tyrosine kinase family of receptors, generally referred to as the “Trk” receptors or “Trks”, which are expressed on cellular surfaces. The Trk family includes, but is not limited to, TrkA, TrkB, and TrkC. In a particular embodiment the neurotrophin receptor is TrkA. In other embodiments, the neurotrophin receptor is p75NTR, also called p75 or low-affinity nerve growth factor receptor or common neurtotrophin receptor. These receptors may be from any animal species that expresses neurotrophin receptors (e.g. human, murine, rabbit, porcine, equine, etc.), and include full length receptors, their truncated and variant forms, such as those arising by alternate splicing and/or insertion, and naturally-occurring allelic variants, as well as functional derivatives of such receptors.
- “Neurotrophin-mediated activity” is a biological activity that is normally modulated (e.g., inhibited or promoted), either directly or indirectly, in the presence of a neurotrophin. Neurotrophin-mediated activities include, for example, neurotrophin binding to the p75NTR receptor or neurotrophin binding to one of the Trk receptors (e.g., TrkA), the ability to promote neurotrophin receptor dimerization and/or phosphorylation, neuron survival, neuron differentiation including neuron process formation and neurite outgrowth, neurotransmission and biochemical changes such as enzyme induction. A biological activity that is mediated by a particular neurotrophin, e.g. NGF or pro-NGF, is referred to herein by reference to that neurotrophin, e.g. NGF-mediated activity. (It is noted that “NGF-mediated activity” also includes “proNGF-mediated activity.”) To determine the ability of a compound to inhibit a neurotrophin-mediated activity, conventional in vitro and in vivo assays can be used. For example, a receptor binding assay, such as the assay described in US 2002/0169182 A1, can be used to assess the extent to which a compound inhibits neurotrophin/receptor binding. Inhibition of neurite survival and outgrowth can be determined using the in vitro assay described by Riopelle et al. in the Can. J. of Phys. and Pharm., 1982, 60: 707. Other examples of in vitro and in vivo assays for use in determining the ability of a compound to inhibit a neurotrophin-mediated activity are described in the “Exemplification of the Invention” section of the application.
- “Neurotransmission,” as used herein, is a process by which small signaling molecules, termed neurotransmitters, are rapidly passed in a regulated fashion from a neuron to another cell. Typically, following depolarization associated with an incoming action potential, a neurotransmitter is secreted from the presynaptic neuronal terminal. The neurotransmitter then diffuses across the synaptic cleft to act on specific receptors on the postsynaptic cell, which is most often a neuron but can also be another cell type (such as muscle fibers at the neuromuscular junction). The action of neurotransmitters can either be excitatory, depolarizing the postsynaptic cell, or inhibitory, resulting in hyperpolarization. Neurotransmission can be rapidly increased or decreased by neuromodulators, which typically act either pre-synaptically or post-synaptically. The neurotrophin family (notably NGF and BDNF) have been shown to have prominent neuromodulatory effects on diverse neuronal types (Lohof et al, Nature. 363(6427):350-3 (1993); Li et al. J Neurosci. 18(24):10231-40. (1998)). BDNF has also been shown to behave like a neurotransmitter, acting directly on target cells to alter their excitability by rapidly and directly gating ion certain ion channels (Rose et al., Bioessays. 26(11):1185-94. (2004)).
- There are several simple fashions in which neurotransmission can be studied. The release of neurotransmitters from cultured neurons can be directly quantified using HPLC, radiolabled neurotransmitters or other methodologies. Neurotransmission can be estimated by dyes such as FM 1-43, a fluorescent marker of synaptic vesicle cycling. Moreover, neurotransmission between neurons can be directly monitored using standard electrophysiological techniques, as can any direct neurotransmitter-like effects of neurotrophins on ion channel currents. These various methodologies have been used to study the effects of neurotrophins, such as BDNF and NGF, on neurotransmitter release and neurotransmission (Lohof et al.; Li et al.; Rose et al.).
- The term “contacting” as used herein refers to bringing a compound of the invention and a target, e.g., NGF, p75NTR and/or TrkA together in such a manner that the compound can affect the activity of the target, either directly; i.e., by interacting with the target itself, or indirectly; i.e., by interacting with another target on which the catalytic activity of the target is dependent. For example, a compound of the invention may effect the activity of TrkA by contacting (e.g., binding to) TrkA directly, or by contacting (e.g., binding to) p75NTR, which may effect the activity of TrkA. Such “contacting”” can be accomplished “in vitro,” i.e., in a test tube, a petri dish or the like, or “in vivo,” i.e., administered to a subject such as a mouse, rat or human. In a test tube, contacting may involve only a compound and a target of interest or it may involve whole cells. Cells may also be maintained or grown in cell culture dishes and contacted with a compound in that environment. “Contacting” can refer to a compound of the invention directly binding to a target, or being in the vicinity of a target.
- Examples of neurotrophin-mediated activities include, but are not limited to, pain (e.g., inflammatory pain, acute pain, chronic malignant pain, chronic nonmalignant pain and neuropathic pain), inflammatory disorders, diseases and disorders of the genitourinary and gastrointestinal systems, and neurological disorders (e.g., neurodegenerative or neuropsychiatric disorders).
- “Pain” is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage (International Association for the Study of Pain—IASP). Pain is classified most often based on duration (i.e., acute vs. chronic pain) and/or the underlying pathophysiology (i.e., nociceptive vs. neuropathic pain).
- Acute pain can be described as an unpleasant experience with emotional and cognitive, as well as sensory, features that occur in response to tissue trauma and disease and serves as a defensive mechanism. Acute pain is usually accompanied by a pathology (e.g., trauma, surgery, labor, medical procedures, acute disease states) and the pain resolves with healing of the underlying injury. Acute pain is mainly nociceptive, but may also be neuropathic.
- Chronic pain is pain that extends beyond the period of healing, with levels of identified pathology that often are low and insufficient to explain the presence, intensity and/or extent of the pain (American Pain Society—APS). Unlike acute pain, chronic pain serves no adaptive purpose. Chronic pain may be nociceptive, neuropathic, or both and caused by injury (e.g., trauma or surgery), malignant conditions, or a variety of chronic conditions (e.g., arthritis, fibromyalgia and neuropathy). In some cases, chronic pain exists de novo with no apparent cause.
- “Nociceptive pain” is pain that results from damage to tissues and organs. Nociceptive pain is caused by the ongoing activation of pain receptors in either the surperficial or deep tissues of the body. Nociceptive pain is further characterized as “somatic pain”, including “cutaneous pain” and “deep somatic pain”, and “visceral pain”.
- “Somatic pain” includes “cutaneous pain” and “deep somatic pain.” Cutaneous pain is caused by injury, diseases, disorders or neoplasms of the skin, subcutaneous tissues and related organs. Examples of conditions associated with cutaneous pain include, but are not limited to, cuts, burns, infections, lacerations, as well as traumatic injury and post-operative or surgical pain (e.g., at the site of incision).
- “Deep somatic pain” results from injuries, diseases, disorders or neoplasms of the musculoskeletal tissues, including ligaments, tendons, bones, blood vessels and connective tissues. Examples of deep somatic pain or conditions associated with deep somatic pain include, but are not limited to, sprains, broken bones, arthralgia, vasculitis, myalgia and myofascial pain. Arthralgia refers to pain caused by a joint that has been injured (such as a contusion, break or dislocation) and/or inflamed (e.g., arthritis). Vaculitis refers to inflammation of blood vessels with pain. Myalgia refers to pain originating from the muscles. Myofascial pain refers to pain stemming from injury or inflammation of the fascia and/or muscles.
- “Visceral” pain is associated with injury, inflammation, disease or neoplasms of the body organs and internal cavities, including but not limited to, the circulatory system, respiratory system, gastrointestinal system, genitourinary system, immune system, as well as the ear, nose and throat. Visceral pain can also be associated with infectious and parasitic diseases that affect the body organs and tissues. Visceral pain is extremely difficult to localize, and several injuries to visceral tissue exhibit “referred” pain, where the sensation is localized to an area completely unrelated to the site of injury. For example, myocardial ischaemia (the loss of blood flow to a part of the heart muscle tissue) is possibly the best known example of referred pain; the sensation can occur in the upper chest as a restricted feeling, or as an ache in the left shoulder, arm or even hand. Phantom limb pain is the sensation of pain from a limb that one no longer has or no longer gets physical signals from—an experience almost universally reported by amputees and quadriplegics.
- “Neuropathic pain” or “neurogenic pain” is pain initiated or caused by a primary lesion, dysfunction or perturbation in the nervous system. “Neuropathic pain” can occur as a result of trauma, inflammation, disease or neoplasms of the peripheral nervous system (“peripheral neuropathic pain”) and/or the central nervous system (“central pain”). For example, neuropathic pain can be caused by a nerve or nerves that are irritated, trapped, pinched, severed or inflamed (neuritis). There are many neuropathic pain syndromes, such as diabetic neuropathy, trigeminal neuralgia, postherpetic neuralgia (“shingles”), post-stroke pain, and complex regional pain syndromes (also called reflex sympathetic dystrophy or “RSD” and causalgia).
- As used herein, the term “inflammatory disease or disorder” includes diseases or disorders which are caused, at least in part, or exacerbated by, inflammation, which is generally characterized by increased blood flow, edema, activation of immune cells (e.g., proliferation, cytokine production, or enhanced phagocytosis), heat, redness, swelling, pain and loss of function in the affected tissue and organ. The cause of inflammation may be due to physical damage, chemical substances, micro-organisms, tissue necrosis, cancer or other agents. Inflammatory disorders include acute inflammatory disorders, chronic inflammatory disorders, and recurrent inflammatory disorders. Acute inflammatory disorders are generally of relatively short duration, and last for from about a few minutes to about one to two days, although they may last several weeks. The main characteristics of acute inflammatory disorders include increased blood flow, exudation of fluid and plasma proteins (edema) and emigration of leukocytes, such as neutrophils. Chronic inflammatory disorders, generally, are of longer duration, e.g., weeks to months to years or longer, and are associated histologically with the presence of lymphocytes and macrophages and with proliferation of blood vessels and connective tissue. Recurrent inflammatory disorders include disorders which recur after a period of time or which have periodic episodes. Some disorders may fall within one or more categories.
- The terms “neurological disorder” and “neurodegenerative disorder” refer to injuries, diseases and dysfunctions of the nervous system, including the peripheral nervous system and central nervous system. Neurological disorders and neurodegenerative disorders include, but are not limited to, diseases and disorders that are associated with neurotrophin-mediated biological activity. Examples of neurological disorders include, but are not limited to, Alzheimer's disease, epilepsy, cancer, neuromuscular diseases, multiple sclerosis, amyotrophic lateral sclerosis, stroke, cerebral ischemia, neuropathy (e.g., chemotherapy-induced neuropathy, diabetic neuropathy), retinal pigment degeneration, Huntington's chorea, and Parkinson's disease, and ataxia-telangiectasia.
- As used herein, “neuropathy” is defined as a failure of the nerves that carry information to and from the brain and spinal cord resulting in one or more of pain, loss of sensation, and inability to control muscles. In some cases, the failure of nerves that control blood vessels, intestines, and other organs results in abnormal blood pressure, digestion problems, and loss of other basic body processes. Peripheral neuropathy may involve damage to a single nerve or nerve group (mononeuropathy) or may affect multiple nerves (polyneuropathy).
- The term “treated,” “treating” or “treatment” includes the diminishment or alleviation of at least one symptom associated with the pain, inflammatory disorder, neurological disorder, genitourinary disorder or gastrointestinal disorder (e.g., associated with or caused by neurotrophin mediated activity) being treated. In certain embodiments, the treatment comprises the modulation of the interaction of a neurotrophin (e.g., monomer or dimer) and its receptor by an NT/NTR modulating compound, for example an NGF/NTR modulating compound, which would in turn diminish or alleviate at least one symptom directly or indirectly associated with or caused by the neurotrophin-mediated activity being treated. For example, treatment can be diminishment of one or several symptoms of a disorder or complete eradication of a disorder.
- As used herein, the phrase “therapeutically effective amount” of the compound is the amount necessary or sufficient to treat or prevent pain, an inflammatory disorder, a neurological disorder, a gastrointestinal disorder or a genitourinary disorder, (e.g., to prevent the various morphological and somatic symptoms of a neurotrophin-mediated activity). In an example, an effective amount of the compound is the amount sufficient to alleviate at least one symptom of the disorder, e.g., pain, inflammation, a neurological disorder, a gastrointestinal disorder or a genitourinary disorder, in a subject.
- The term “subject” is intended to include animals, which are capable of suffering from or afflicted with a neurotrophin-associated state or neurotrophin-associated disorder, or any disorder involving, directly or indirectly, neurotrophin signaling. In another embodiement, a subject is also intended to include animals, which are capable of suffering from pain, an inflammatory disorder, a neurological disorder, a respiratory disorder, a gastrointestinal disorder or a genitourinary disorder. Examples of subjects include mammals, e.g., humans, dogs, cows, horses, pigs, sheep, goats, cats, mice, rabbits, rats, and transgenic non-human animals. In certain embodiments, the subject is a human, e.g., a human suffering from, at risk of suffering from, or potentially capable of suffering from pain, inflammation, a neurological disorder, a gastrointestinal disorder or a genitourinary disorder (e.g. associated with neurotrophin-associated activity).
- The language “NT/NTR modulator” refers to compounds that modulate, i.e., inhibit, promote or otherwise alter the interaction of a neurotrophin with a neurotrophin receptor. For example, “NGF/NTR modulator” refers to compounds that modulate, e.g., inhibit, promote, or otherwise alter, the interaction of NGF (or proNGF) with p75NTR, TrkA, or p75NTR and TrkA. Examples of NGF/NTR modulators include compounds of
Formulas Formulas - Modulators of Neurotrophin/Neurotrophin Receptor Interaction
- In one aspect, the present invention provides compounds which modulate the interaction of a neurotrophin with a neurotrophin receptor. In certain embodiments, the compounds modulate the interaction of nerve growth factor (NGF) and/or a precursor thereof with a neurotrophin receptor (NTR). In other embodiments the compound modulates the interaction of NGF and/or a precursor thereof with the p75NTR receptor. In still other embodiments, the compound also modulates the interaction of NGF (or proNGF) with the TrkA receptor. In further embodiments, the compound modulates the interaction of NGF (or proNGF) with both the p75NTR and TrkA receptor.
- In another aspect, the compounds of the invention treat pain, inflammatory disorders, neurological disorders, respiratory disorders, gastrointestinal disorders or genitourinary disorders in a subject in need thereof, comprising administering to the subject an effective amount of a compound of the invention.
- Without being bound by theory, it is believed that an electronegative atom of the compound of the invention, e.g, an NGF/NTR modulator, bears a full or partial negative charge under physiological conditions and can, therefore, interact electrostatically with the positively charged side chain of an NGF lysine residue. Thus, there will be an interaction, such as, for example, a hydrogen bond, an ion/ion interaction, an ion/dipole interaction or a dipole/dipole interaction. The hydrophobic region or moiety of the NGF/NTR modulator can interact with a hydrophobic region of NGF via a hydrophobic interaction. Without being bound by theory, it is believed that compounds of the invention can interact with NGF in such a way as to interfere with, and thereby modulate, the interaction of NGF and p75mm and/or TrkA. In one embodiment, the compound of the invention is of the general Formula 16,
wherein R1, R2, R3, R4 and R5 are each, independently, selected from the group consisting of a hydrogen atom, —N(H)—, alkyl, alkoxy, amino, halogen, hydroxyl, acid, cyano, sulfonamide, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amide, ester, ether, thioether, alkene, furan, thiophene, thiazole, nitro, alkene, tetrazole, sulfone, urea, thiourea, morpholine, piperidine, piperazine, azepane, and any combination thereof; or a pharmaceutically acceptable salt thereof. - In another embodiment of Formula 16, R1, R1a, R2, R3, R4 and R5 are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
- wherein the alkyl, C1-6-alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl or azepanyl.
- In another embodiment of Formula 16, R2, R3, R4 and R5 are each, independently, selected from the group consisting of hydrogen, C1-C6-alkyl, halogen, NO2, COOH, and N(R8)R9, wherein R8 and R9 are each, independently, selected from the group consisting of —H and —C1-4alkyl)0-1G, wherein G is selected from the group consisting of —COOH, —PO3H, —SO3H, —Br, —Cl, —F, —OC1-4alkyl, —SC1-4alkyl, aryl, C1-C6-alkyl, —C(O)OC1-C6-alkyl, —C(O)C1-C4-alkyl and —C(O)-aryl.
- In still another embodiment of Formula 16, R2, R3, R4 and R5 are hydrogen, and R1 and R1a are (CH2)xR13, wherein R13 is selected from the group consisting of hydrogen, C1-6-alkyl, amino, C1-6-alkoxy, —OH, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and x is 0, 1, 2, 3 or 4.
- In yet another embodiment of Formula 16, R13 is selected from the group consisting of —COOH, imidazolyl, —SO3H, —OSO3H, —OH, morpholino, piperazinyl, —PO3H, —PO3C1-4alkyl and —NO2.
- In another embodiment of Formula 16, R13 is selected from the group consisting of —COOH and —COO−Na+. In another embodiment of Formula 16, x is 3 and R13 is COOH. In still another embodiment of Formula 16, R13 is C(O)N(R8)R9 or N(R8)R9, wherein R8 and R9 are each, independently, selected from the group consisting of —H and —C1-4alkyl)0-1G, wherein G is selected from the group consisting of —COOH, —H, —PO3H, —SO3H, —Br, —Cl, —F, —OC1-4alkyl, —SC1-4alkyl, aryl, —C(O)OC1-C6-alkyl, —C(O)C1-4alkyl-COOH, —C(O)C1-C4-alkyl and —C(O)-aryl; or N(R8)R9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morpholino.
-
- R6, R7 and R12 are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
- In another embodiment of Formula 16, R6 and R7 are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C1-C4-alkyl, —NH2, —N(H)C(O)C1-4alkyl, methoxy, morpholino, piperazinyl and C1-C4-alkyl-ester; and R12 is hydrogen.
- In another embodiment of Formula 16, R6 and R7 are each, independently, selected from the group consisting of hydrogen, SO3H, chloro, fluoro, —OH, —COOH, and —COO−Na+; and R12 is hydrogen. In still another embodiment of Formula 17, R6 and R12 are hydrogen, and R7 is —COOH; or R6 is chloro, R12 is hydrogen, and R7 is —COOH; or R6 and R12 are hydrogen, and R7 is SO3H.
- In another embodiment of Formula 16, R2, R3, R4 and R5 are hydrogen, R1 is (CH2)xR13, wherein
- R13 is selected from the group consisting of hydrogen, C1-6-alkyl, amino, C1-6-alkoxy, —OH, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; x is 0, 1, 2, 3 or 4; and
-
- R6, R7 and R12 are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
- In another embodiment of Formula 16, R13 is C(O)N(R8)R9 or N(R8)R9, wherein R8 and R9 are each, independently, selected from the group consisting of —H and —C1-4alkyl)0-1G, wherein G is selected from the group consisting of —COOH, —H, —PO3H, —SO3H, —Br, —Cl, —F, —OC1-4alkyl, —SC1-4alkyl, aryl, —C(O)OC1-C6-alkyl, —C(O)C1-4alkyl-COOH, —C(O)C1-C4-alkyl and —C(O)-aryl; or N(R8)R9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morpholino. In still another embodiment, R13 is NH2 or N(CH3)2.
- In another embodiment of Formula 16, R2, R3, R4 and R5 are hydrogen, R1 is (CH2)xR13, wherein R13 is selected from the group consisting of —COOH, imidazolyl, —SO3H, —OSO3H, —OH, morpholino, piperazinyl, —PO3H, —PO3C1-4alkyl and —NO2;
- x is 0, 1, 2, 3 or 4; and
-
- wherein R6 and R7 are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C1-C4-alkyl, —NH2, —N(H)C(O)C1-4alkyl, methoxy, morpholino, piperazinyl and C1-C4-alkyl-ester; and
- R12 is hydrogen.
- In another embodiment of Formula 16, x is 3 and R13 is COOH, R6and R12 are hydrogen, and R7 is —COOH; or R6 is chloro, R12 is hydrogen, and R7 is —COOH; or R6 and R12 are hydrogen, and R7 is SO3H.
- In another embodiment, the compound of the invention is of the general Formula 17,
wherein R6, R7, R12, R6a, R7a and R12a are each, independently, selected from the group consisting of a hydrogen atom, —N(H)—, alkyl, alkoxy, amino, halogen, hydroxyl, acid, cyano, sulfonamide, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, amide, ester, ether, thioether, alkene, furan, thiophene, thiazole, nitro, alkene, tetrazole, sulfone, urea, thiourea, morpholine, piperidine, piperazine, azepane, and any combination thereof or a pharmaceutically acceptable salt thereof. - In one embodiment of Formula 17, R6, R6a, R7 and R7a are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C1-C4-alkyl, —NH2, —C(O)N(H)C1-4alkyl, methoxy, morpholino, piperazinyl and C1-C4-alkyl-ester; and R12 and R12a are hydrogen.
- In another embodiment of Formula 17, R6 and R7 are each, independently, selected from the group consisting of hydrogen, chloro, fluoro, —OH, —COOH, and —COO−Na+; R12 is hydrogen; R6a is selected from the group consisting of hydrogen, chloro, fluoro, —OH, —COOH, and —COO−Na+; and R7a and R12a are hydrogen.
- In another embodiment of Formula 17, R6 is COOH, R7 is Cl, R6a is —H, NO2, OCH3, COOCH3 or Cl, and R7a, R12 and R12a are hydrogen. In still another embodiment of Formula 17, R6 and R6a are COOH, and R7, R7a, R12 and R12a are hydrogen.
-
- and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof,
- wherein
- R6a, R7a and R12a are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl; and
- R1 is (CH2)xR13, wherein R13 is selected from the group consisting of hydrogen, C1-6-alkyl, amino, C1-6-alkoxy, -OH, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and
- x is 0, 1, 2, 3 or 4.
- In one embodiment of
Formula 18, R13 is selected from the group consisting of —COOH, imidazolyl, —SO3H, —OSO3H, —OH, morpholino, piperazinyl, —PO3H, —PO3C1-4alkyl and —NO2. In another embodiment ofFormula 18, x is 3 and R13 is COOH. In still another embodiment ofFormula 18, R13 is C(O)N(R8)R9 or N(R8)R9, wherein R8 and R9 are each, independently, selected from the group consisting of —H and —(C1-4alkyl)0-1G, wherein G is selected from the group consisting of —COOH, —H, —PO3H, —SO3H, —Br, —Cl, —F, —OC1-4alkyl, —SC1-4alkyl, aryl, —C(O)OC1-C 6-alkyl, —C(O)C1-4alkyl-COOH, —C(O)C1-C4-alkyl and —C(O)-aryl; or N(R8)R9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morpholino. In another embodiment ofFormula 18, R13 is NH2 or N(CH3)2. -
- and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
- wherein
- R6a, R7a, R8a and R9a are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
- In one embodiment of
Formulas 19 or 20, R6a and R8a are hydrogen, and R7a and R9a are COONa; or R6a, R7a, R8a and R9a are hydrogen. -
- and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
- wherein
- R1, R8a, and R9a are each, independently, selected from the group consisting of a hydrogen atom, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
- wherein the alkyl, C1-6-alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl or azepanyl.
- In one embodiment of Formula 21, R1 is (CH2)xR13, wherein
- R13 is selected from the group consisting of hydrogen, C1-6-alkyl, amino, C1-6-alkoxy, —OH, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and
- x is 0, 1, 2, 3 or 4.
- In another embodiment of Formula 21, R13 is C(O)N(R8)R9 or N(R8)R9, wherein R8 and R9 are each, independently, selected from the group consisting of —H and —C1-4alkyl)0-1G, wherein G is selected from the group consisting of —COOH, —H, —PO3H, —SO3H, —Br, —Cl, —F, —OC1-4alkyl, —SC1-4alkyl, aryl, —C(O)OC1-C6-alkyl, —C(O)C1-4alkyl-COOH, —C(O)C1-C4-alkyl and —C(O)-aryl;
- or N(R8)R9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morpholino.
- In another embodiment of Formula 21, R13 is NH2 or N(CH3)2. In still another embodiment of Formula 21, x is 3, R13 is COOH, R8a is H and R9a is COOH. In yet another embodiment of Formula 21, R1 is
wherein R6, R7 and R12 are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl. - In yet another embodiment of Formula 21, R6 and R7 are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C1-C4-alkyl, —NH2, —N(H)C(O)C1-4alkyl, methoxy, morpholino, piperazinyl and C1-C4-alkyl-ester; and R12 is hydrogen. In still another embodiment of Formula 21, R6 is COOH, R7 is Cl, R12 is H, R8a is H and R9a is COOH.
-
- and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
- wherein
- R1, R2, R3, R4 and R5 are each, independently, selected from the group consisting of a hydrogen atom, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
- wherein the alkyl, C1-6-alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl or azepanyl.
- In one embodiment of Formula 22, R2, R3, R4 and R5 are hydrogen, and each R1 is: (CH2)xR13, wherein
- R13 is selected from the group consisting of hydrogen, C1-6-alkyl, amino, C1-6-alkoxy, —OH, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and
- x is 0, 1, 2, 3 or 4.
- In another embodiment of Formula 22, R13 is C(O)N(R8)R9 or N(R8)R9, wherein R8 and R9 are each, independently, selected from the group consisting of —H and —(C1-4alkyl)0-1G, wherein G is selected from the group consisting of —COOH, —H, —PO3H, —SO3H, —Br, —Cl, —F, —OC1-4alkyl, —SC1-4alkyl, aryl, —C(O)OC1-C6-alkyl, —C(O)C1-4alkyl-COOH, —C(O)C1-C4-alkyl and —C(O)-aryl;
- or N(R8)R9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morpholino.
- In another embodiment of Formula 22, R13 is NH2 or N(CH3)2. In still another embodiment of Formula 22, R13 is selected from the group consisting of —COOH, imidazolyl, —SO3H, —OSO3H, —OH, morpholino, piperazinyl, —PO3H, —PO3C1-4alkyl and —NO2. In still another embodiment of Formula 22, R13 is selected from the group consisting of —COOH and —COO−Na+. In yet another embodiment of Formula 22, x is 3 and R13 is COOH.
-
- R6, R7 and R12 are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
- In yet another embodiment of Formula 22, R6 and R7 are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C1-C4-alkyl, —NH2, —N(H)C(O)C1-4alkyl, methoxy, morpholino, piperazinyl and C1-C4-alkyl-ester; and R12 is hydrogen.
- In another embodiment of Formula 22, R6 and R7 are each, independently, selected from the group consisting of hydrogen, chloro, fluoro, —OH, —COOH, and —COO−Na+; and R12 is hydrogen. In yet another embodiment of Formula 22, R6 and R12 are hydrogen, and R7 is —COOH; or R6 is Cl, R12 is hydrogen, and R7 is COOH.
- It is to be understood that all of the compounds of
Formulas - In a particular embodiment of the invention, the NGF/NTR modulator of
Formulas - In another embodiment, the invention pertains to the NGF/NTR modulators of
Formulas - In yet another embodiment, the invention pertains to pharmaceutical compositions comprising NT/NTR modulating compounds described herein and a pharmaceutical acceptable carrier.
- In another embodiment, the invention includes any novel compound or pharmaceutical compositions containing compounds of the invention described herein. For example, compounds and pharmaceutical compositions containing compounds set forth herein (e.g., Table 1) are part of this invention, including salts thereof, e.g., pharmaceutically acceptable salts.
- The method for acquiring the PC12 data described in Table 1 is described herein in Example 1. Each experiment was done at least once with an n value of 4 for each data point. (n/a=not acquired)
TABLE 1 PC12 (TrkA & p75) Single point (% max binding) Concentration Abfix IC50 Compound Name Structure (μM) Mean Mean 4-[7-(3-Carboxy-propyl)-1,3,6,8- tetraoxo-3,6,7,8-tetrahydro-1H- benzo[lmn][3,8]phenanthrolin-2- yl]-butyric acid (12) n/a n/a *** 3-[7-(3-Carboxy-phenyl)- 1,3,6,8-tetraoxo-3,6,7,8- tetrahydro-1H- benzo[lmn][3,8]phenanthrolin-2- yl]-4-benzoic acid (17) n/a n/a *** 3-[7-(1-chloro-4-carboxy- phenyl)-1,3,6,8-tetraoxo-3,6,7,8- tetrahydro-1H- benzo[lmn][3,8]phenanthrolin-2- yl]-4-chloro-benzoic acid (18) 50 *** *** 3-(1,3,6,8-Tetraoxo-1,3,6,8- tetrahydro-2-oxa-7-aza-pyren-7- yl)-benzoic acid (45) n/a n/a * 4-(1,3,6,8-Tetraoxo-7-(4- benzenesulfonic acid)-3,6,7,8- tetrahydro-1H- benzo[lmn][3,8]phenanthrolin-2- yl)-benzenesulfonic acid (54) 50 *** n/a 3-(1,3,6,8-Tetraoxo-7-(3- benzenesulfonic acid)-3,6,7,8- tetrahydro-1H- benzo[lmn][3,8]phenanthrolin-2- yl)-benzenesulfonic acid (55) 50 **/*** * 4-Chloro-3-(1,3,6,8-tetraoxo- 1,3,6,8-tetrahydro-2-oxa-7-aza- pyren-7-yl)-benzoic acid (58) 50 *** *** 3-[7-(3-Carboxy-propyl)-1,3,6,8- tetraoxo-3,6,7,8-tetrahydro-1H- benzo[lmn][3,8]phenanthrolin-2- yl]-4-chloro-benzoic acid (59) 50 *** *** 2-(5-Carboxy-2-chloro-phenyl)- 1,3,6-trioxo-1,2,3,6-tetrahydro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]phenanthroline-9- carboxylic acid (90) 0.2 *** *** 1,3,6-trioxo-1,2,3,6-tetrahydro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]diphenanthroline-9- carboxylic acid (91) (mixture of isomers) n/a n/a *** 1,3,6-trioxo-1,2,3,6-tetrahydro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]diphenanthroline potassium salt (92) 50 * n/a 2-(3-Carboxy-phenyl)-1,3,6- trioxo-1,2,3,6-tetrahydro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]phenanthroline-9- carboxylic acid (93) 50 ** *** 4-(1,3,6,8-Tetraoxo-3,6,7,8- tetrahydro-1H-2-oxa-pyren-7- yl)-butyric acid (94) 25 *** *** 2-(3-Carboxy-propyl)-1,3,6- trioxo-1,2,3,6-tetrahydro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]phenanthroline-9- carboxylic acid (95) 25 * n/a Mixture of two isomers (96) n/a n/a *** Mixture of two isomers (97) n/a n/a *** 2-(5-Carboxy-2-chloro-phenyl)- 1,3,6-trioxo-1,2,3,6-tetrahydro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]phenanthroline-9 (98) 25 *** *** 2-(5-Carboxy-2-chloro-phenyl)- 1,3,6-trioxo-1,2,3,6-tetrahydro- 9-chloro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]phenanthroline (99) 10 *** *** 2-(5-Carboxy-2-chloro-phenyl)- 1,3,6-trioxo-1,2,3,6-tetrahydro- 9-nitro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]phenanthroline (100) 10 *** *** 2-(5-Carboxy-2-chloro-phenyl)- 1,3,6-trioxo-1,2,3,6-tetrahydro- 9-methoxy- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]phenanthroline (101) 10 ** *** Methyl-2-(5-Carboxy-2-chloro- phenyl)-1,3,6-trioxo-1,2,3,6- tetrahydro- benzo[lmn]benzo[4,5]imidazo[2,1- b][3,8]phenanthroline-9- carboxylic acid ester (102) 10 * *** % max binding Key IC50 Key 0 > *** > 30 10 0 > *** > 10 30 > ** > 50 10 > ** > 20 * > 50 * > 20 - In one embodiment of the invention, of 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (Compound 90) is used to treat pain in a subject.
- In another embodiment of the invention, 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (Compound 90) is used to treat inflammation in a subject.
- In one embodiment of the invention, of 3-[7-(1-chloro-4-carboxy-phenyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-4-chloro-benzoic acid (Compound 18) is used to treat pain in a subject.
- In another embodiment of the invention, 3-[7-(1-chloro-4-carboxy-phenyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-4-chloro-benzoic acid (Compound 18) is used to treat inflammation in a subject.
- In one embodiment of the invention, the modulating compounds of the invention are capable of chemically interacting with NGF, p75NTR, and/or TrkA. The language “chemical interaction” is intended to include, but is not limited to, reversible interactions such as hydrophobic/hydrophilic, ionic (e.g., coulombic attraction/repulsion, ion-dipole, charge-transfer), covalent bonding, Van der Waals, and hydrogen bonding. In certain embodiments, the chemical interaction is a reversible Michael addition. In a specific embodiment, the Michael addition involves, at least in part, the formation of a covalent bond.
- Compounds of the invention can be synthesized according to standard organic synthesis procedures that are known in the art. Synthesis procedures for compounds of the invention are described herein in the Exemplification section.
- Acid addition salts of the compounds of the invention are most suitably formed from pharmaceutically acceptable acids, and include for example those formed with inorganic acids, e.g., hydrochloric, sulphuric or phosphoric acids and organic acids e.g. succinic, maleic, acetic or fumaric acid. Other non-pharmaceutically acceptable salts, e.g., oxalates, may be used for example in the isolation of the invention, and the compounds of Table 1 for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt. Also included within the scope of the invention are solvates and hydrates of the invention.
- The conversion of a given compound salt to a desired compound salt is achieved by applying standard techniques, in which an aqueous solution of the given salt is treated with a solution of base, e.g., sodium carbonate or potassium hydroxide, to liberate the free base which is then extracted into an appropriate solvent, such as ether. The free base is then separated from the aqueous portion, dried, and treated with the requisite acid to give the desired salt. Particularly preferred salts are sodium, lysine and argentine salts of the compounds of the invention.
- In vivo hydrolyzable esters or amides of certain compounds of the invention can be formed by treating those compounds having a free hydroxy or amino functionality with the acid chloride of the desired ester in the presence of a base in an inert solvent such as methylene chloride or chloroform. Suitable bases include triethylamine or pyridine. Conversely, compounds of the invention, and the compounds of Table 1 having a free carboxy group may be esterified using standard conditions which may include activation followed by treatment with the desired alcohol in the presence of a suitable base.
- Assays
- The present invention also relates to a method of modulating the interaction of NGF (or proNGF) with a neurotrophin receptor, e.g, p75NTR and/or TrkA. In certain embodiments, the method comprises contacting NGF and/or a precursor thereof (proNGF) in the presence of p75NTR and/or TrkA with a NGF/NTR modulating amount of a NGF/NTR modulator compound (i.e., a compound of the invention), thereby modulating the interaction of NGF (and/or proNGF) with p75NTR and/or TrkA.
- The methods of the invention can be practiced in vitro, for example, in a cell culture screening assay to screen compounds which potentially modulate, directly or indirectly, receptor function. In such a method, the modulating compound can function by interacting with and eliminating any function or activity (e.g., receptor binding) of NGF and/or a precursor thereof in the sample or culture. The modulating compounds can also be used to control NGF activity in neuronal cell culture. In vitro cross-linking assays for determining the ability of a compound within the scope of the invention to modulate the interaction of NGF with p75NTR and/or TrkA, are well known in the art and described in the examples herein. Other assays for determining the ability of a compound to modulate the activity of NGF with its respective receptors are also readily available to the skilled artisan (see, Barker et al., Neuron 13(1): 203-215; (1994), Dehant et al., Development 119: 545-558 (1993); and US 2002/016982).
- Recombinant and native neurotrophin polypeptides from different species, including humans, are commercially available from several sources (e.g., Promega Corporation and R&D Systems). In addition, neurotrophin polypeptides for use in the assays described herein can be readily produced by standard biological techniques or by chemical synthesis. For example, a host cell transfected with an expression vector containing a nucleotide sequence encoding the desired neurotrophin can be cultured under appropriate conditions to allow expression of the peptide to occur. The secreted peptide can then be isolated according to standard techniques. Coding polynucleotides, precursors and promoters for a number of neurotrophins are known, including coding sequences for neurotrophins of some mammalian species. For example, GenBank M61176 sets for the coding sequence for BDNF (see also, XM.006027); BDNF precursor is set forth at BF439589; and a BDNF specific promoter is set forth at Eo5933. A similar range of coding sequences for other neurotrophins, including proNGF and mature NGF (e.g., NCBI ACCESSION NO P01138 and CAA37703), NT-4/5 and NT-3, are also available through GenBank and other publicly accessible nucleotide and amino acid sequence databases. Alternatively, the neurotrophin, e.g., NGF can be obtained by culturing a primary cell culture or an established cell line that can produce the neurotrophin, and isolating from the culture broth thereof (e.g., culture supernatant, cultured cells).
- The method can also be practiced in vivo, for example, to modulate one or more processes mediated by the interaction of NGF (and/or proNGF) with p75NTR, and/or the interaction of NGF with TrkA. Animal models for determining the ability of a compound of the invention to treat a disorder associated with or caused by a neurotrophin-mediated biological activity (e.g, pain, inflammatory disorders, respiratory disorders, neurological disorders, genitourinary disorders and gastrointestinal disorders) are well known and readily available to the skilled artisan.
- For example, animal models of neuropathic pain based on injury inflicted to a nerve (mostly the sciatic nerve) are described in Zeltser et al., 2000, Pain 89:19-24; Bennett et al., 1988, Pain 33:87-107; Seltzer et al., 1990, Pain 43:205-218; Kim et al., 1992, Pain 50:355-363; Decosterd et al., 2000, Pain 87:149-158 and DeLeo et al., 1994, Pain 56:9-16. There are also models of diabetic neuropathy (STZ induced diabetic neuropathy—Courteix et al., 1994, Pain 57:153-160) and drug induced neuropathies (vincristine induced neuropathy—Aley et al., 1996, Neuroscience 73: 259-265; oncology-related immunotherapy, anti-GD2 antibodies—Slart et al., 1997, Pain 60:119-125). Acute pain in humans can be reproduced using in murine animals chemical stimulation: Martinez et al., Pain 81: 179-186; 1999 (the writhing test—intraperitoneal acetic acid in mice), Coderre et al., Pain. 1993, 54:43-50 (intraplantar injection of formalin). Other types of acute pain models are described in Whiteside et al., 2004, Br J Pharmacol 141:85-91 (the incisional model, a post-surgery model of pain) and Johanek and Simone, 2004, Pain 109:432-442 (a heat injury model). An animal model of inflammatory pain using complete Freund's adjuvant (intraplantar injection) is described in Jasmin et al., 1998, Pain 75: 367-382. Intracapsular injection of irritant agents (complete Freund's adjuvant, iodoacetate, capsaicine, urate crystals, etc.) is used to develop arthritis models in animals (Fernihough et al., 2004, Pain 112:83-93; Coderre and Wall, 1987, Pain 28:379-393; Otsuki et al., 1986, Brain Res. 365:235-240). A stress-induced hyperalgesia model is described in Quintero et al., 2000, Pharmacology, Biochemistry and Behavior 67:449-458. Further animal models for pain are considered in an article of Walker et al. 1999 Molecular Medicine Today 5:319-321, comparing models for different types of pain, which are acute pain, chronic/inflammatory pain and chronic/neuropathic pain, on the basis of behavioral signs. Animal models for depression are described by E. Tatarczynska et al., Br. J. Pharmacol. 132(7): 1423-1430 (2001) and P. J. M. Will et al., Trends in Pharmacological Sciences 22(7):331-37 (2001)); models for anxiety are described by D. Treit, “Animal Models for the Study of Anti-anxiety Agents: A Review,” Neuroscience & Biobehavioral Reviews 9(2):203-222 (1985). Additional animal models for pain are also described herein in the Exemplification section.
- Genitourinary models include methods for reducing the bladder capacity of test animals by infusing either protamine sulfate and potassium chloride (See, Chuang, Y. C. et al., Urology 61(3): 664-670, 2003) into the bladder. These methods also include the use of a well accepted model of for urinary tract disorders involving the bladder using intravesically administered acetic acid as described in Sasaki et al. (2002) J. Urol. 168: 1259-64. Efficacy for treating spinal cord injured patients can be tested using methods as described in Yoshiyama et al. (1999) Urology 54: 929-33.
- Gastrointestinal models can be found in: Gawad, K. A., et al., Ambulatory long-term pH monitoring in pigs, Surg Endosc, (2003); Johnson, S. E. et al., Esophageal Acid Clearance Test in Healthy Dogs, Can. J. Vet. Res. 53(2): 244-7 (1989); and Cicente, Y. et al., Esophageal Acid Clearance: More Volume-dependent Than Motility Dependent in Healthy Piglets, J. Pediatr. Gastroenterol. Nutr. 35(2): 173-9 (2002). Models for a variety of assays can be used to assess visceromotor and pain responses to rectal distension. See, for example, Gunter et al., Physiol. Behav., 69(3): 379-82 (2000), Depoortere et al., J. Pharmacol. and Exp. Ther., 294(3): 983-990 (2000), Morteau et al., Fund. Clin. Pharmacol., 8(6): 553-62 (1994), Gibson et al., Gastroenterology (Suppl. 1), 120(5): A19-A20 (2001) and Gschossmann et al., Eur. J. Gastro. Hepat., 14(10): 1067-72 (2002) the entire contents of which are each incorporated herein by reference.
- Gastrointestinal motility can be assessed based on either the in vivo recording of mechanical or electrical events associated intestinal muscle contractions in whole animals or the activity of isolated gastrointestinal intestinal muscle preparations recorded in vitro in organ baths (see, for example, Yaun et al., Br. J. Pharmacol., 112(4):1095-1100 (1994), Jin et al., J. Pharm. Exp. Ther., 288(1): 93-97 (1999) and Venkova et al., J. Pharm. Exp. Ther., 300(3): 1046-1052 (2002)). Tatersall et al. and Bountra et al., European Journal of Pharmacology, 250: (1993) R5 and 249:(1993) R3-R4 and Milano et al., J. Pharmacol. Exp. Ther., 274(2): 951-961 (1995).
- Animal models for investigating neurological disorders include, but are not limited to, those described in Morris et al., (Learn. Motiv. 1981; 12: 239-60) and Abeliovitch et al., Cell 1993; 75: 1263-71). For example, neurological models for studying spinal cord injury, are described in Yoshiyama, M. et al., Urology 54(5): 929-933 (1999).
- Further examples of animal models for pain and inflammation include, but are not limited to the models listed in Table 2.
TABLE 2 Modality Non-limiting examples of potential Model Name tested Brief Description clinical indications (Reference) ACUTE PHASIC PAIN Tail-flick Thermal Tip of tail of rats is immersed if hot water and time Acute nociceptive pain to withdrawal from water is measured. Alternatively, (Hardy et al. Am J Physiol 1957; 189: 1-5.; a radiant heat source is applied to the tail and time Ben-Bassat et al. Arch Intern to withdrawal is determined. Analgesic effect is Pharmacodyn Ther 1959; 122: 434-47.) evidenced by a prolongation of the latency period hot-plate Thermal Rats walk over a heated surface with increasing Acute nociceptive pain temperature and observed for specific nociceptive (Woolfe et al. J Pharmacol Exp Ther behavior such paw licking, jumping. Time to 1944; 80: 300-7.) appearance of such behavior is measured. Analgesic effects are evidenced by a prolonged latency. Hargreaves Thermal A focused beam of light is projected onto a small Acute nociceptive pain Test surface of the hind leg of a rat with increasing (Yeomans et al. Pain 1994; 59: 85-94.) temperature. Time to withdrawal is measured. Analgesic effect translates into a prolonged latency Pin Test or Mechanical An increasing calibrated pressure is applied to the Acute nociceptive pain Randall paw of rats with a blunt pin. Pressure intensity is (Green et al. Br J Pharmacol 1951; 6: 572- Selitto measured. Alternatively increased pressure is 85.; Randall et al. Arch Int Pharmacodyn applied to the paw using a caliper until pain Ther 1957; 111: 409-19) threshold is reached and animals withdraw the paw. HYPERALGESIA MODELS/CHRONIC INFLAMMATORY PAIN MODELS Hargreaves or Thermal A sensitizing agent (e.g, complete Freund's Chronic pain associated with tissue Randal & and/or adjuvant (CFA). carrageenin, turpentine etc.) is inflammation, e.g. post-surgical pain, Selitto mechanical injected into the paw of rats creating a local (Hargreaves et al. Pain 1988; 32: 77- inflammation and sensitivities to mechanical 88.) (Randall & Selitto) and/or therma (Hargreaves)l Randall L O, Selitto J J. Arch Int stimulation are measured with comparison to the Pharmacodyn1957; 3: 409-19. contralateral non-sensitized paw Yeomans Thermal Rat hind paw in injected with capsaicin, a Chronic pain associated with tissue model sensitizing agent for small C-fibers or DMSO, a inflammation, e.g. post-surgical pain sensitizing agent for A-delta fibers. A radiant heat is (Yeomans et al. Pain 1994; 59: 85-94.; applied with different gradient to differentially Otsuki et al. Brain Res 1986; 365: 235- stimulate C-fibers or A-delta fibers and discriminate 240.) between the effects mediated by both pathways CHRONIC MALIGNANT PAIN (CANCER PAIN) Bone Cancer Thermal In this model, osteolytic mouse sarcoma Bone cancer pain Model and/or NCTC2472 cells are used to induce bone cancer by (Schwei et al., J. Neurosci. 1999; 19: mechanical injecting tumor cells into the marrow space of the 10886-10897.) femur bone and sealing the injection site Cancer Thermal Meth A sarcoma cells are implanted around the Malignant neuropathic pain invasion pain and/or sciatic nerve in BALB/c mice and these animals (Shimoyama et al., Pain 2002; 99: 167- model (CIP) mechanical develop signs of allodynia and thermal hyperalgesia 174.) as the tumor grows, compressing the nerve. Spontaneous pain (paw lifting) is also visible. CHRONIC MALIGNANT PAIN Muscle Pain Thermal Repeated injections of acidic saline into one Fibromyalgia and/or gastrocnemius muscle produces bilateral, long- (Sluka et al. Pain 2003; 106: 229-239.) mechanical lasting mechanical hypersensitivity of the paw (i.e. hyperalgesia) without associated tissue damage UV-irradiation Thermal Exposure of the rat hind paw to UV irradiation Inflammatory pain associated with first- and/or produces highly reliable and persistent allodynia. and second-degree burns. mechanical Various irradiation periods with UV-B produce skin (Perkins et al. Pain 1993; 53: 191-197.) inflammation with different time courses CHRONIC NEUROPATHIC PAIN Chronic Mostly Loose chronic ligature of the sciatic nerve. Thermal Clinical Neuropathic pain: nerve Constriction mechanical or mechanical sensitivities are tested using Von compression and direct mechanical Injury (CCI) or but aso Frey hairs or the paw withdrawal test (Hargreaves) neuronal damage might be relevant Bennett and thermal clinical comparisons Xie model (Bennett & Xie, Neuropharmacology 1984; 23: 1415-1418.) Chung's Mostly Tight ligation of one of the two spinal nerves of the Same as above: root compression model or mechanical sciatic nerve. Thermal or mechanical sensitivities might be a relevant clinical comparison Spinal Nerve but aso are tested using Von Frey hairs or the paw (Kim and Chung, Pain 1990; 41: 235- Ligation thermal withdrawal test (Hargreaves) 251.) model (SNL) - Accordingly, an agent identified as described herein (e.g., an NGF/NTR modulator) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
- Accordingly, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein
- Pharmaceutical Compositions
- The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically (or prophylactically) effective amount of a NGF/NTR modulator, and preferably one or more compounds of the invention described above, and a pharmaceutically acceptable carrier or excipient. Suitable pharmaceutically acceptable carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The carrier and composition can be sterile. The formulation should suit the mode of administration.
- The phrase “pharmaceutically acceptable carrier” is art recognized and includes a pharmaceutically acceptable material, composition or vehicle, suitable for administering compounds of the present invention to mammals. The carriers include liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agent from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Some examples of materials which can serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations.
- Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
- Examples of pharmaceutically acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions (e.g., NaCl), alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose, amylose or starch, cyclodextrin, magnesium stearate, talc, silicic acid, viscous paraffin, perfume oil, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrolidone, etc. The pharmaceutical preparations can be sterilized and if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or aromatic substances and the like which do not deleteriously react with the active compounds.
- The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. The composition can be formulated as a suppository, with traditional binders and carriers such as trilycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrollidone, sodium saccharine, cellulose, magnesium carbonate, etc.
- The composition can be formulated in accordance with the routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachet indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose/water. Where the composition is administered by injection, an ampule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
- The pharmaceutical compositions of the invention can also include an agent which controls release of the compound of the invention, thereby providing a timed or sustained relase composition.
- The present invention also relates to prodrugs of the compounds disclosed herein, as well as pharmaceutical compositions comprising such prodrugs. For example, compounds of the invention which include acid functional groups or hydroxyl groups can also be prepared and administered as a corresponding ester with a suitable alcohol or acid. The ester can then be cleaved by endogenous enzymes within the subject to produce the active agent.
- Formulations of the present invention include those suitable for oral, nasal, topical, transmucosal, transdermal, buccal, sublingual, rectal, vaginal and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound that produces a therapeutic effect. Generally, out of one hundred per cent, this amount will range from about 1 per cent to about ninety-nine percent of active ingredient, preferably from about 5 per cent to about 70 per cent, most preferably from about 10 per cent to about 30 per cent.
- Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.
- Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.
- In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluent commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
- Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be required.
- The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
- Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.
- Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- Examples of suitable aqueous and nonaqueous carriers that may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminum monostearate and gelatin.
- In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissue.
- Methods of Administration
- The invention provides a method of treating a condition mediated by an NGF/NTR interaction in a subject, including, but not limited to, pain, inflammatory disorders, respiratory disorders, neurological disorders, gastrointestinal disorders and genitourinary disorders. The method comprises the step of administering to the subject a therapeutically effective amount of a NGF/NTR modulator. The condition to be treated can be any condition which is mediated, at least in part, by the interaction of a neurotrophin (e.g. NGF) with a neurotrophin receptor (e.g., p75NTR and TrkA).
- The quantity of a given compound to be administered will be determined on an individual basis and will be determined, at least in part, by consideration of the individual's size, the severity of symptoms to be treated and the result sought. The NGF/NTR modulators described herein can be administered alone or in a pharmaceutical composition comprising the modulator, an acceptable carrier or diluent and, optionally, one or more additional drugs.
- These compounds may be administered to humans and other animals for therapy by any suitable route of administration. The NGF/NTR modulator can be administered subcutaneously, intravenously, parenterally, intraperitoneally, intradermally, intramuscularly, topically, enterally (e.g., orally), rectally, nasally, buccally, sublingually, systemically, vaginally, by inhalation spray, by drug pump or via an implanted reservoir in dosage formulations containing conventional non-toxic, physiologically acceptable carriers or vehicles. The preferred method of administration is by oral delivery. The form in which it is administered (e.g., syrup, elixir, capsule, tablet, solution, foams, emulsion, gel, sol) will depend in part on the route by which it is administered. For example, for mucosal (e.g., oral mucosa, rectal mucosa, intestinal mucosa, bronchial mucosa) administration, nose drops, aerosols, inhalants, nebulizers, eye drops or suppositories can be used. The compounds and agents of this invention can be administered together with other biologically active agents, such as analgesics, e.g., opiates, anti-inflammatory agents, e.g., NSAIDs, anesthetics and other agents which can control one or more symptoms or causes of an NTR-mediated condition.
- In a specific embodiment, it may be desirable to administer the agents of the invention locally to a localized area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, transdermal patches, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes or fibers. For example, the agent can be injected into the joints or the urinary bladder.
- The compounds of the invention can, optionally, be administered in combination with one or more additional drugs which, for example, are known for treating and/or alleviating symptoms of the condition mediated by NGF p75NTR or TrkA. The additional drug can be administered simultaneously with the compound of the invention, or sequentially. For example, the compounds of the invention can be administered in combination with at least one of an analgesic, an anti-inflammatory agent, an anesthetic, a corticosteroid (e.g., dexamethasone, beclomethasone diproprionate (BDP) treatment), an anti-convulsant, an antidepressant, an anti-nausea agent, an anti-psychotic agent, a cardiovascular agent (e.g., a beta-blocker) or a cancer therapeutic. In certain embodiments, the compounds of the invention are administered in combination with a pain drug. As used herein the phrase, “pain drugs” is intended to refer to analgesics, anti-inflammatory agents, anesthetics, corticosteroids, antiepileptics, barbiturates, antidepressants, and marijuana.
- The combination treatments mentioned above can be started prior to, concurrent with, or after the administration of the compositions of the present invention. Accordingly, the methods of the invention can further include the step of administering a second treatment, such as a second treatment for the disease or disorder or to ameliorate side effects of other treatments. Such second treatment can include, e.g., anti-inflammatory medication and any treatment directed toward treating pain. Additionally or alternatively, further treatment can include administration of drugs to further treat the disease or to treat a side effect of the disease or other treatments (e.g., anti-nausea drugs, anti-inflammatory drugs, anti-depressants, anti-psychiatric drugs, anti-convulsants, steroids, cardiovascular drugs, and cancer chemotherapeutics).
- As used herein, an “analgesic” is an agent that relieves pain without significant impairment of consciousness or sense perception and may result in the reduction of inflammation as do corticosteroids, e.g., an anti-inflammatory agent. Analgesics can be subdivided into NSAIDs (non-steroidal-anti-inflammatory agents), narcotic analgesics, and non-narcotic analgesics. NSAIDs can be further subdivided into non-selective COX (cyclooxygenase) inhibitors, and selective COX2 inhibitors. Opioid analgesics can be natural, synthetic or semi-synthetic opioid (narcotic) analgesics, and include for example, morphine, codeine, meperidine, propxyphen, oxycodone, hydromorphone, heroine, tramadol, and fentanyl. Non-opioid analgesics (non-narcotic) analgesics include, for example, acetaminophen, clonidine, NMDA antagonists, and cannabinoids. Non-selective COX inhibitors include, but are not limited to acetylsalicylic acid (ASA), ibuprofen, naproxen, ketoprofen, piroxicam, etodolac, and bromfenac. Selective COX2 inhibitors include, but are not limited to celecoxib, valdecoxib, parecoxib, and etoricoxib.
- As used herein an “anesthetic” is an agent that interferes with sense perception near the site of administration, a local anesthetic, or result in alteration or loss of consciousness, e.g., systemic anesthetic agents. Local anesthetics include but are not limited to lidocaine and buvicaine.
- Non-limiting examples of antiepileptic agents are carbamazepine, phenytoin and gabapentin. Non-limiting examples of antidepressants are amitriptyline and desmethylimiprimine.
- Non-limiting examples of anti-inflammatory drugs include corticosteroids (e.g., hydrocortisone, cortisone, prednisone, prednisolone, methyl prednisone, triamcinolone, fluprednisolone, betamethasone and dexamethasone), salicylates, antihistamines and H2 receptor antagonists.
- The phrases “parenteral administration” and “administered parenterally” as used herein mean modes of administration other than enteral and topical administration, usually by injection, and include, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
- The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the subject's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
- Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.
- Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without being toxic to the subject.
- The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well known in the medical arts.
- A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, dosages of a compound of the invention may be determined by deriving dose-response curves using an animal model for the condition to be treated. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
- In general, a suitable daily dose of a compound of the invention will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, intravenous and subcutaneous doses of the compounds of this invention for a subject, when used for the indicated analgesic effects, will range from about 0.0001 to about 100 mg per kilogram of body weight per day, more preferably from about 0.01 to about 100 mg per kg per day, and still more preferably from about 1.0 to about 50 mg per kg per day. An effective amount is that amount treats a neurotrophin-associated state or neurotrophin disorder.
- If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
- While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical composition.
- Methods of Treatment
- The above compounds can be used for administration to a subject for the modulation of a neurotrophin-mediated activity, involved in, but not limited to, pain, inflammatory disorders, neurological disorders, and any abnormal function of cells, organs, or physiological systems that are modulated, at least in part, directly or indirectly by a neurotrophin-mediated activity. Additionally, it is understood that the compounds may also alleviate or treat one or more additional symptoms of a disease or disorder discussed herein.
- Accordingly, in one aspect, the compounds of the invention may be used to treat pain, including acute, chronic, malignant and non-malignant somatic pain (including cutaneous pain and deep somatic pain), visceral pain, and neuropathic pain. It is further understood that the compounds may also alleviate or treat one or more additional signs or symptoms of pain and sensory deficits (e.g., hyperalgesia, allodynia, dysesthesia, hyperesthesia, hyperpathia, paresthesia).
- In some embodiments of this aspect of the invention, the compounds of the invention may be used to treat somatic or cutaneous pain associated with injuries, inflammation, diseases and disorders of the skin, subcutaneous tissues and related organs including, but not limited to, cuts, burns, lacerations, punctures, incisions, surgical pain, post-operative pain, orodental surgery, psoriasis, eczema, dermatitis, and allergies. The compounds of the invention may also be used to treat somatic pain associated with malignant and non-malignant neoplasm of the skin, subcutaneous tissues and related organs (e.g., melanoma, basal cell carcinoma).
- In other embodiments of this aspect of the invention, the compounds of the invention may be used to treat deep somatic pain associated with injuries, inflammation, diseases and disorders of the musculoskeletal and connective tissues including, but not limited to, arthralgias, myalgias, fibromyalgias, myofascial pain syndrome, dental pain, lower back pain, pain during labor and delivery, surgical pain, post-operative pain, headaches, idiopathic pain disorder, sprains, bone fractures, bone injury, osteoporosis, severe burns, gout, arthiritis, osteoarthithis, myositis, and dorsopathies (e.g., spondylolysis, subluxation, sciatica, and torticollis). The compounds of the invention may also be used to treat deep somatic pain associated with malignant and non-malignant neoplasm of the musculoskeletal and connective tissues (e.g., sarcomas, rhabdomyosarcomas, and bone cancer).
- In other embodiments of this aspect of the invention, compounds of the invention may be used to treat visceral pain associated with injuries, inflammation, diseases or disorders of the circulatory system, the respiratory system, the genitourinary system, the gastrointestinal system and the eye, ear, nose and throat.
- For example, the compounds of the invention may be used to treat visceral pain associated with injuries, inflammation and disorders of the circulatory system including, but are not limited to, ischaemic diseases, ischaemic heart diseases (e.g., angina pectoris, acute myocardial infarction, coronary thrombosis, coronary insufficiency), diseases of the blood and lymphatic vessels (e.g., peripheral vascular disease, intermittent claudication, varicose veins, haemorrhoids, embolism or thrombosis of the veins, phlebitis, thrombophlebitis lymphadenitis, lymphangitis), and visceral pain associated with malignant and non-malignant neoplasm of the circulatory system (e.g., lymphomas, myelomas, Hodgkin's disease).
- In another example, the compounds of the invention may be used to treat visceral pain associated with injuries, inflammation, diseases and disorders of the respiratory system including, but are not limited to, upper respiratory infections (e.g., nasopharyngitis, sinusitis, and rhinitis), influenza, pneumoniae (e.g., bacterial, viral, parasitic and fungal), lower respiratory infections (e.g., bronchitis, bronchiolitis, tracheobronchitis), interstitial lung disease, emphysema, bronchiectasis, status asthmaticus, asthma, pulmonary fibrosis, chronic obstructive pulmonary diseases (COPD), diseases of the pleura, and visceral pain associated with malignant and non-malignant neoplasm of the respiratory system (e.g., small cell carcinoma, lung cancer, neoplasm of the trachea, of the larynx).
- In another example, the compounds of the invention may be used to treat visceral pain associated with injuries, inflammation and disorders of the gastrointestinal system including, but are not limited to, injuries, inflammation and disorders of the tooth and oral mucosa (e.g., impacted teeth, dental caries, periodontal disease, oral aphthae, pulpitis, gingivitis, periodontitis, and stomatitis), of the oesophagus, stomach and duodenum (e.g., ulcers, dyspepsia, oesophagitis, gastritis, duodenitis, diverticulitis and appendicitis), of the intestines (e.g., Crohn's disease, paralytic ileus, intestinal obstruction, irritable bowel syndrome, neurogenic bowel, megacolon, inflammatory bowel disease, ulcerative colitis, and gastroenteritis), of the peritoneum (e.g. peritonitis), of the liver (e.g., hepatitis, liver necrosis, infarction of liver, hepatic veno-occlusive diseases), of the gallbladder, biliary tract and pancreas (e.g., cholelithiasis, cholecystolithiasis, choledocholithiasis, cholecystitis, and pancreatitis), functional abdominal pain syndrome (FAPS), gastrointestinal motility disorders, as well as visceral pain associated with malignant and non-malignant neoplasm of the gastrointestinal system (e.g., neoplasm of the oesophagus, stomach, small intestine, colon, liver and pancreas).
- In another example, the compounds of the invention may be used to treat visceral pain associated with injuries, inflammation, diseases, and disorders of the genitourinary system including, but are not limited to, injuries, inflammation and disorders of the kidneys (e.g., nephrolithiasis, glomerulonephritis, nephritis, interstitial nephritis, pyelitis, pyelonephritis), of the urinay tract (e.g. include urolithiasis, urethritis, urinary tract infections), of the bladder (e.g. cystitis, neuropathic bladder, neurogenic bladder dysfunction, overactive bladder, bladder-neck obstruction), of the male genital organs (e.g., prostatitis, orchitis and epididymitis), of the female genital organs (e.g., inflammatory pelvic disease, endometriosis, dysmenorrhea, ovarian cysts), as well as pain associated with malignant and non-malignant neoplasm of the genitourinary system (e.g., neoplasm of the bladder, the prostate, the breast, the ovaries).
- In further embodiments of this aspect of the invention, compounds of the invention may be used to treat neuropathic pain associated with injuries, inflammation, diseases and disorders of the nervous system, including the central nervous system and the peripheral nervous systems. Examples of such injuries, inflammation, diseases or disorders associated with neuropathic pain include, but are not limited to, neuropathy (e.g., diabetic neuropathy, drug-induced neuropathy, radiotherapy-induced neuropathy), neuritis, radiculopathy, radiculitis, neurodegenerative diseases (e.g., muscular dystrophy), spinal cord injury, peripheral nerve injury, nerve injury associated with cancer, Morton's neuroma, headache (e.g., nonorganic chronic headache, tension-type headache, cluster headache and migraine), multiple somatization syndrome, postherpetic neuralgia (shingles), trigeminal neuralgia complex regional pain syndrome (also known as causalgia or Reflex Sympathetic Dystrophy), radiculalgia, phantom limb pain, chronic cephalic pain, nerve trunk pain, somatoform pain disorder, central pain, non-cardiac chest pain, central post-stroke pain.
- In another aspect, the compounds of the invention may be used to treat inflammation associated with injuries, diseases or disorders of the skin, subcutaneous tissues and related organs, the musculoskeletal and connective tissue system, the respiratory system, the circulatory system, the genitourinary system and the gastrointestinal system.
- In some embodiments of this aspect of the invention, examples of inflammatory conditions, diseases or disorders of the skin, subcutaneous tissues and related organs that may be treated with the compounds of the invention include, but are not limited to allergies, atopic dermatitis, psoriasis, eczema and dermatitis.
- In other embodiments of this aspect of the invention, inflammatory conditions, diseases or disorders of the musculoskeletal and connective tissue system that may be treated with the compounds of the invention include, but are not limited to arthritis, osteoarthritis, and myositis.
- In other embodiments of this aspect of the invention, inflammatory conditions, diseases or disorders of the respiratory system that may be treated with the compounds of the invention include, but are not limited to allergies, asthma, rhinitis, neurogenic inflammation, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, nasopharyngitis, sinusitis, and bronchitis.
- In still other embodiments of this aspect of the invention, inflammatory conditions, disease or disorders of the circulatory system that may be treated with the compounds of the invention include, but are not limited to, endocarditis, pericarditis, myocarditis, phlebitis, lymphadenitis and artherosclerosis.
- In further embodiments of this aspect of the invention, inflammatory conditions, diseases or disorders of thegenitourinary system that may be treated with the compounds of the invention include, but are not limited to, inflammation of the kidney (e.g., nephritis, interstitial nephritis), of the bladder (e.g., cystitis), of the urethra (e.g., urethritis), of the male genital organs (e.g., prostatitis), and of the female genital organs (e.g., inflammatory pelvic disease).
- In further embodiments of this aspect of the invention, inflammatory conditions, diseases or disorders of the gastrointestinal system that may be treated with the compounds of the invention include, but are not limited to, gastritis, gastroenteritis, colitis (e.g., ulcerative colitis), inflammatory bowel syndrome, Crohn's disease, cholecystitis, pancreatitis and appendicitis.
- In still further embodiments of this aspect of the invention, inflammatory conditions, diseases or disorders that may be treated with the compounds of the invention, but are not limited to inflammation associated with microbial infections (e.g., bacterial, viral and fungal infections), physical agents (e.g., burns, radiation, and trauma), chemical agents (e.g., toxins and caustic substances), tissue necrosis and various types of immunologic reactions and autoimmune diseases (e.g., Lupus erythematosus).
- In another aspect, the compounds of the invention may be used to treat injuries, diseases or disorders of the nervous system including, but not limited to neurodegenerative diseases (e.g., Alzheimer's disease, Duchenne's disease), epilepsy, multiple sclerosis, amyotrophic lateral sclerosis, stroke, cerebral ischemia, neuropathies (e.g., chemotherapy-induced neuropathy, diabetic neuropathy), retinal pigment degeneration, trauma of the central nervous system (e.g., spinal cord injury), and cancer of the nervous system (e.g., neuroblastoma, retinoblastoma, brain cancer, and glioma), and other certain cancers (e.g., melanoma, pancreatic cancer).
- In further aspects of the invention, the compounds of the invention may also be used to treat other disorders of the skin, subcutaneous tissues and related organs (e.g., hair loss), of the respiratory system (e.g., asthma), of the circulatory system, (e.g., cardiac arrhythmias and fibrillation and sympathetic hyper-innervation), and of the genitourinary system (e.g., neurogenic bladder dysfunction and overactive bladder).
- The present invention provides a method for treating a subject that would benefit from administration of a composition of the present invention. Any therapeutic indication that would benefit from a NGF/NTR modulator (i.e., a compound of the invention) can be treated by the methods of the invention. The method includes the step of administering to the subject a composition of the invention, such that the disease or disorder is treated.
- The invention further provides a method for preventing in a subject, a disease or disorder which can be treated with administration of the compositions of the invention. Subjects “at risk” may or may not have detectable disease, and may or may not have displayed detectable disease prior to the treatment methods described herein. “At risk” denotes that an individual who is determined to be more likely to develop a symptom based on conventional risk assessment methods or has one or more risk factors that correlate with development of a disease or disorder that may be treated according the methods of the invention. For example, risk factors include family history, medication history, and history of exposure to an environmental substance which is known or suspected to increase the risk of disease. Subjects at risk for a disease or condition which can be treated with the agents mentioned herein can also be identified by, for example, any or a combination of diagnostic or prognostic assays known to those skilled in the art. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the disease or disorder, such that the disease or disorder is prevented or, alternatively, delayed in its progression.
- The invention is further illustrated by the following example, which could be used to examine the neurotrophin/neurotrophin precursor binding inhibition of the compounds of the invention. The example should not be construed as further limiting. The animal models used throughout the Examples are accepted animal models and the demonstration of efficacy in these animal models is predictive of efficacy in humans.
- To a stirred solution of naphthalic anhydride derivative (1 equiv.) in glacial acetic acid was added, under an N2 atmosphere, the primary amine (1 equiv.) and sodium acetate (1 equiv.). The reaction mixture was brought to reflux. Refluxing was continued and the progress of the reaction was monitored by TLC. Upon completion, if the resultant solution was clear, then the solvent was evaporated under reduced pressure and the residual solid was reprecipitated and/or recrystallised from appropriate solvent(s). If the final mixture contained precipitate then the mixture was cooled to room temperature and the solid was collected by filtration, washed with distilled water or dilute acid and further reprecipitated and/or recrystallised from appropriate solvent(s). The filtrate was recovered and treated as the clear solution to obtain further product. The final products were dried in vacuum for 24-48 hours.
-
- The compound was prepared from 1,4,5,8-naphthalene tetracarboxylic dianhydride (1.34 g, 5 mmol) and 3-amino-4-chlorobenzoic acid (1.71 g, 10 mmol) in 100 mL glacial acetic acid using the general procedure shown in Example 1.
- 1H NMR (d6-DMSO, 400 MHz): 7.89 (d, J=8.4 Hz, 2H), 8.12 (dd, J=8.4 Hz, 2.0 Hz, 2H), 8.30 (d, J=2.0 Hz, 2H), 8.82 (s, 4H), 13.40 (bs, 2H);
- 13C NMR (dept): 131.1, 132.0, 132.3, 133.1;
- MS (ES-) m/z: 574.2 (M, 100%).
-
- The intermediate compound was prepared from 1,4,5,8-naphthalene tetracarboxylic dianhydride (1.34 g, 5 mmol) and 3-amino-4-chlorobenzoic acid (0.86 g, 5 mmol) in 100 mL glacial acetic acid using the general procedure from Example 1.
- 1H NMR (d6-DMSO, 400 MHz): 7.89 (d, J=8.4 Hz, 1H), 8.12 (dd, J=8.4 Hz, 2.0 Hz, 1H), 8.30 (d, J=2.0 Hz, 1H), 8.78 (s, 4H);
- MS (ES-) m/z: 420.1 (M-1, 100%).
-
Compound 90 was prepared from the intermediate (Example 1; 0.42 g, 1 mmol) and 3,4-diamino benzoic acid (0.15 g, 1 mmol) in 20 mL glacial acetic acid using the general procedure from Example 1. - 1H NMR (d6-DMSO, 400 MHz): 7.88 (d, J=4.4 Hz, 1H), 7.90 (d, J=4.0 Hz, 1H), 8.01 (dd, J=8.4 Hz, 1.6 Hz, 1H), 8.11 (dd, J=8.4 Hz, 2.0 Hz, 1H), 8.34 (d, J=2.0 Hz, 1H), 8.73-8.79 (m, 2H), 8.85-8.91 (m, 3H), 13.29 (bs, 2H);
- 13C NMR (dept): 117.4, 121.0, 127.8, 127.9, 131.0, 131.8, 131.9, 132.2, 132.3, 133.2;
- MS (ES-) m/z: 536.2 (M-1, 100%).
-
- The compound was prepared from 1,4,5,8-naphthalene tetracarboxylic dianhydride (1.34 g, 5 mmol) and 3,4-diaminobenzoic acid (10 mmol) in 100 mL glacial acetic acid using the general procedure shown in Example 1.
- Cell Culture
- All cells were incubated at 37° C. in 5% CO2. PC12 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS). A875 human melanoma cells were maintained in DMEM with 10% FBS. HEK 293 cells were stably transfected with human TrkA plasmid (see below) and maintained in DMEM with 10% FBS and G418 (600 μg/mL) for selection.
- Cell Transfections:
- Expression of human TrkA in HEK cells was achieved by transfecting the cells with the TrkA expression vector using Lipofectamine (Invitrogen) reagent. HEK cells were plated in 100 mm Petri dishes at a concentration of 106 cells per dish. The next day, a solution of DNA diluted in 1 mL OptiMEM (Invitrogen) per dish was prepared and incubated for 15 min at room temperature. Concurrently, 42 μl of Lipofectamine reagent was prepared in OPtiMEM (1 mL per dish) and incubated for 15 min at room temperature. The DNA and lipofectamine reagent solutions were then mixed together and incubated for a further 15 minutes. During this 30 min of incubation, the cells were rinsed twice with OptiMEM. The DNA-lipofectamine solution in OptiMEM was then added to the dish, which was then placed in the incubator (37° C.; 5% CO2) for 3 h. This solution was then aspirated and the cells were rinsed with DMEM. From this point, cells were grown in DMEM+FBS (10%), their normal growth medium. For stable cell lines, the culture medium contained G418 (600 μg/mL) a selection agent for maintenance of TrkA expression in the cells. The presence of TrkA was confirmed with 125I-NGF binding (see below) and Western blots (see below) labeled with TrkA specific antisera.
- NGF binding was evaluated using methods familiar to those who are skilled in the art. Briefly, cells expressing one or both NGF receptors (PC12: TrkA+p75; A875: p75 alone; HEK_TrkA: TrkA alone) were harvested by replacing the medium with calcium-magnesium free balanced salt (Grey's) solution and incubating at 37° C. for 15 min. For NGF binding, cells were resuspended at a concentration of 2×106 cells/mL in HEPES-Krebs-Ringer (HKR) buffer (10 mM HEPES; 125 mM NaCl; 4.8 mM KCl; 1.3 mM CaCl2; 1.2 mM MgSO4; 1.2 mM KH2PO4; 1 mg/ml BSA; 1 mg/ml glucose; pH 7.4) and exposed to 125I-NGF (˜0.1 nM) in the presence or absence of varying concentrations of the compound. Non-specific binding was determined for reference by incubating 125I-NGF with an excess of non-radioactive NGF in the abence of compound. Following a two-hour incubation period at 4° C., 125I-NGF bound to the cells was quantified in a gamma radiation counter following separation from unbound NGF by filtration or centrifugation through glycerol (10% in HKR). Inhibition of binding was calculated as a percent of the specific binding (calculated as the differential between 125I-NGF binding in the absence and presence of an excess of non-radioactive NGF without compound). Dose-response inhibition curves were typically generated with seven concentrations of a given compound, with three replicates for each concentration. For most compounds, multiple dose-response curves were generated.
- The IC50 data shown in Table 1 were acquired using the procedure described herein using PC12 cells. Examples of IC50 calculation curves from individual experiments using this procedure are shown in
FIGS. 2A, 2B , 3A, 4A, and 5, in which compounds 90, 91 and 18 are shown to effectively block NGF binding to TrkA and/or p75. - NGF binding to TrkA and p75 was qualitatively evaluated following chemical cross-linking, and separation of proteins according to molecular weight with SDS-PAGE. PC12 (for p75 and TrkA binding), HEK_TrkA (for TrkA only) and A875 (for p75 only) cells were recovered using Grey's solution, pelleted by centrifugation, and suspended in HKR. In a total volume of 1 mL, 2×106 cells/mL were incubated, rotating, with ˜0.1 nM 125I-NGF, with or without compound, for 2 h at 4° C. At the conclusion of the binding reaction, a 20 μL volume of BS3 (Bis[sulfosuccinimidyl]suberate) crosslinker was added for a final concentration 0.4 mM and incubated, rocking, for an additional 30 min at room temperature. Cells were washed twice in HKR. Following centrifugation, the pellets were solubilized directly in SDS sample buffer and heated for 10 min at 95° C. All samples were electrophoresed on a 6% SDS-PAGE gel, which was then dried and autoradiographed. Bands at the appropriate molecular weights for p75-NGF conjugates and TrkA-NGF conjugates were visualized by exposing the dried gel to film overnight (BioMax, Kodak) overnight. Modulatory effects of the compounds on NGF binding were determined by variations in band intensity. Reduced binding of NGF to its receptors was represented by lighter bands.
- Results from this qualitative evaluation are in accordance with the quantitative data from the binding assay of Example 1.
- This assay is useful for establishing that the compounds of the invention are functional NGF antagonists, not receptor agonists (an agonist could conceivably block NGF binding but actually activate the receptor).
Erk 1/2 is a kinase activated down stream of TrkA and is a well studied member of the NGF-induced signal transduction cascade. - PC12 cells expressing TrkA and p75 were acutely exposed to 5 ng/mL NGF (15 min; 37° C.; 5% CO2) that was pre-incubated (30 min; room temperature) with or without the compounds. Cells were lysed in Laemmli sample buffer (for SDS-PAGE) or a lysis buffer containing Triton X-100 (for ELISA). Following SDS-PAGE, proteins were electroblotted onto nitrocellulose and immunoprobed for phosphorylated
Erk - Representative examples of a
phosphoryated Erk 1/2 blot forCompound FIGS. 1 and 4 A, which demonstrate thatCompounds Erk 1/2 phosphorylation in PC12 cells.FIG. 6 shows an additionalphosphorylated Erk 1/2 blot forCompound 90 as acquired using this procedure, which demonstrates thatCompound 90 inhibits NGF-inducedErk 1/2 phosphorylation in PC12 cells. - To detect phosphorylated
Erk 1/2 by ELISA, a kit from R&D (Minneapolis, Minn.) Systems is used. Briefly, cells are lysed in buffer (1 mM EDTA, 0.5% Triton X-100, 5 mM NaF, 1 M urea, 10 μg/mL, Leupeptin, 10 μg/mL Pepstatin, 100 μM PMSF, 3 μg/mL Aprotinin, 2.5 mM sodium pyrophosphate, 1 mM sodium orthovanadate in PBS, pH 7.2-7.4). Lysates are incubated overnight at 4° C. in ELISA plates coated with an anti-Erk 1/2 capture antibody.Immobilized Erk 1/2 is then exposed to a biotinylated detection antibody specific for phosphorylated Erk. The quantity ofphosphoryated Erk 1/2 is quantified colorometrically with a standard HRP-streptavidin reaction. - This assay was run as a further functional marker of NGF antagonism and takes advantage of the differentiation of PC12 cells (neurite outgrowth) induced by NGF. Cultures of PC12 cells were grown on Terasaki plates pre-coated with poly-D-lysine. Cells were exposed to NGF (1-50 (preferably 5) ng/ml) to induce neurite outgrowth as described elsewhere [L A Greene & A S Tischler, Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor, Proc Natl Acad Sci USA. July 1976; 73(7): 2424-2428]. In addition to NGF, cells were exposed to varying concentration of the compounds or vehicle. Following 4 days of exposure to NGF in the presence or absence of compound, neurite outgrowth was quantified. A neurite was scored if its caliber from origin to terminal was approximately the same and the length was equal to or greater than 1.5 the cell body diameter. The number of neurite bearing cells per total number of viable cells was calculated for each condition; the number of cells with neurites in the presence of NGF (without compound exposure) was considered to represent maximal (100%) outgrowth, to which the inhibitory effect of compounds of the invention on NGF-induced outgrowth was compared.
- Results from this experiment are shown in
FIG. 3B , which demonstrates thatcompound 90 effectively inhibits neurite outgrowth induced by 5 ng/mL NGF in a dose-dependent fashion. The x-axis represents the log concentration in M. - Male Sprague-Dawley rats are given a subcutaneous injection of 50 μl of 2.5% formalin into the plantar surface of one hindpaw using a 27 gauge syringe needle, and nociceptive responses are measured for the next 60 min. The compound or vehicle was administered (i.p. or s.c.) 15-45 minutes prior to the formalin injection. A nociceptive score was determined for each 5 min. block by measuring the amount of time spent in each of four behavioral categories: 0, the injected hindpaw is indistinguishable from that of the contralateral paw; 1, the injected paw has little or no weight placed on it; 2, the injected paw is elevated and is not in contact with any surface; 3, the injected paw is licked, bitten, or shaken. A weighted nociceptive score, ranging from 0 to 3 is calculated by multiplying the time spent in each category by the category weight, summing these products, and dividing by the total time for each 5 min block of time (Coderre et al., Pain 1993; 54: 43). On the basis of the resulting response patterns, 2 phases of nociceptive behaviour are identified and scored: first phase (P1; 0-5 min) and second phase (P2; 11-40 min).
- Statistical analysis is performed using Prism™ 4.01 software package (GraphPad, San Diego, Calif., USA). The difference in response levels between treatment groups and control vehicle group is analyzed using an ANOVA followed by Bonferroni's method for post-hoc pair-wise comparisons. A p value <0.05 is considered to be significant.
- The acetic acid abdominal contraction test (Martinez et al., Pain 1999; 81: 179) was used to determine the efficacy of different compounds in a model of acute visceral chemical nociception. Mice were given an intraperitoneal (i.p.) injection of 200 μl of 0.6% acetic acid in saline and observed for the number of abdominal contractions (writhing) they exhibited in the 30 minutes following the injection. Compound or vehicle was administered (i.p. or s.c.) 15-45 minutes prior to the acetic acid injection. Each episode of writhing is characterized by a lengthwise stretching of the torso with a concomitant arching of the back.
- Statistical analysis was performed using Prism™ 4.01 software package (GraphPad, San Diego, Calif., USA). The difference in response levels between treatment groups and control vehicle group was analyzed using an ANOVA followed by Bonferroni's method for post-hoc pair-wise comparisons. A p value <0.05 was considered to be significant
- Results from this experiment are shown in
FIG. 7 . Animals were treated with vehicle (VEH) or Compound 91 (5 mg/kg i.p.; [CMP 1] and 50 mg/kg i.p. [CMP 2])) 10-20 minutes before the intraperitoneal injection of acetic acid, as described in this example.Compound 91 displayed a significant antinociceptive effect (** p<0.01, compared to vehicle treated group) as indicated by the attenuation of the chemically-induced abdominal contractions (from 58±4 [n=6] to 16±9 [n=6]). - Injection of complete Freunds adjuvant (CFA) in the hindpaw of the rat has been shown to produce a long-lasting inflammatory condition, which is associated with behavioural hyperalgesia and allodynia at the injection site (Hylden et al., Pain 1989; 37: 229). Rats (body weight 200-250 g) receive a s.c. injection of CFA (50% in saline, 100 μl, Sigma) into the plantar surface of the hindpaw under brief halothane anaesthesia. After 24 h, animals are treated with vehicle or compound (s.c. or i.p.) and, after different time-points following the treatment (e.g., 30, 60 or 90 min.), they are tested for hindpaw weight bearing responses, as assessed using an Incapacitance Tester (e.g., Linton Instrumentation, UK), (Zhu et al., 2005). The instrument incorporates a dual channel scale that separately measures the weight of the animal distributed to each hindpaw. While normal rats distribute their body weight equally between the two hindpaws (50-50), the discrepancy of weight distribution between an injured and non-injured paw is a natural reflection of the discomfort level in the injured paw (nocifensive behavior). The rats are placed in a plastic chamber designed so that each hindpaw rests on a separate transducer pad. The averager is set to record the load on the transducer over 5 s time period and two numbers displayed represent the distribution of the rat's body weight on each paw in grams (g). For each rat, three readings from each paw are taken and then averaged. Side-to-side weight bearing difference is calculated as the average of the absolute value of the difference between two hindpaws from three trials (right paw reading—left paw reading).
- The Partial Nerve Ligation (PNL) model (Seltzer et al., Pain 1990; 43:205) is used to induce chronic neuropathic pain. Male Sprague-Dawley rats are anesthetized with isoflurane, and injury to the sciatic nerve is achieved by tying a tight ligature around ⅓ to ½ of the sciatic nerve just proximal to the nerve's trifurcation in the mid-thigh. Animals develop thermal and mechanical hyperalgesia and allodynia, as well as a long-lasting spontaneous pain or dysesthesia after the nerve injury.
- Mechanical allodynia testing: Pre- and post-injury baselines as well as post-treatment values (vehicle or compound-treated animals) for mechanical allodynia are evaluated using Von Frey filaments (Stoelting, Wood Dale, Ill., USA) with varying stiffness. Animals are placed on a perforated metallic platform and allowed to acclimate to their surroundings for a minimum of 30 minutes before testing. The mean and standard error of the mean (SEM) are determined for each paw in each treatment group (ipsilateral/injured paw and contralateral/non-injured paw). Since this stimulus is normally not considered painful, significant injury-induced increases in responsiveness (i.e., lower response thresholds) in this test are interpreted as a measure of mechanical allodynia. Effects of compounds are evaluated two weeks after the injury. Compound or vehicle is administered (i.p. or s.c.) and effects on mechanical allodynia are measured at different time points after dosing (e.g., 30, 60 and 90 min.).
- Data analysis: Statistical analyses are conducted using Prism™ 4.01 (GraphPad, San Diego, Calif., USA). Mechanical hypersensitivity of the injured paw is determined by comparing contralateral to ipsilateral paw values within the vehicle group at each time point. Effect of vehicle (VEH) and compound are determined by comparing the post-injury baseline (BL) to post treatment values using RM-ANOVA or one-way ANOVA followed by Bonferroni's method for post-hoc pair-wise comparisons (e.g., vehicle vs compound).
- The Spared Nerve Injury (SNI) model (Decosterd et al., Pain 2000; 87: 149) is used to induce chronic neuropathic pain. Male Sprague-Dawley rats are anesthetized with isoflurane, and two of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) are transected, leaving the remaining sural nerve intact. Animals develop thermal and mechanical hyperalgesia and allodynia, as well as a long-lasting spontaneous pain or dysesthesia the last month after the nerve injury.
- Mechanical allodynia testing: Pre- and post-injury baselines as well as post-treatment values (vehicle or compound-treated animals) for mechanical allodynia are evaluated using Von Frey filaments (Stoelting, Wood Dale, Ill., USA) with varying stiffness. Animals are placed on a perforated metallic platform and allowed to acclimate to their surroundings for a minimum of 30 minutes before testing. The mean and standard error of the mean (SEM) are determined for each paw in each treatment group (ipsilateral/injured paw and contralateral/non-injured paw). Since this stimulus is normally not considered painful, significant injury-induced increases in responsiveness (i.e. lower response thresholds) in this test are interpreted as a measure of mechanical allodynia. Effects of compounds are evaluated two weeks after the injury. Compound or vehicle is administered (i.p. or s.c.) and effects on mechanical allodynia were measured at different time points after dosing (e.g., 30, 60 and 90 min.).
- Data analysis: Statistical analyses is conducted using Prism™ 4.01 (GraphPad, San Diego, Calif., USA). Mechanical hypersensitivity of the injured paw is determined by comparing contralateral to ipsilateral paw values within the vehicle group at each time point. Effect of vehicle (VEH) and compound are determined by comparing the post-injury baseline (BL) to post treatment values using RM-ANOVA or one-way ANOVA followed by Bonferroni's method for post-hoc pair-wise comparisons (e.g. vehicle vs compound).
- The Spinal Nerve Ligation (SNL) model (Kim and Chung, Pain 1992; 50: 355) is used to induce chronic neuropathic pain. Male Sprague-Dawley rats (Harlan, Indianapolis, Ind., USA) are anesthetized with isoflurane, the left L5 transverse process is removed, and the L5 and L6 spinal nerves aree tightly ligated with 6-0 silk suture. The wound is then closed with internal sutures and external staples.
- Mechanical allodynia testing: Pre- and post-injury baselines as well as post-treatment values (vehicle or compound-treated animals) for non-noxious mechanical sensitivity are evaluated using 8 Semmes-Weinstein filaments (Stoelting, Wood Dale, Ill., USA) with varying stiffness according to the up-down method (Chaplan et al., J Neurosci Methods 1994; 53: 55). Animals are placed on a perforated metallic platform and allowed to acclimate to their surroundings for a minimum of 30 minutes before testing. The mean and standard error of the mean (SEM) are determined for each paw in each treatment group. Since this stimulus is normally not considered painful, significant injury-induced increases in responsiveness (i.e., lower response thresholds) in this test are interpreted as a measure of mechanical allodynia. Effects of compounds are evaluated two weeks after the injury. Compound or vehicle is administered (i.p. or s.c.) and effects on mechanical allodynia are measured at different time points after dosing (e.g., 30, 60 and 90 min.). Injections are performed by a separate experimenter who was not involved in testing the animals.
- Data analysis: Statistical analyses is conducted using Prism™ 4.01 (GraphPad, San Diego, Calif., USA). Mechanical hypersensitivity of the injured paw is determined by comparing contralateral to ipsilateral paw values within the vehicle group at each time point. Effect of vehicle (VEH) and compound are determined by comparing the post-injury baseline (BL) to post treatment values using RM-ANOVA or one-way ANOVA followed by Bonferroni's method for post-hoc pair-wise comparisons (e.g. vehicle vs. compound).
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
- The entire contents of all patents, published patent applications and other references cited herein are hereby expressly incorporated herein in their entireties by reference. The entire contents of copending applications attorney docket number PCI-030, filed on even date herewith, titled “METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY”; and attorney docket number PCI-048, filed on even date herewith, titled “METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY” are expressly incorporated herein, in their entirety, as applied to the compounds of the present invention.
Claims (38)
1. A method of modulating the interaction of a neurotrophin and a neurotrophin receptor, comprising contacting cells expressing a neurotrophin receptor with an effective amount of a compound of Formula 16,
and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
wherein
R1, R1a, R2, R3, R4 and R5 are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
wherein the alkyl, C1-6-alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl or azepanyl.
2-12. (canceled)
13. The method of claim 1 , wherein R2, R3, R4 and R5 are hydrogen, R1 is (CH2)xR13, wherein
R13 is selected from the group consisting of hydrogen, C1-6-alkyl, amino, C1-6-alkoxy, —OH, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl;
x is 0, 1, 2, 3 or 4; and
R1a is:
wherein
R6, R7 and R12 are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
14-17. (canceled)
18. The method of claim 1 , wherein the compound is selected from the group consisting of 4-[7-(3-Carboxy-propyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-butyric acid (12), 3-[7-(3-Carboxy-phenyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-4-benzoic acid (17), 3-[7-(1-chloro-4-carboxy-phenyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-4-chloro-benzoic acid (18), 4-(1,3,6,8-Tetraoxo-7-(4-benzenesulfonic acid)-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl)-benzenesulfonic acid (54), 3-(1,3,6,8-Tetraoxo-7-(3-benzenesulfonic acid)-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl)-benzenesulfonic acid (55) and 3-[7-(3-Carboxy-propyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-4-chloro-benzoic acid (59).
19. A method of modulating the interaction of a neurotrophin and a neurotrophin receptor, comprising contacting cells expressing a neurotrophin receptor with an effective amount of a compound of Formula 17,
and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
wherein
R6, R7, R12, R6a, R7a and R12a are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
20. The method of claim 19 , wherein
R6, R6a, R7 and R7a are each, independently, selected from the group consisting of hydrogen, halogen, hydroxyl, trihalomethyl, cyano, nitro, —N(H)C(O)C1-C4-alkyl, —NH2, —C(O)N(H)C1-4alkyl, methoxy, morpholino, piperazinyl and C1-C4-alkyl-ester; and
R12 and R12a are hydrogen.
21-23. (canceled)
24. The method of claim 19 , wherein the compound is selected from the group consisting of 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (90), 2-(3-Carboxy-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (93), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9 (98), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-9-chloro-benzo[[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline (99), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-9-nitro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline (100), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-9-methoxy-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline (101) and Methyl-2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid ester (102).
25. A method of modulating the interaction of a neurotrophin and a neurotrophin receptor, comprising contacting cells expressing a neurotrophin receptor with an effective amount of a compound of Formula 18,
and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
wherein
R6a, R7a and R12a are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl; and
R1 is (CH2)xR13, wherein R13 is selected from the group consisting of hydrogen, C1-6-alkyl, amino, C1-6-alkoxy, —OH, halogen, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperazinyl, piperidinyl and azepanyl; and
x is 0, 1, 2, 3 or 4.
26. The method of claim 25 , wherein R13 is selected from the group consisting of —COOH, imidazolyl, —SO3H, —OSO3H, —OH, morpholino, piperazinyl, —PO3H, —PO3C1-4alkyl and —NO2.
27. The method of claim 25 , wherein x is 3 and R13 is COOH.
28. The method of claim 25 , wherein R13 is C(O)N(R8)R9 or N(R8)R9, wherein R8 and R9 are each, independently, selected from the group consisting of —H and —(C1-4alkyl)0-1G, wherein G is selected from the group consisting of —COOH, —H, —PO3H, —SO3H, —Br, —Cl, —F, —OC1-4alkyl, —SC1-4alkyl, aryl, —C(O)OC1-C6-alkyl, —C(O)C1-4alkyl-COOH, C(O)C1-C4-alkyl and —C(O)-aryl;
or N(R8)R9 is pyrrolyl, tetrazolyl, pyrrolidinyl, pyrrolidin-2-one, dimethylpyrrolyl, imidazolyl, morpholino.
29. The method of claim 25 , wherein R13 is NH2 or N(CH3)2.
30. The method of claim_25, wherein the compound is 2-(3-Carboxy-propyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (95).
31. A method of modulating the interaction of a neurotrophin and a neurotrophin receptor, comprising contacting cells expressing a neurotrophin receptor with an effective amount of a compound of Formulas 19 or 20,
and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
wherein
R6a, R7a, R8a and R9a are each, independently, selected from the group consisting of hydrogen, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl.
32. The method of claim 31 , wherein R6a and R8a are hydrogen, and R7a and R9a are COONa; or R6a, R7a, R8a and R9a are hydrogen.
33. A method of modulating the interaction of a neurotrophin and a neurotrophin receptor, comprising contacting cells expressing a neurotrophin receptor with an effective amount of a compound of Formula 21,
and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
wherein
R1, R8a, and R9a are each, independently, selected from the group consisting of a hydrogen atom, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
wherein the alkyl, C1-6-alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl or azepanyl.
34-40. (canceled)
41. A method of modulating the interaction of a neurotrophin and a neurotrophin receptor, comprising contacting cells expressing a neurotrophin receptor with an effective amount of a compound of Formula 22,
and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof;
wherein
R1, R2, R3, R4 and R5 are each, independently, selected from the group consisting of a hydrogen atom, C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl and azepanyl;
wherein the alkyl, C1-6-alkoxy, amino, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups may be further independently substituted one or more times with C1-6-alkyl, C1-6-alkoxy, amino, halogen, hydroxyl, acid, cyano, C1-6-alkyl-sulfonamide, aryl, heteroaryl, C3-6-cycloalkyl, C3-6-heterocycloalkyl, C1-6-alkyl-amide, C1-6-alkyl-ester, O—C1-6-alkyl, S—C1-6-alkyl, C1-6-alkene, furanyl, thiophenyl, thiazolyl, nitro, C1-6-alkene, tetrazolyl, sulfone, urea, thiourea, morpholino, piperidinyl, piperazinyl or azepanyl.
42-51. (canceled)
52. The method of claim 41 , wherein the compound is 3-(1,3,6,8-Tetraoxo-1,3,6,8-tetrahydro-2-oxa-7-aza-pyren-7-yl)-benzoic acid (45), 4-Chloro-3-(1,3,6,8-tetraoxo-1,3,6,8-tetrahydro-2-oxa-7-aza-pyren-7-yl)-benzoic acid (58), and Tetraoxo-3,6,7,8-tetrahydro-1H-2-oxa-pyren-7-yl)-butyric acid (94).
53-57. (canceled)
58. The method of any one of claims 1, 19, 25, 31, 33 or 41, wherein the method is used to modulate a neurotrophin-mediated activity in a subject in need thereof.
59. The method of claim 58 , wherein the neurotrophin-mediated activity is associated with pain.
60. The method of claim 58 , wherein the neurotrophin-mediated activity is associated with an inflammatory disorder.
61. The method of claim 58 , wherein the neurotrophin-mediated activity is associated with a neurological disorder.
62-82. (canceled)
83. A method of treating pain in a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from the group consisting of Formula 16, Formula 17, Formula 18, Formula 19, Formula 20, Formula 21 and Formula 22, or pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof.
84-85. (canceled)
86. A method of treating an inflammatory disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from the group consisting of Formula 16, Formula 17, Formula 18, Formula 19, Formula 20, Formula 21 and Formula 22 or pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof.
87. (canceled)
88. A method of treating a neurological disorder in a subject in need thereof, comprising administering an effective amount of a compound selected from the group consisting of Formula 16, Formula 17, Formula 18, Formula 19, Formula 20, Formula 21 and Formula 22, or pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof.
89. (canceled)
90. A method of treating a disease or disorder associated with the genitourinary and/or gastrointestinal systems of a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from the group consisting of Formula 16, Formula 17, Formula 18, Formula 19, Formula 20, Formula 21 and Formula 22, or pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof.
91-100. (canceled)
101. A compound of the Formula 16, Formula 17, Formula 18, Formula 19, Formula 20, Formula 21 or Formula 22, or pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof.
102. The compound of claim 101 , wherein the compound is selected from the group consisting of 4-[7-(3-Carboxy-propyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-butyric acid (12), 3-[7-(3-Carboxy-phenyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-4-benzoic acid (17), 3-[7-(1-chloro-4-carboxy-phenyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-4-chloro-benzoic acid (18), 4-(1,3,6,8-Tetraoxo-7-(4-benzenesulfonic acid)-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl)-benzenesulfonic acid (54), 3-(1,3,6,8-Tetraoxo-7-(3-benzenesulfonic acid)-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl)-benzenesulfonic acid (55), 3-[7-(3-Carboxy-propyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-4-chloro-benzoic acid (59), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (90), 2-(3-Carboxy-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (93), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9 (98), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-9-chloro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline (99), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-9-nitro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline (100), 2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-9-methoxy-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline (101), Methyl-2-(5-Carboxy-2-chloro-phenyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid ester (102), 2-(3-Carboxy-propyl)-1,3,6-trioxo-1,2,3,6-tetrahydro-benzo[lmn]benzo[4,5]imidazo[2,1-b][3,8]phenanthroline-9-carboxylic acid (95), 3-(1,3,6,8-Tetraoxo-1,3,6,8-tetrahydro-2-oxa-7-aza-pyren-7-yl)-benzoic acid (45), 4-Chloro-3-(1,3,6,8-tetraoxo-1,3,6,8-tetrahydro-2-oxa-7-aza-pyren-7-yl)-benzoic acid (58), and Tetraoxo-3,6,7,8-tetrahydro-1H-2-oxa-pyren-7-yl)-butyric acid (94).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/521,591 US20070099900A1 (en) | 2005-09-15 | 2006-09-14 | Methods of modulating neurotrophin-mediated activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71825605P | 2005-09-15 | 2005-09-15 | |
US11/521,591 US20070099900A1 (en) | 2005-09-15 | 2006-09-14 | Methods of modulating neurotrophin-mediated activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070099900A1 true US20070099900A1 (en) | 2007-05-03 |
Family
ID=37865286
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/521,592 Expired - Fee Related US7579468B2 (en) | 2005-09-15 | 2006-09-14 | Methods of modulating neurotrophin-mediated activity |
US11/521,591 Abandoned US20070099900A1 (en) | 2005-09-15 | 2006-09-14 | Methods of modulating neurotrophin-mediated activity |
US11/521,582 Abandoned US20070123514A1 (en) | 2005-09-15 | 2006-09-14 | Methods of modulating neurotrophin-mediated activity |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/521,592 Expired - Fee Related US7579468B2 (en) | 2005-09-15 | 2006-09-14 | Methods of modulating neurotrophin-mediated activity |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/521,582 Abandoned US20070123514A1 (en) | 2005-09-15 | 2006-09-14 | Methods of modulating neurotrophin-mediated activity |
Country Status (10)
Country | Link |
---|---|
US (3) | US7579468B2 (en) |
EP (2) | EP1931664A4 (en) |
JP (2) | JP2009507860A (en) |
KR (2) | KR20080058403A (en) |
CN (2) | CN101304973A (en) |
AU (2) | AU2006291927A1 (en) |
BR (2) | BRPI0615930A2 (en) |
CA (2) | CA2622571A1 (en) |
IL (2) | IL189975A0 (en) |
WO (3) | WO2007030934A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011159762A1 (en) * | 2010-06-15 | 2011-12-22 | Cornell University | Methods of limiting microvascular damage following acute myocardial ischemia |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0615930A2 (en) | 2005-09-15 | 2016-08-23 | Painceptor Pharma Corp | methods of modulating the interaction of a neurotrophin and neurotrophin receptor, treating pain in an individual, treating inflammatory disorder in an individual, treating a neurological disorder in an individual, and treating a disease or disorder associated with the genitourinary systems and / or gastrointestinal tract of an individual, and, compound |
US20090082368A1 (en) * | 2007-09-24 | 2009-03-26 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
BRPI0818201B8 (en) | 2007-10-24 | 2021-05-25 | Astellas Pharma Inc | azolecarboxamide compound or salt thereof and use thereof for the treatment of urinary frequency, urinary urgency, urinary incontinence and lower urinary tract pain associated with various lower urinary tract diseases, and various diseases accompanied by pain |
US8119656B2 (en) * | 2007-12-07 | 2012-02-21 | The Board Of Regents Of The University Of Texas System | Inhibitors of the influenza virus non-structural 1 protein |
US8674103B2 (en) | 2009-02-27 | 2014-03-18 | Nitto Denko Corporation | Lyotropic liquid crystal systems based on aromatic tetracarboxylic bisbenzoimidazole derivatives and methods for making |
WO2012115945A1 (en) * | 2011-02-21 | 2012-08-30 | The Board Of Regents Of The University Of Texas System | Viral inhibitors |
EP2718978B1 (en) * | 2011-06-09 | 2018-05-16 | Novaled GmbH | Organic electronic device |
EP2606894A1 (en) * | 2011-12-20 | 2013-06-26 | Sanofi | Novel therapeutic use of p75 receptor antagonists |
US20150183885A1 (en) * | 2012-06-08 | 2015-07-02 | Glenmark Pharmaceuticals S.A. | Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof |
CN104994853B (en) | 2012-09-28 | 2018-11-30 | 协同医药发展有限公司 | For treating that non-ene derivative of dihydro -6- azepine of CNS, oncology diseases and associated disease |
EP3013354B1 (en) * | 2013-01-16 | 2020-08-19 | Alumend, LLC | Composition for decreasing inflammatory response in a blood vessel |
CN103450176B (en) * | 2013-08-15 | 2016-07-06 | 大连理工大学 | One class is containing 2-(4-aminophenyl) benzothiazole naphthalimide compound and application thereof |
CN103623741B (en) * | 2013-11-27 | 2015-05-20 | 中国科学院长春应用化学研究所 | Graphene dispersing agent, preparation method thereof and preparation method of graphene |
MY176049A (en) | 2013-12-06 | 2020-07-22 | Genentech Inc | Serine/threonine kinase inhibitors |
CN104003935A (en) * | 2014-05-16 | 2014-08-27 | 上海应用技术学院 | 4-aroyl-1,8-naphthalimide compound and preparation method and use thereof |
CN104059062B (en) * | 2014-06-05 | 2017-06-27 | 大连理工大学 | Fused ring compound and its application containing benzothiazole and the double heterocycles of triazole |
US20160175292A1 (en) * | 2014-12-22 | 2016-06-23 | James Tour | Antioxidants Having Aromatic Structures Reacting with Superoxide |
CN106892859B (en) * | 2017-03-22 | 2019-06-25 | 河南大学 | Benzo [c, d] indoles -2 (H) -one-polyamines conjugate and its preparation method and application |
CN111334083B (en) * | 2018-12-18 | 2022-03-18 | 中国科学院大连化学物理研究所 | High-brightness high-stability active fluorescent dye and synthesis and application thereof |
CN111333645B (en) * | 2018-12-18 | 2021-10-15 | 中国科学院大连化学物理研究所 | Fluorescent probe for marking cytoskeleton |
CN109665987B (en) * | 2018-12-28 | 2022-02-18 | 河南大学 | Naphthaleneimide-polyamine conjugates, methods of making and uses thereof |
MX2021009328A (en) * | 2019-02-21 | 2021-11-12 | Univ Claude Bernard Lyon | Structured molecular vectors for anti-inflammatory compounds and uses thereof. |
CN110590663A (en) * | 2019-09-23 | 2019-12-20 | 广西师范大学 | 1, 8-naphthalimide derivative and application thereof |
CN110804039B (en) * | 2019-11-13 | 2020-08-14 | 大连理工大学 | Phthalimide-containing 1, 8-naphthalic anhydride derivatives, pharmaceutically acceptable salts thereof and application of anti-tumor drugs thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3574171A (en) * | 1969-10-20 | 1971-04-06 | Celanese Corp | Process for producing improved bbb type polymer |
US3879200A (en) * | 1970-12-01 | 1975-04-22 | Xerox Corp | Novel xerographic plate containing photoinjecting bis-benzimidazole pigments |
US4281053A (en) * | 1979-01-22 | 1981-07-28 | Eastman Kodak Company | Multilayer organic photovoltaic elements |
US6387727B1 (en) * | 1999-03-29 | 2002-05-14 | Agere Systems Guardian Corp. | Device comprising n-channel semiconductor material |
US20030153005A1 (en) * | 2001-09-28 | 2003-08-14 | Gunter Schmid | Fluorescent naphthalene -1,4,5,8-tetracarboxylic bisimides with an electron-donating substituent on the nucleus |
US20040116493A1 (en) * | 2000-11-14 | 2004-06-17 | Giichi Sugimori | Anti-helicobacterial agents |
US20060237712A1 (en) * | 2005-04-20 | 2006-10-26 | Eastman Kodak Company | N,N'-di(arylalkyl)-substituted naphthalene-based tetracarboxylic diimide compounds as n-type semiconductor materials for thin film transistors |
US20060251922A1 (en) * | 2005-05-06 | 2006-11-09 | Eastman Kodak Company | OLED electron-injecting layer |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1278643B (en) * | 1963-10-23 | 1968-09-26 | Basf Ag | Process for the production of pigment dyes |
DE2239923C3 (en) * | 1972-08-14 | 1981-08-13 | Hoechst Ag, 6000 Frankfurt | Electrophotographic recording material |
US3821383A (en) | 1972-07-10 | 1974-06-28 | Ayerst Mckenna & Harrison | Compositions for and a method of treating diabetic complications |
DE2246111C3 (en) * | 1972-09-20 | 1980-07-31 | Hoechst Ag, 6000 Frankfurt | Process for the preparation of naphthalimide-43-dicarboxylic acids |
SU531537A1 (en) * | 1975-04-04 | 1976-10-15 | Ордена Трудового Красного Знамени Научно-Исследовательский Институт Экспериментальной Медицины Амн Ссср | Bis- (p-sulfophenylimide) naphthalate salts of 1,4,5,8-tetracarboxylic acid exhibiting antigonadotropic activity |
US4006238A (en) | 1975-08-28 | 1977-02-01 | E. R. Squibb & Sons, Inc. | Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents |
ES459497A1 (en) | 1977-06-04 | 1978-04-16 | Made Labor Sa | N(Aminoalkyl)-naphthalimides and their derivatives |
US4254109A (en) | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives |
RU2051677C1 (en) | 1982-02-10 | 1996-01-10 | Украинский научно-исследовательский институт эндокринологии и обмена веществ | Agent for prophylaxis and treatment of diabetic complications, angiopathy, neuropathy, cataract |
JPS58141277A (en) * | 1982-02-17 | 1983-08-22 | Mitsubishi Chem Ind Ltd | Guest-host type liquid crystal composition and liquid crystal display element |
US4588517A (en) * | 1982-06-30 | 1986-05-13 | Hitachi, Ltd. | Liquid crystal composition |
JPS59182878A (en) * | 1983-04-01 | 1984-10-17 | Hitachi Ltd | Liquid crystal composition |
US5183821A (en) | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
IT1214618B (en) | 1985-06-27 | 1990-01-18 | I P A International Pharmaceut | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THERAPY OF RETINOPATHIES AND DIABETIC NEUROPATHIES. |
DE3635711A1 (en) | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-NITROBENZO (DE) ISOCHINOLIN-1,3-DIONE, THEIR PRODUCTION AND USE |
DE3707652A1 (en) | 1987-03-10 | 1988-09-22 | Knoll Ag | Use of benzo[de]isoquinoline-1,3-diones for preparing pharmaceuticals |
DE3707651A1 (en) | 1987-03-10 | 1988-09-22 | Knoll Ag | BIS-NAPHTHALIMIDES, THEIR PRODUCTION AND USE |
US5420137A (en) | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
CA2030129A1 (en) | 1989-11-29 | 1991-05-30 | Thomas Saupe | 1,8-napthalenedicarboximides as antidotes |
US5342942A (en) | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
DE4232739A1 (en) | 1992-09-30 | 1994-03-31 | Knoll Ag | New asymmetrically substituted bis-naphthalimides |
IL110460A (en) | 1993-08-18 | 2001-01-11 | Basf Ag | Bis-naphthalimides, their preparation and pharmaceutical compositions containing them |
US6291247B1 (en) | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
DE19505941A1 (en) | 1995-02-21 | 1996-08-22 | Bayer Ag | 1,8-naphthalimide derivatives, process for their preparation and their use as intermediates |
TW430660B (en) * | 1996-05-30 | 2001-04-21 | Mochida Pharm Co Ltd | Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them |
GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
US5895656A (en) * | 1996-10-18 | 1999-04-20 | Life Medical Sciences, Inc. | Gas or gel-filled silicone cushion for treatment of keloid and hypertrophic scars |
WO1998017278A1 (en) * | 1996-10-21 | 1998-04-30 | Allelix Biopharmaceuticals Inc. | Neurotrophin antagonist compositions |
WO2000000472A1 (en) | 1998-06-30 | 2000-01-06 | Du Pont Pharmaceuticals Company | 5-ht7 receptor antagonists |
CA2300069C (en) | 1998-07-03 | 2006-01-17 | Taiho Pharmaceutical Co., Ltd. | Naphthalimidobenzamide derivatives |
US6015458A (en) | 1998-12-15 | 2000-01-18 | Bayer Corporation | Process for the preparation of highly chromatic perylene pigments |
US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
JP2001117247A (en) * | 1999-10-21 | 2001-04-27 | Mitsubishi Paper Mills Ltd | Electrophotographic photoreceptor |
JP2001293967A (en) * | 2000-04-14 | 2001-10-23 | Fuji Photo Film Co Ltd | Heat transfer material and image forming material employing the heat transfer material |
JP2002154984A (en) | 2000-11-21 | 2002-05-28 | Mori Yuichi | Cancer cell growth inhibitor and cancer cell growth inhibiting composition comprising the same |
US6403797B1 (en) | 2000-12-22 | 2002-06-11 | Bayer Corporation | Process for the preparation of perylene pigments |
US6855720B2 (en) | 2001-03-01 | 2005-02-15 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
US6403604B1 (en) | 2001-03-01 | 2002-06-11 | California Pacific Medical Center | Nitrogen-based camptothecin derivatives |
WO2003101998A1 (en) | 2002-06-03 | 2003-12-11 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
EP1718308A4 (en) | 2004-02-11 | 2007-07-18 | Painceptor Pharma Corp | Methods of modulating neurotrophin-mediated activity |
GB0419850D0 (en) | 2004-09-07 | 2004-10-13 | Angeletti P Ist Richerche Bio | Therapeutic agents |
BRPI0615930A2 (en) | 2005-09-15 | 2016-08-23 | Painceptor Pharma Corp | methods of modulating the interaction of a neurotrophin and neurotrophin receptor, treating pain in an individual, treating inflammatory disorder in an individual, treating a neurological disorder in an individual, and treating a disease or disorder associated with the genitourinary systems and / or gastrointestinal tract of an individual, and, compound |
-
2006
- 2006-09-14 BR BRPI0615930A patent/BRPI0615930A2/en not_active IP Right Cessation
- 2006-09-14 CN CNA200680041723XA patent/CN101304973A/en active Pending
- 2006-09-14 US US11/521,592 patent/US7579468B2/en not_active Expired - Fee Related
- 2006-09-14 CA CA002622571A patent/CA2622571A1/en not_active Abandoned
- 2006-09-14 WO PCT/CA2006/001510 patent/WO2007030934A2/en active Application Filing
- 2006-09-14 AU AU2006291927A patent/AU2006291927A1/en not_active Abandoned
- 2006-09-14 KR KR1020087009029A patent/KR20080058403A/en not_active Application Discontinuation
- 2006-09-14 EP EP06790683A patent/EP1931664A4/en not_active Withdrawn
- 2006-09-14 EP EP06790687A patent/EP1931637A4/en not_active Withdrawn
- 2006-09-14 BR BRPI0615940A patent/BRPI0615940A2/en not_active IP Right Cessation
- 2006-09-14 US US11/521,591 patent/US20070099900A1/en not_active Abandoned
- 2006-09-14 JP JP2008530286A patent/JP2009507860A/en active Pending
- 2006-09-14 JP JP2008530287A patent/JP2009507861A/en active Pending
- 2006-09-14 US US11/521,582 patent/US20070123514A1/en not_active Abandoned
- 2006-09-14 KR KR1020087009032A patent/KR20080052665A/en not_active Application Discontinuation
- 2006-09-14 CN CNA2006800416720A patent/CN101305002A/en active Pending
- 2006-09-14 WO PCT/CA2006/001516 patent/WO2007030939A2/en active Application Filing
- 2006-09-14 CA CA002622574A patent/CA2622574A1/en not_active Abandoned
- 2006-09-14 AU AU2006291994A patent/AU2006291994A1/en not_active Abandoned
- 2006-09-14 WO PCT/CA2006/001517 patent/WO2007030940A2/en active Application Filing
-
2008
- 2008-03-06 IL IL189975A patent/IL189975A0/en unknown
- 2008-03-06 IL IL189976A patent/IL189976A0/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3574171A (en) * | 1969-10-20 | 1971-04-06 | Celanese Corp | Process for producing improved bbb type polymer |
US3879200A (en) * | 1970-12-01 | 1975-04-22 | Xerox Corp | Novel xerographic plate containing photoinjecting bis-benzimidazole pigments |
US4281053A (en) * | 1979-01-22 | 1981-07-28 | Eastman Kodak Company | Multilayer organic photovoltaic elements |
US6387727B1 (en) * | 1999-03-29 | 2002-05-14 | Agere Systems Guardian Corp. | Device comprising n-channel semiconductor material |
US20040116493A1 (en) * | 2000-11-14 | 2004-06-17 | Giichi Sugimori | Anti-helicobacterial agents |
US20030153005A1 (en) * | 2001-09-28 | 2003-08-14 | Gunter Schmid | Fluorescent naphthalene -1,4,5,8-tetracarboxylic bisimides with an electron-donating substituent on the nucleus |
US20060237712A1 (en) * | 2005-04-20 | 2006-10-26 | Eastman Kodak Company | N,N'-di(arylalkyl)-substituted naphthalene-based tetracarboxylic diimide compounds as n-type semiconductor materials for thin film transistors |
US20060251922A1 (en) * | 2005-05-06 | 2006-11-09 | Eastman Kodak Company | OLED electron-injecting layer |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011159762A1 (en) * | 2010-06-15 | 2011-12-22 | Cornell University | Methods of limiting microvascular damage following acute myocardial ischemia |
Also Published As
Publication number | Publication date |
---|---|
EP1931637A4 (en) | 2009-09-16 |
EP1931637A2 (en) | 2008-06-18 |
WO2007030940A3 (en) | 2007-06-07 |
CN101304973A (en) | 2008-11-12 |
AU2006291927A1 (en) | 2007-03-22 |
US20070123514A1 (en) | 2007-05-31 |
KR20080052665A (en) | 2008-06-11 |
CA2622574A1 (en) | 2007-03-22 |
WO2007030934A2 (en) | 2007-03-22 |
US20070093474A1 (en) | 2007-04-26 |
CN101305002A (en) | 2008-11-12 |
CA2622571A1 (en) | 2007-03-22 |
IL189976A0 (en) | 2008-08-07 |
IL189975A0 (en) | 2008-08-07 |
BRPI0615940A2 (en) | 2016-08-23 |
WO2007030940A2 (en) | 2007-03-22 |
EP1931664A4 (en) | 2010-12-08 |
WO2007030939A2 (en) | 2007-03-22 |
EP1931664A2 (en) | 2008-06-18 |
BRPI0615930A2 (en) | 2016-08-23 |
WO2007030939A3 (en) | 2007-05-03 |
WO2007030934A3 (en) | 2007-05-03 |
AU2006291994A1 (en) | 2007-03-22 |
US7579468B2 (en) | 2009-08-25 |
JP2009507861A (en) | 2009-02-26 |
JP2009507860A (en) | 2009-02-26 |
KR20080058403A (en) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7579468B2 (en) | Methods of modulating neurotrophin-mediated activity | |
US20090082368A1 (en) | Methods of modulating neurotrophin-mediated activity | |
US7718641B2 (en) | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | |
US20080004306A1 (en) | Compositions and methods for modulating gated ion channels | |
US7442790B2 (en) | Caspase inhibitors and uses thereof | |
US20070197509A1 (en) | Compositions and methods for modulating gated ion channels | |
US20090023773A1 (en) | Compositions and methods for modulating gated ion channels | |
US20080021034A1 (en) | Compositions and methods for modulating gated ion channels | |
US20080004272A1 (en) | Compositions and methods for modulating gated ion channels | |
KR20000029564A (en) | Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist | |
MX2008003747A (en) | Methods of modulating neurotrophin-mediated activity | |
MX2008007889A (en) | Compositions and methods for modulating gated ion channels |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |